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General Abstract 
Nontypeable Haemophilus influenzae (NTHi) is an opportunistic pathogen that is associated 
with a range of respiratory infections, including acute exacerbations of chronic obstructive 
pulmonary disease (COPD), and community acquired pneumonia (CAP).  Macrolide 
antibiotics such as azithromycin are being more frequently used to manage these conditions, 
including those where NTHi may be involved, despite macrolides having relatively poor 
antibiotic activity against H. influenzae (azithromycin MICs of wild-type strains typically 
cover the range of 0.25-4 µg/mL).  The efficacy of these antibiotics in managing these 
conditions is further threatened by the emergence of strains of NTHi exhibiting high-level 
macrolide resistance. 
A range of different mechanisms of macrolide resistance are recognised broadly within 
bacteria.  Resistance has been attributed to the presence of mutations in structural 
components of the ribosomal binding site of macrolides.  Such mutations can occur in the 
23S rRNA gene, as well as in the L4 and L22 structural proteins.  Increased expression of 
inherent macrolide efflux mechanisms such as acrAB resulting from mutations in regulatory 
regions of these efflux pumps have also been recognised as a potential cause of macrolide 
resistance.  Finally, resistance has also been attributed to the acquisition of macrolide 
resistance genes (AMRGs), which are readily disseminated among species on mobile genetic 
elements.  There are a large number of different AMRGs and associated proteins, and the 
mechanisms by which they produce resistance vary.  For example, the erm genes encode 
enzymes which modify the ribosomal binding site, the mef genes encode alternate efflux 
systems, and an additional group of genes encode enzymes which directly deactivate the 
macrolide. 
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High-level macrolide resistance in NTHi is uncommon and has historically been attributed to 
chromosomal mutations in ribosomal structural elements or regulatory regions controlling 
acrAB.  In contrast, AMRGs have not been widely associated with NTHi and a number of 
studies have failed to detect these genes in this particular species.  There has been a single 
study in which these genes have been reported to be highly prevalent in NTHi.  In that study, 
among a collection of 106 NTHi isolates from children with cystic fibrosis enrolled in a 
placebo-controlled azithromycin trial, all isolates had at least one AMRG, with many of the 
isolates carrying two or three of these genes.  However, the phenotypic effect of these genes 
was not consistent; only 27 of the AMRG-carrying isolates exhibited phenotypic resistance to 
macrolides.  While the findings of that study identify the emergence and potential spread of 
AMRGs in NTHi, it raises a number of questions regarding the prevalence of these genes 
within NTHi isolates more broadly and the role they play in generating a resistant phenotype. 
In Chapter 4 of this thesis, a collection of 186 NTHi respiratory isolates of variable 
azithromycin resistance phenotype (azithromycin MIC range: 0.09 to >256 µg/mL; MIC50: 
1.5  µg/mL; MIC90: 3 µg/mL) derived from both cystic fibrosis and non-cystic fibrosis 
patients was established and analysed for; 1) the presence of macrolide resistance-associated 
L4, L22 and 23S rRNA mutations, and 2) the presence of the AMRGs erm(A), erm(B), 
erm(C), erm(F), mef(A) and mef(E).  For the detection of the AMRGs, two methods were 
used; 1) a novel PCR using locked nucleic acid dual-labelled hydrolysis probes, and 2) the 
original primer set used by the authors of the previous study.  While L22 and 23S rRNA 
alterations were detected in 2 isolates with high-level macrolide resistance (azithromycin 
MIC ≥ 256 µg/mL), none of the isolates were found to carry any of the AMRGs using the 
novel PCR detection method.  When using the primers described in the original study, mef(A) 
and erm(A) were detected in a number of isolates.  Subsequent analysis of these amplicons 
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revealed them to be false positive results, raising questions as to the possibility of false 
positive results in the original study. 
Over 100 different AMRGs have been recognised, and the development and increasing 
availability of whole genome sequencing (WGS) techniques now allows for efficient and 
thorough analysis of sequences for the detection of antibiotic resistance mechanisms.  In 
Chapter 5 of this thesis, WGS was utilised to further investigate the presence of a broad 
selection of other AMRGs (n=72) in NTHi, using the SPANDx pipeline.  WGSs of two 
isolates of NTHi exhibiting high-level macrolide resistance obtained from the study of 
Chapter 4, as well as an additional 89 publically available WGSs of NTHi isolates of variable 
resistance phenotype, were examined in the study.  None of the specified AMRGs were 
detected among this collection of WGSs.  In addition, the WGSs of the 2 isolates from 
Chapter 4 with high-level macrolide resistance were interrogated for any AMRGs using the 
Comprehensive Antibiotic Resistance Database (CARD), and none were detected.  Both 
isolates underwent further WGS analysis to confirm the L22 and 23S findings in Chapter 4; 
one isolate carried R88P in L22 and C2611G in 23S rRNA and the other isolate carried 
A2058G in 23S rRNA, all previously associated with decreased macrolide susceptibility in H. 
influenzae.  Alterations in regulatory regions of acrAB were also detected in both isolates.  
Finally, transformation studies using donor genomic DNA from these 2 isolates were 
performed on H. influenzae Rd KW20.  While none of the transformants that were generated 
exhibited as high an azithromycin MIC as the donors, a number of different regions of donor 
origin were detected in various transformants.  The role of these regions in generating 
resistance in individual transformants was not clear but, with respect to the lower MICs 
exhibited by these transformants, the findings suggested a multifactorial aetiology for the 
high-level macrolide resistance seen in the donor isolates. 
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In the Roberts et al. study, the effect of the AMRGs appeared to be inconsistent, with some 
isolates not exhibiting increased MICs (compared to a typical wild-type strain).  The effect of 
these AMRGs on macrolide susceptibility in H. influenzae remains to be established.  As a 
result, the aim of Chapter 6 was to transfer select AMRGs (erm(A), erm(B), erm(C), mef(A) 
and mef(E)) to H. influenzae Rd KW20 and examine the phenotypic effect of expression of 
these genes.  Initially, attempts were made to conjugatively transfer these AMRGs from 
select Gram positive donors to H. influenzae Rd KW20.  These attempts were unsuccessful.  
As a result, the AMRGs were cloned into the shuttle vector pLS88 and H. influenzae Rd 
KW20 was transformed with these constructed plasmids by electroporation.  Clones were 
generated with a range of approaches, including with and without the native regulatory 
regions of the AMRG inserts, and in the former, tested for expression with and without the 
presence of an inducing agent.  High-level expression of erm(A), erm(B) and erm(C) was 
demonstrated in at least some of the various conditions and resulted in increased macrolide 
resistance in these transformants.  In contrast, expression of mef(A) and mef(E) did not have 
an effect on macrolide resistance.  In the Roberts et al. study, conjugative transfer of mef(A) 
to H. influenzae Rd KW20 resulted in a moderate increase in azithromycin and erythromycin 
MICs; our findings therefore suggest that mef only increases MICs in combination with other 
macrolide resistance mechanisms such as msr(D) (found downstream of mef and not covered 
by our cloned inserts) or underlying chromosomal alterations. 
The above AMRGs are commonly encountered among human pathogens which share a 
respiratory niche with NTHi, including Staphylococcus aureus and various respiratory 
Streptococcus spp..  A number of other AMRGs, such as erm(42), msr(E) and mph(E), are 
typically encountered among animal commensals and pathogens such as Pasteurella spp. and 
Mannheimia spp..  H. influenzae is closely related to these pathogens and previous studies 
have demonstrated that they are able to exchange resistance determinants, including beta-
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lactamases.  Therefore, the work of Chapter 7 explored the potential for conjugative transfer 
of erm(42), msr(E) and mph(E) (carried on the mobile multiresistance integrative and 
conjugative element ICEPmu1) and associated macrolide resistance from a bovine 
Pasteurella multocida isolate to H. influenzae Rd KW20.  Transconjugants generated in this 
study were found to carry a truncated form of ICEPmu1 that lacked msr(E) and mph(E) but 
carried erm(42); transconjugants were found to exhibit increased erythromycin and 
clindamycin resistance.  This truncated ICEPmu1 was successfully transferred from primary 
transconjugants to secondary H. influenzae Rd KW20 recipients, indicating that transfer 
functions were retained during conjugation.  The acquisition of ICEPmu1 did not appear to 
have an impact on the fitness of H. influenzae Rd KW20 and the ICE was found to be stable 
in the absence of antibiotic selective pressure. 
In summary, the major findings of this thesis are that AMRGs are not widespread in NTHi 
and that the high prevalence of a selected set of these genes described in one recent study is 
probably unique to the circumstances of that study. Although complex regulatory regions in 
many AMRGs mean that expression and associated resistance may be dependent on the 
specific genetic context, we have shown that under favourable conditions, erm(A), erm(B) 
and erm(C) can produce macrolide resistance in H. influenzae in their own right, but this is 
unlikely for the mef genes. Although we were unable to demonstrate conjugative transfer of 
common AMRGs from respiratory Gram positive organisms to H. influenzae, we were able 
to demonstrate conjugative transfer of an AMRG encoding multi-resistance replicon from a 
closely related organism of animal origin. This replicon produced macrolide resistance, was 
stably maintained without a significant fitness cost and was capable of ongoing conjugative 
transfer within H. influenzae. This thesis concludes that there is little evidence for the 
imminent and widespread emergence of AMRG associated macrolide resistance in NTHi; 
however, the increasing use of macrolides in both animals and humans and the prevalence of 
Abstract 
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AMRGs in other organisms suggest that it is prudent to undertake ongoing periodic 
surveillance for these genes in NTHi. 
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Chapter 1: Summary of Thesis 
1.1 Background 
Respiratory tract infections (RTIs), including those associated with chronic obstructive 
pulmonary disease (COPD), are among the most common infections encountered in Australia 
and globally.  The bacterial pathogen nontypeable Haemophilus influenzae (NTHi) is 
frequently implicated as a cause of these infections.  Antibiotic therapy has historically been 
utilised to treat RTIs associated with NTHi, with the β-lactam antibiotics amoxicillin, 
amoxicillin-clavulanate and cefuroxime (or other appropriate oral cephalosporins) commonly 
prescribed to these patients.  Macrolide antibiotics such as erythromycin, clarithromycin and 
azithromycin are being increasingly prescribed for COPD-related RTIs, and while many 
strains of NTHi exhibit reduced susceptibility to macrolides compared to Gram positive 
organisms due to the presence of an inherent intrinsic efflux system, macrolides are 
commonly prescribed for infections where NTHi may be involved. 
High-level macrolide resistance mechanisms in bacteria can be categorised into two broad 
groups.  Firstly, resistance can occur due to mutations in particular structural elements of the 
bacterial ribosome, including within 23S rRNA, and the L4 and L22 ribosomal proteins.  
Secondly, resistance has been attributable to the acquisition of macrolide resistance genes 
(AMRGs) which code for a variety of resistance mechanisms, including enzymes which alter 
the ribosomal binding site of the macrolide (such as those coded by the erm genes), and 
alternate efflux systems (including those encoded by the mef genes). 
AMRGs have been widely documented among Gram positive bacteria in particular, including 
among respiratory organisms that frequently co-exist with NTHi in the respiratory tract, such 
as Streptococcus pneumoniae.  However, high-level macrolide resistance in NTHi has 
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historically been attributed to the presence of mutations within L4, L22 and 23S rRNA.  By 
contrast, the role of AMRGs in causing macrolide resistance in NTHi remains controversial; 
while a number of previous studies have failed to detect these genes in H. influenzae isolates 
exhibiting high-level macrolide resistance, a more recent study by Roberts et al. (2011) 
reported the presence of these genes in large numbers among a collection of NTHi isolates of 
variable macrolide resistance phenotype derived from children with cystic fibrosis enrolled in 
a placebo-controlled azithromycin trial.  As a result, the research presented in this thesis aims 
to address the scientific gaps in the understanding of the prevalence, role and potential 
acquisition of AMRGs among respiratory isolates of NTHi. 
1.2 Chronology of Works and Thesis Organisation 
This chapter of the thesis (Chapter 1) comprises a general introduction into the overall 
themes and rationale of the thesis along with a note on the chronology of the laboratory 
works conducted. 
Chapter 2 presents a review of the current literature that summarises the background 
information on the main themes of the thesis.  This includes a general overview of macrolide 
structure, function and use, an overview of H. influenzae as a bacterial pathogen 
(bacteriology and pathogenesis), and the prevalence of macrolide resistance among key 
respiratory organisms.  Subsequently, Chapter 2 provides a detailed review of the macrolide 
resistance mechanisms that have been documented, including the various AMRGs currently 
described in the literature as well as chromosomal mutations within ribosomal structural 
elements.  This section is first considered broadly among the global bacterial population, and 
is then narrowed down to focus on NTHi and other phylogenetically related organisms.  
Finally, this chapter finishes with the specific aims of the thesis. 
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Chapter 3 describes general methodologies that were applied throughout multiple studies of 
this thesis, including culture media, extraction of genetic materials from study strains (DNA 
and RNA), and genetic sequencing methodologies. 
Chapter 4 presents the first study of this work, which aimed to investigate the potential 
presence of select AMRGs in clinical respiratory isolates of NTHi through the replication of 
the study performed by Roberts et al. (2011). 
Particular components of this work were published as: 
Atkinson CT, Kunde DA, Tristram SG (2015).  Acquired macrolide resistance genes in 
Haemophilus influenzae?.  J Antimicrob Chemother; 70 (8): 2234-6. [doi: 
10.1093/jac/dkv093]. 
The findings from this study were that the AMRGs chosen for this work were not present 
among the established collection of NTHi isolates, which correlates with previous studies 
demonstrating that these genes are not widespread among H. influenzae, and that the findings 
reported by Roberts et al. (2011) may have been unique to the circumstances of that particular 
study. 
Chapter 5 presents the second study of this work, which aimed to utilise whole genome 
sequencing techniques to further investigate the presence of a larger assortment of AMRGs 
among a collection of publically available whole genome sequences of NTHi and to detect 
other potential macrolide resistance mechanisms in isolates of NTHi exhibiting high-level 
macrolide resistance from our collection.  The findings of this study further supported 
previous studies and the findings of Chapter 4 of this thesis (through the inability to detect 
AMRGs among the collection of whole genome sequences included in this study) that the 
acquisition of AMRGs is not a widespread phenomenon in NTHi.  The high-level macrolide 
Chapter 1: Thesis Summary 
20 
 
resistance detected in the relevant isolates included in this study was attributed to 
chromosomal mutations in 23S rRNA and L22; a number of other potential mechanisms were 
identified through the utilisation of transformation assays performed for this chapter, 
although the role of these has not been established. 
Chapter 6 presents the third study of this thesis, which aimed to investigate the phenotypic 
effect of AMRGs in H. influenzae through the utilisation of conjugation and cloning assays to 
generate recombinant strains with AMRGs, and expression assays and antibiotic resistance 
testing to examine the effect of the AMRGs.  The novel findings from this study were that 
expression of various erm genes in H. influenzae resulted in a clear reduction in susceptibility 
to macrolides, with erm(B) and erm(C) having a greater effect than erm(A).  By contrast, 
expression of mef did not appear to have an appreciable effect on susceptibility, which did not 
match the findings of Roberts et al. (2011), although further work is required to clarify this 
finding due to the potential co-operative role of msr(D). 
Chapter 7 presents the final study of this thesis, which aimed to investigate an alternate 
potential pathway of AMRG acquisition by H. influenzae by way of conjugative transfer from 
animal-derived but phylogenetically related organisms such as Pasteurella multocida.  The 
novel findings of this study demonstrated successful transfer of erm(42) (but not of msr(E) 
and mph(E)) to H. influenzae Rd KW20 on the integrative and conjugative element (ICE) 
ICEPmu1, with an associated decrease in macrolide susceptibilities.  ICEPmu1 was shown to 
be a stable element which had minimal impact on the fitness of H. influenzae Rd KW20 and 
retained its transfer functions in the transconjugants. 
Chapter 8 presents a general discussion and concluding remarks of the major findings from 
the studies of this thesis.  Potential limitations of the study design that were not previously 
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addressed in the prior chapters and justifications of the designing of the studies are also 
discussed here. 
A complete reference list is presented in Chapter 9 of this thesis.  The referencing style used 
for this thesis conforms to the style of the Journal of Antimicrobial Chemotherapy.  Finally, 
two appendices are presented at the end of the thesis.  Appendix 1 contains PDF 
reproductions of published letters by Roberts et al. (2015) and Atkinson et al. (2015) that 
were produced in response to the original manuscript published based on the work presented 
in Chapter 4 of this thesis (see Chapter 4 section above for reference details for the original 
manuscript).  Appendix 2 contains supplementary data for the work described in Chapter 5 
of this thesis. 
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Chapter 2: General Introduction and Review of the Literature 
2.1 Macrolide structure, binding and function 
2.1.1 Macrolide structure 
The macrolide antibiotics are compounds that are characterised by the presence of a 
macrocyclic lactone ring and the size of the lactone ring varies between the different 
macrolides.  Erythromycin, roxithromycin, and clarithromycin have a 14-membered lactone 
ring, azithromycin has a 15-membered ring, and josamycin, carbomycin, and tylosin have a 
16-membered ring.
1,2
  To this lactone ring are attached a number of deoxy sugars, via 
glycosidic bonds, which differ for each macrolide, although in general a mono- or poly-
saccharide side chain will occur at atom C5 of the lactone ring (note that numbering starts at 
the macrolide ester bond, see Figure 2.1).
1
  The different sizes of the lactone ring and the 
different sugar moieties attached to this ring give each macrolide distinct properties and 
efficacies.  As an example of the different structures of various macrolides, erythromycin and 
clarithromycin both have a cladinose attached at position C3 and desosamine at position C5, 
but are distinguished by the substitution of the C6 hydroxyl group (erythromycin) for a 
methoxy group (clarithromycin).  Azithromycin also has these sugars attached, but is made 
into a 15-membered macrolide by the addition of a nitrogen atom into the lactone ring.  
Roxithromycin shares structural similarities with erythromycin, but the oxygen bound at C9 
in erythromycin is replaced with an N-oxime side chain. 
2.1.2 The bacterial ribosome, macrolide binding and antibiotic properties 
The ribosome is an organelle involved in the translation of mRNA into proteins.
3
  The 
ribosome is made up of rRNA and dozens of distinct proteins that are arranged into smaller 
subunits and active sites.  The 2 major subunits of the bacterial ribosome are the smaller 30S 
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Figure 2.1: Example of the differing chemical structure of particular macrolides.  Each macrolide has a lactone r ing to which sugar 
substituents are attached.
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subunit and the larger 50S subunit.  The 16S subunit exists within the 30S subunit, and the 5S 
and 23S subunits exist within the 50S subunit.  Three active sites exist in the ribosome: the P-
site (in which peptidyl tRNA is formed and in which the first aminoacyl tRNA enters), the A-
site (the point of entry of subsequent aminoacyl tRNA), and the E-site (the exit site of tRNA 
after it has delivered its amino acid to the polypeptide chain). 
Protein synthesis is initiated by the binding of mRNA to the 30S subunit.  During the process 
of polypeptide elongation, the ribosome undergoes several conformational changes that allow 
for the entry and accurate recognition of the appropriate type of tRNA.  Elongation begins 
with the entry of the first aminoacyl tRNA (carrying fMET) into the P-site, which initiates a 
conformational change allowing for more aminoacyl tRNA (carrying the next amino acids in 
the protein sequence) to enter the A-site.  At this point, peptide bond formation between the 
last amino acids in the polypeptide (which is detached from the P-site tRNA) and the 
following amino acid (still attached to tRNA in the A-site) occurs.  After this, the uncharged 
tRNA moves to the E-site to be released from the ribosome, the polypeptide in the A-site 
moves into the P-site, and a new codon moves into the A-site.  This process is known as 
translocation.  Elongation continues until a stop codon is recognised, with the growing 
protein exiting the ribosome through the larger subunit of the ribosome. 
Macrolides are protein synthesis inhibitors that have long been valued for their antibiotic 
properties ever since erythromycin was discovered in the 1950s.
1
  Macrolides have broader 
activities than penicillins and are less likely to produce an allergic response.
5
  In general, 
macrolides bind to the larger 50S subunit of the ribosome, inside the peptide exit tunnel, 
making contact with hairpin 35 in domain II and the peptidyl transferase loop in domain V 
(these two regions act as the binding pocket).
6
  This can result in a number of effects, 
including the inhibition of peptide bond formation,
7
 interference with 50S assembly,
8
 and 
early dissociation of peptidyl tRNA from the ribosome during translocation.
9
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Macrolides and their derivatives interact with the bacterial ribosome in a number of ways (see 
Figure 2.2) and the way in which these drugs interact with the ribosome depends on the 
sugars attached to the lactone ring and can also affect the mechanism in which they inhibit 
protein synthesis.
10
  For example, erythromycin does not affect peptide bond formation, but 
has been shown to affect 50S assembly
8
 and can promote early dissociation of peptidyl 
tRNA.
9
  The mono- or polysaccharide side chain of C5 forms an important contact with 
rRNA.  In the case of erythromycin and its numerous derivatives, the desosamine sugar forms 
hydrogen bonds with nitrogen bases located at the nucleotide residues A2058 and A2059 
(note that the nucleotide numbering used here is based on that of Escherichia coli).
10
  The 
base pair 2611-2057 (particularly the latter nucleotide of this pair) and the backbone 
phosphate oxygen of G2505 may also be involved with macrolide binding.
10
  In the case of 
the larger 16-membered macrolides such as carbomycin and spiramycin, the mycaminose-
mycarose forms a hydrogen bond with A2058 along with a number of mostly hydrophobic 
interactions.
10
  In addition, the acetaldehyde group at C6 of these 16-membered macrolides 
appears to form a reversible covalent bond with A2062.
10
  Ketolides, derived from 
erythromycin by the substitution of cladinose for a 3-keto,
6
 can also interact with the loop of 
helix 35 in domain II of 23S rRNA if a ketolide extension (an alkyl-aryl chain from a 
carbamate group) is present at position 11 or 12 of the lactone ring, specifically with 
nucleotide A752.
6
 
In addition, the L4 and L22 ribosomal proteins are located within the peptide exit tunnel of 
the 50S subunit, which is otherwise lined with RNA loops.
3
  Macrolides bind in a narrow part 
of this tunnel between the peptidyl transferase centre and a constriction in the tunnel near L4 
and L22.
4
  It is known that some macrolides are able to interact with these ribosomal proteins.  
For example, the forosamine moiety of spiramycin reaches L4, while the mycinose sugar of 
tylosin is able to interact with L22.
4
  Azithromycin and other smaller macrolides do not 
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Figure 2.2: Hairpin 35 (A) and the peptidyl transferase centre (B) of 23S rRNA.  Circled nucleotides represent particular macrolide 
(including derivative drugs) interaction sites.
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appear to make contact with these proteins however.
4
 
The macrolide drug class displays a degree of overlap with other drug classes based on where 
it binds on the ribosome (the peptidyl transferase centre of the 50S subunit) and the resulting 
effects of this binding.  This overlap occurs with the lincosamide antibiotics and 
streptogramin B.
1
  Despite being chemically distinct from one another, the overlap means that 
macrolides often have similar activities to lincosamides and streptogramin B, and they are 
therefore considered together as a superfamily.  This group has traditionally been referred to 
using the umbrella term MLSB.
11
  In some instances, the MLSB group has also been grouped 
with the ketolides (larger derivatives of macrolides) and the oxazolidinones for similar 
reasons; this group is referred to as MLSKO.
1
 
Erythromycin has traditionally been more effective against Gram-positive organisms, 
particularly staphylococci and streptococci.  Gram-negative organisms are typically more 
resistant to erythromycin.  Derivatives of erythromycin such as azithromycin, clarithromycin 
and roxithromycin have an expanded spectrum of activity that provides better coverage 
against particular groups of organisms and exhibit superior stability.
12
  Erythromycin and 
azithromycin tend to have a similar spectrum of activity against Gram-positive organisms, 
but azithromycin has stronger activity against Gram-negative organisms.  Clarithromycin is 
less active than azithromycin against Gram-negative organisms (although still superior to 
erythromycin in this respect), but tends to have a broader spectrum of activity against Gram-
positive organisms.  Roxithromycin is more stable in the presence of gastric acid than 
erythromycin and has improved activity against particular organisms including Pasteurella 
multocida and H. influenzae. 
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2.1.3 Macrolides as immunomodulatory and anti-inflammatory agents 
Distinct from their direct antibacterial effects, it has also been demonstrated that macrolides 
have the ability to modulate the immune response
13
 at sub-inhibitory doses.
14
  In general, 14- 
and 15-membered macrolides have similar immune-modulatory effects, while 16-membered 
macrolides lack these effects.
14
  The modulation effects of macrolides are broad.  Macrolides 
are known to be able to exert inhibitory effects on immune signalling components.  For 
example, erythromycin, clarithromycin, and roxithromycin all inhibit NF-κB, a protein 
complex involved in the upregulation of genes involved in T-cell production and function 
(see Figure 2.3).
14-16
  Macrolides have also demonstrated inhibitory effects on acute phase 
response proteins released during inflammation, including IL-1, IL-8, and TNF-α.14 
Furthermore, evidence suggests that some macrolides have the ability to upregulate the 
production of β-defensin-1 and β-defensin-2 on the surface of human airway epithelial cells, 
reducing the susceptibility of the airways to bacterial infection.
17,18
  Macrolides are also able 
to stimulate phagocytosis and enhance mannose receptor expression on macrophages, 
facilitating the elimination of bacterial pathogens.
17,19
 
Macrolides have been shown to exert effects on a variety of cell lines; notably, macrolides are 
able to upregulate apoptosis in neutrophils, eosinophils, and lymphocytes.
14
  Furthermore, 
macrolides can limit the tissue damage of neutrophil action through the inhibition of 
granulation and the respiratory burst.
14
  This is believed to be beneficial in the management 
of chronic pulmonary inflammatory diseases, although the benefits of macrolides in 
managing acute inflammation are less clear.
20
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Figure 2.3: Inflammatory molecular targets of macrolides.  Macrolides can exert their effects on several targets, including NF—κB.21 
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2.2 Clinical applications of macrolides in respiratory infections 
Macrolide have been used for decades in the clinical setting, and they remain among the most 
commonly prescribed drug classes because of their antibiotic and anti-inflammatory 
properties.  Macrolides are commonly prescribed for respiratory infections, particularly those 
where inflammation is a likely contributing factor.  The following section describes some of 
these conditions. 
2.2.1 Chronic Obstructive Pulmonary Disease 
Chronic Obstructive Pulmonary Disease (COPD) is a condition defined by persistent airflow 
deficiency as a result of emphysema (lung tissue breakdown), and is characterised by a 
chronic cough, excessive sputum production, and shortness of breath.  COPD affects 5% - 
10% of adults globally,
17
 and was recognised as the sixth leading cause of death in the world 
in 2008.
14
  Up to one in five Australian’s over 40 are believed to be affected by COPD;22 in 
2008, COPD was estimated to cost the Australian economy an estimated $98 billion.
23
  
Tobacco smoke is recognised as the most common trigger for the COPD-associated 
inflammatory response in the lung.   Patients with a diagnosis of COPD often experience 
exacerbations of their symptoms, including increasing shortness of breath, and changes in 
sputum production and consistency.  These exacerbations are frequently attributable to 
bacterial and viral infections; H. influenzae, S. pneumoniae, Moraxella catarrhalis, and S. 
aureus are among the more common bacterial causes. 
The disease process is known to involve neutrophil and eosinophil activation, and the 
inflammatory markers involved in this activation tend to be elevated in the sputum of patients 
during an exacerbation.
5
  Management of COPD involves reducing the frequency of these 
exacerbations.
17
  Although the ability of macrolides to control airway inflammation has been 
known for some time,
5
 there is limited data available on the effectiveness of long-term 
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administration of macrolides in the management of COPD. Both erythromycin and 
azithromycin have been proposed as reducers of the frequency of exacerbations in many 
patients,
24,25
 but the exact mechanism that causes this is unclear.
26
  One theory suggests that 
the stimulatory effect of macrolides on phagocytosis may be an important factor.  Notably, 
defective alveolar macrophages and impaired monocyte-derived macrophage phagocytosis 
are common features of COPD,
27,28
 so macrolide administration may counter these effects.
17
 
While macrolides may be an effective management tool of the inflammatory aspects of 
COPD, more recent evidence suggests that macrolides may not be as effective in eradicating 
particular bacterial species associated with acute exacerbations in COPD patients.  Pettigrew 
et al. (2016) reported that macrolide therapy did not appear to be effective in eradicating H. 
influenzae in COPD patients, and that it may in fact encourage the emergence of macrolide-
resistant H. influenzae isolates in these patients.  By contrast, fluoroquinolones appeared to be 
more effective in eradicating H. influenzae in these patients.
29
 
2.2.2 Cystic fibrosis 
Cystic fibrosis (CF) is the most common fatal genetically inherited disease in Caucasians, 
with highest prevalence in Europe, North America and Australia.
30
  The disease occurs in 
approximately 1 in 3000 live births.
31
  The disease is caused by defects in the CFTR gene, 
which results in impaired salt and water transport across epithelial surfaces.
30,32
  Although 
this affects several organs, the most apparent effects are within the respiratory system.  The 
gene mutation ultimately leads to unusually thick secretions, and patients are unable to clear 
their lungs of bacteria-containing mucus as a result.  Therefore, CF patients develop chronic 
pulmonary infections and associated inflammation, ultimately resulting in respiratory failure 
and death in many cases.
33
 
Chapter 2: General Introduction 
32 
 
The bacterial species that cause these infections appears to be age-dependent (see Figure 2.4).  
In younger patients, the predominant organisms are S. aureus
34
 and H. influenzae.
32
  As 
patients grow older, these organisms are less commonly isolated in favour of Pseudomonas 
aeruginosa,
34
 although there is contention as to whether this is because of true replacement 
by P. aeruginosa or simply because standard laboratory techniques are unable to detect these 
“childhood” organisms in the presence of the far more easily isolated P. aeruginosa.35 
There has been recent interest in using macrolide antibiotics to treat CF patients, which has 
direct killing action against many of the common pathogens in childhood CF-associated 
infections.
34
  Although H. influenzae is relatively insensitive to macrolides and P. aeruginosa 
is typically resistant to azithromycin, there is some speculation that the drug may still benefit 
adult patients through its anti-inflammatory actions.  Furthermore, it has been proposed that 
azithromycin may be able to inhibit the production of certain virulence factors associated 
with P. aeruginosa infection, such as bio-film formation.
34
 
2.2.3 Pneumonia 
Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality 
globally; treating the disease carries a significant cost burden on the world’s health systems.  
CAP can affect individuals of all ages, with infants and the elderly being particularly 
susceptible.
36
  Among the more common bacterial causes of CAP are S. pneumoniae,
37
 and 
NTHi.
38
  Because of their broad coverage, azithromycin and clarithromycin are among the 
more highly recommended antibiotics for treating CAP in adults where no other treatments 
have been previously administered.
37
  In cases of hospital-acquired pneumonia, S. aureus and 
P. aeruginosa are more commonly isolated than species normally seen in CAP.
39
  Macrolides 
are less frequently used in nosocomial pneumonia cases, but some clinicians may opt to add a 
macrolide to treat these patients for coverage against atypical pathogens and for their 
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Figure 2.4: The relationship between CF patient age and the causative agent of respiratory infection.
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anti-inflammatory effects.
39
 
2.2.4 Pharyngitis (“strep throat”) 
Pharyngitis is a common and generally non-life threatening condition characterised by 
inflammation of the pharynx.  The majority of acute cases are viral in aetiology, although 
bacterial causes are also frequently encountered.
41
  Streptococcus pyogenes, also referred to 
as group A streptococcus (GAS), has historically been identified as the most common cause 
of bacterial pharyngitis,
41
 with such cases commonly referred to as “strep throat”.  
Streptococcal pharyngitis is more commonly encountered in children, accounting for around 
15-30% of cases of acute pharyngitis, although adults also commonly present the condition.
41
  
Less common and less widely recognised and accepted causes of bacterial pharyngitis include 
S. pneumoniae and H. influenzae.
42
 
The condition is often self-limiting but antibiotic therapy is commonly used to manage 
bacterial pharyngitis.  β-lactam antibiotics such as penicillin and amoxicillin are considered 
the antibiotic of choice for several reasons.  Aside from S. pyogenes remaining susceptible to 
β-lactams overall, the drug class has a narrow spectrum of activity and is effective in 
preventing post-streptococcal sequelae, including rheumatic fever.
43
  In cases where β-
lactams are not an appropriate choice (such as where the patient has an allergy to β-lactams), 
azithromycin and clarithromycin have been recommended as first-line alternatives, although 
macrolide resistance prevalence has increased among S. pyogenes, and cephalosporins have 
been investigated as another alternative to β-lactams.41,43,44 
2.2.5 Asthma and other inflammatory disorders 
Asthma affects 1 in 10 adults in Australia, and up to 1 in 9 children.
45
  Exacerbations in 
asthma patients, which are primarily neutrophilic, are often attributable to bacterial or viral 
infection, and patients with asthma are prone to developing persistent and highly 
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symptomatic inflammatory responses upon rhinovirus infection.
5
  The first macrolide used to 
treat asthma was troleandomycin in the 1960s, but its adverse effects on the hepatic system 
were undesirable.
46
  Telithromycin has been proposed as a safer option for relieving the 
effects of exacerbations in asthma patients,
46
 while azithromycin and clarithromycin have 
been indicated as useful tools in the management of chronic asthma.
47,48
 
Research is continuing into the application of macrolides in other inflammatory conditions.  
A 1998 study demonstrated improvement in the conditions of patients with diffuse 
panbronchiolitis after taking low-dose erythromycin,
49
 while evidence is suggestive of the 
possible benefits for azithromycin, clarithromycin, erythromycin use in non-CF-associated 
bronchiectasis.
46
  There is also evidence for the potential benefits of azithromycin use in 
patients who develop bronchiolitis obliterans following a lung-transplant.
46
 
2.2.6 Haemophilus influenzae and macrolides 
H. influenzae is a fastidious, pleomorphic, Gram-negative bacterial species that is said to be 
“human-specific”, in the sense that humans form the only known reservoir.50  H. influenzae is 
distinguished from most other Haemophilus spp. by its characteristic dependence on haemin 
(factor X) and nicotinamide adenine dinucleotide (NAD, or factor V) for growth.
51
  It grows 
best at 37°C in a 5% CO2 environment.
50
 
H. influenzae can be separated into 2 subgroups based on the presence or absence of a 
polysaccharide capsule.  The ability to produce a capsule is among the most important 
virulence factors in H. influenzae as it facilitates survival, most notably within the blood 
stream (thus allowing these strains to cause invasive disease).
51
  The encapsulated strains 
produce mucoid colonies when cultured and are further distinguished into serotypes “a” to 
“f” based on the antigenic profile of the capsule, with serotype “b” (commonly referred to as 
Hib) being the most clinical significant serotype.
51
  Hib is frequently involved in serious 
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infections in childhood and is a known cause of a variety of diseases, including 
meningitis
51,52
 and pneumonia;
51,53
 at one point, Hib accounted for 95% of all reported H. 
influenzae disease.
54
  The incidence of Hib disease in the developed world has dropped 
dramatically since the introduction of the Hib vaccine in the 1970s
51,55
 and other serotypes 
have become more commonly associated with opportunistic invasive disease.
56,57
  For 
example, serotypes a, d and f are linked to cases of bacteraemia and pneumonia in 
immunocompromised adults.  Hib remains a significant threat in countries where routine Hib 
vaccination has not been introduced, however.
56
 
The non-encapsulated strains are referred to as NTHi.  They are non-mucoid on culture and 
are frequently isolated as normal flora of the human respiratory tract, with colonisation 
typically occurring early in life.
58
  While NTHi isolates are considered less pathogenic than 
the encapsulated variants, NTHi has been identified as an important cause of number of acute 
opportunistic respiratory infections in children and adults.
53
  NTHi has been attributed to 
causing between 2 and 12% of cases of community-acquired pneumonia (CAP) in adults,
37
 
and is also an uncommon cause of hospital-acquired pneumonia.
59
  Furthermore, NTHi is the 
second-most common cause of acute otitis media (AOM), behind S. pneumoniae,
60
 causing 
between 23 and 67% of cases.
37
  NTHi also plays a role in acute and chronic cases of 
sinusitis,
60
 with 35% of acute episodes in adults and 28% in children being attributable to 
NTHi.
61
  NTHi has been acknowledged as among the most common bacterial causes of acute 
exacerbations of chronic bronchitis (AECB) in patients with COPD.
37
  Note that while NTHi 
is considered less invasive than the encapsulated strains, the reduced incidence of Hib has 
resulted in NTHi now being recognised as an opportunistic invasive pathogen that has been 
implicated in meningitis and bacteraemia in immunocompromised children and adults with 
underlying medical conditions.
57,60
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Compared to other respiratory pathogens, NTHi tends to be less susceptible (although not 
necessarily completely resistant) to the antimicrobial effects of macrolides.
37
  This lower 
baseline susceptibility is believed to be due to an inherent efflux mechanism that has activity 
against macrolides (see section 1.5 for more information on this topic).  In any case, 
macrolides such as azithromycin and roxithromycin continue to be used in situations where 
NTHi may be involved, including the conditions described previously in this review.  Given 
their immunomodulatory and anti-inflammatory properties, macrolides may still be clinically 
beneficial even in situations where NTHi may itself not be responsive to the drug. 
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2.3 Macrolide resistance prevalence among key respiratory 
bacteria 
The focus of this thesis will be to investigate the role that acquired macrolide resistance genes 
(AMRGs) currently play, or may play in the future, in macrolide resistance in NTHi.  In order 
to assess the potential for the transfer of AMRGs to NTHi to occur in the upper respiratory 
tract, it is necessary to examine the prevalence of macrolide resistance in common respiratory 
isolates known to frequently harbour AMRGs. For the purposes of this review, the prevalence 
of macrolide resistance in S. pneumoniae, S. pyogenes and S. aureus will be examined 
because the macrolide resistance in these organisms is commonly associated with AMRGs, 
and these organisms are both frequent upper respiratory commensals that will regularly co-
exist with NTHi, and pathogens for which a large body of susceptibility data exists. 
Within just years of the introduction of erythromycin as an antibiotic in 1952, erythromycin-
resistant bacterial isolates had emerged.
62
  The increasing use of erythromycin and in 
particular its derivatives like azithromycin and clarithromycin for managing infection and 
inflammation has led to an increase in the proportion of macrolide-resistant isolates among 
both Gram-positive and Gram-negative species;
63
 by the 1990s, resistance had become 
widely disseminated and had been detected in isolates of Staphylococcus spp., Streptococcus 
spp., Enterococcus spp., Corynebacterium spp., Bacteroides spp., Clostridium spp., Bacillus 
spp., Lactobacillus spp., Mycoplasma pneumoniae, Campylobacter spp., Propionibacterium 
spp., and various members of the family Enterobacteriaceae.
62
  The risks associated with 
increasing macrolide resistance rates are substantial, but it should be said that the risks are not 
necessarily great to the individual patients taking them.
26
  Rather, there is an emerging issue 
regarding the effects of long-term macrolide use to the community at large.  Because 
infecting bacteria rarely exist alone in the lungs, but are also in the presence of “innocent 
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bystander” organisms, any macrolide therapy used to treat the target organism can result in 
macrolide exposure to these “bystanders” as well.  These organisms are generally transmitted 
to other people in the community rather easily, and they may potentially transfer any acquired 
macrolide resistance mechanisms to other organisms.  This means that if long-term macrolide 
therapy is undertaken by a significant proportion of the community, the proportion of 
resistant organisms circulating within the community may also increase.
26,64
 
A large number of studies have been conducted that have analysed the overall prevalence of 
macrolide resistance among respiratory pathogens.  Much of the available data is based on 
phenotypic resistance, although it must be stressed that resistance in any one isolate based on 
minimum inhibitory concentration will not necessarily by clinically useful.  Difficulties are 
presented when attempting to define “resistance” in this case because there is no consensus as 
to which macrolide/s should be used to determine whether an isolate is resistant to the drug 
class as a whole.  Furthermore, there is often a lack of consensus for the resistance 
breakpoints used to define resistance in particular species provided by the more commonly 
referenced antibiotic susceptibility testing methods (see Tables 2.1-2.4).  These differences 
can be attributed to the variable processes in which these breakpoints are determined.
65
  
Regardless of these issues, the data obtained from surveillance studies such as the Alexander 
Project and the PROTEKT surveillance study made it clear that the prevalence of macrolide 
resistance in particular species was increasing in response to the increasing use of macrolides 
for treating infections. 
2.3.1 Streptococcus pneumoniae 
In S. pneumoniae, where macrolide resistance rates have been well documented, macrolide 
resistance prevalence increased at an alarming rate throughout the 1990s, and has been 
associated with the increased reliance on macrolides therapy.
66
  In the United States, where 
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Table 2.1: Susceptibility breakpoints provided by commonly used susceptibility interpretation 
methods for Streptococcus pneumoniae. 
Method 
Erythromycin resistance 
breakpoints (MIC, µg/mL) 
Azithromycin resistance 
breakpoints (MIC, µg/mL) 
Clarithromycin resistance 
breakpoints (MIC, µg/mL) 
S I R S I R S I R 
Clinical and 
Laboratory 
Standards Institute 
(CLSI)
67,68
 
≤0.25 0.5 ≥1 ≤0.5 1 ≥2 ≤0.25 0.5 ≥1 
European Committee 
on Antimicrobial 
Susceptibility Testing 
(EUCAST)
69
 
≤0.25 0.5 >0.5 ≤0.25 0.5 >0.5 ≤0.25 0.5-1 >1 
PK/PD
37
 ≤0.25 ---- ≥0.5 ≤0.12 ---- ≥0.25 <0.25 ---- ≥0.5 
 
 
 
 
 
 
 
 
Table 2.2: Susceptibility breakpoints provided by commonly used susceptibility interpretation 
methods for Staphylococcus aureus. 
Method 
Erythromycin resistance 
breakpoints (MIC, µg/mL) 
Azithromycin resistance 
breakpoints (MIC, µg/mL) 
Clarithromycin resistance 
breakpoints (MIC, µg/mL) 
S I R S I R S I R 
Clinical and 
Laboratory 
Standards Institute 
(CLSI)
67,68
 
≤0.5 1-4 ≥8 ≤2 4 ≥8 ≤2 4 ≥8 
European Committee 
on Antimicrobial 
Susceptibility Testing 
(EUCAST)
69
 
≤1 2 >2 ≤1 2 >2 ≤1 2 >2 
PK/PD
37
 ≤0.25 ---- ≥0.5 ≤0.12 ---- ≥0.25 <0.25 ---- ≥0.5 
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Table 2.3: Susceptibility breakpoints provided by commonly used susceptibility interpretation 
methods for Streptococcus pyogenes. 
Method 
Erythromycin resistance 
breakpoints (MIC, µg/mL) 
Azithromycin resistance 
breakpoints (MIC, µg/mL) 
Clarithromycin resistance 
breakpoints (MIC, µg/mL) 
S I R S I R S I R 
Clinical and 
Laboratory 
Standards Institute 
(CLSI)
67,68
 
≤0.25 0.5 ≥1 ≤0.5 1 ≥2 ≤0.25 0.5 ≥1 
European Committee 
on Antimicrobial 
Susceptibility Testing 
(EUCAST)
69
 
≤0.25 0.5 >0.5 ≤0.25 0.5 >0.5 ≤0.25 0.5 >0.5 
PK/PD
37
 ≤0.25 ---- ≥0.5 ≤0.12 ---- ≥0.25 <0.25 ---- ≥0.5 
 
 
 
 
 
 
 
 
Table 2.4: Susceptibility breakpoints provided by commonly used susceptibility interpretation 
methods for Haemophilus influenzae. 
Method 
Erythromycin resistance 
breakpoints (MIC, µg/mL) 
Azithromycin resistance 
breakpoints (MIC, µg/mL) 
Clarithromycin resistance 
breakpoints (MIC, µg/mL) 
S I R S I R S I R 
Clinical and 
Laboratory 
Standards Institute 
(CLSI)
67,68
 
---- ---- ---- ≤4 ---- --- ≤8 16 ≥32 
European Committee 
on Antimicrobial 
Susceptibility Testing 
(EUCAST)
69
 
≤0.5 1-16 >16 ≤0.125 0.25-4 >4 ≤1 2-32 >32 
PK/PD
37
 ≤0.25 ---- ≥0.5 ≤0.12 ---- ≥0.25 <0.25 ---- ≥0.5 
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macrolide use increased significantly from 1993 to 1999,
70
 erythromycin resistance 
prevalence had increased from 0.2% (using CLSI breakpoints) in 1987 to 23% by 1999 
(using CLSI breakpoints).
71,72
  This increase in macrolide resistance prevalence in the United 
States was also observed in other studies.  Doern et al. (2001), in a study that formed part of a 
longitudinal surveillance program, found erythromycin, azithromycin and clarithromycin 
resistance rates among a collection of 1531 clinical S. pneumoniae isolates exceeded 25% 
(using CLSI breakpoints) for all three drugs, representing an approximate increase of 16% 
over a period of 5 years ending in the winter of 1999-2000.
73
  An overall rate of 27.9% (using 
CLSI breakpoints) was observed by a study by Farrell and Jenkins (2004) on a collection of 
10012 S. pneumoniae isolates submitted as part of the PROTEKT study, with rates varying 
by state.
74
  Pfaller et al. (2012), reporting on antibiotic resistance trends in the USA as part of 
the AWARE Ceftaroline Surveillance Program, reported an erythromycin non-susceptibility 
prevalence rate of 41.7% including both respiratory and bloodstream infection isolates of S. 
pneumoniae in 2010, a slight increase from the 38.4% prevalence rate recorded in 2008 
(using CLSI methodology).
75
 
This trend of increased resistance has also been observed globally.  The overall prevalence of 
resistance to erythromycin, azithromycin and clarithromycin among a collection 8882 S. 
pneumoniae isolates submitted as part of the Alexander Project was shown to be 
approximately 25% (using CLSI breakpoints) by the turn of the century.
67
  This study also 
showed that macrolide resistance was particularly prevalent in Asia, with overall rates 
approaching 70% for all 3 antibiotics.  Resistance rates exceeded 80% (using CLSI 
breakpoints) in Hong Kong and 70% (using CLSI breakpoints) in Japan.
67
  Resistance was 
also prevalent in parts of Europe, particularly in France (exceeding 50% for all 3 antibiotics 
using CLSI breakpoints), Italy (approximately 35% for all 3 antibiotics using CLSI 
breakpoints) and Spain (approaching 30% for all 3 antibiotics using CLSI breakpoints).
67
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Similar findings have also been observed in studies performed on isolates gathered from the 
PROTEKT surveillance study.  Felmingham et al. (2002) found that among 3362 S. 
pneumoniae isolates, 31% were resistance to erythromycin.  Again, resistance rates varied by 
country, with particularly high rates observed in Hong Kong (71.4%), Japan (77.9%), South 
Korea (87.6%), France (57.6%), Hungary (55.6%) and Italy (42.9%) (all using CLSI 
breakpoints).
76
  In Australia, 12.3% (using CLSI breakpoints) of isolates were defined as 
resistant to erythromycin, and in most countries resistance rates not only exceeded 10% 
(using CLSI breakpoints), but also exceeded rates of penicillin resistance.
76
  In China, 
macrolide resistance remains a common feature of S. pneumoniae isolates, with one study 
demonstrating erythromycin and azithromycin resistance rates of 96.4% and 95.8% (both 
using CLSI breakpoints), respectively.
77
 
2.3.2 Streptococcus pyogenes and Staphylococcus aureus 
Macrolide resistance is also prevalent among S. pyogenes isolates, with prevalence varying 
by country.  However, prevalence has been shown to fluctuate over time in certain regions, 
with some reports suggesting that prevalence may have declined in recent years in some 
regions, even where macrolide use remained stable.  Yamaguchi et al. (2015) demonstrated 
increasing rates of erythromycin and azithromycin resistance among community acquired S. 
pyogenes isolates in Japan over the period of 2007 to 2010, while Smit et al. (2015) observed 
resistance rates among a group of invasive isolates in Finland to have increased over the 
period of 2008 to 2013 from 1.9% to 8.7% against erythromycin and from 0.9% to 9.2% 
against clarithromycin (EUCAST breakpoints).
78,79
  On the other hand, Silva-Costa et al. 
demonstrated a gradual decline in erythromycin resistance prevalence among a large 
collection of S. pyogenes isolates from Portugal from throat swabs of patients diagnosis with 
tonsillo-pharyngitis over the period of 1999 (20%) to 2006 (12%), with a subsequent decline 
over the period of 2007 (10%) to 2013 (1%) (using CLSI breakpoints).
44,80
  While resistance 
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among pharyngeal isolates has historically been highly prevalent in Italy (Dicuonzo 2002),
81-
83
 resistance appears to have declined in recent years, with one study finding a relatively low 
rate of erythromycin resistance (7.4%) among a collection of 592 isolates from children with 
pharyngitis (using EUCAST breakpoints).
84
  Evidence suggests that these fluctuations in 
overall resistance, which are also often associated with changes in phenotype (MLSB and M 
phenotypes) dominance and composition, and observed variations in resistance prevalence by 
region may be related not only to potential changes in macrolide use but also to changes and 
instability in bacterial population clonality over time.  A number of studies have analysed the 
prevalence of different emm type clones among populations of S. pyogenes and have found 
fluctuations in the proportions of different clones within the population alongside resistance 
prevalence changes, emphasizing the importance of both antibiotic consumption and 
population clonal structure in explaining resistance prevalence within S. pyogenes 
populations.
79,80,85
 
Macrolide resistance is a well-known issue among S. aureus isolates.  Erythromycin 
resistance has been detected globally among isolates and it has been demonstrated that 
macrolide-resistant strains can be isolated from healthy people and patients alike.
86
  Abbas et 
al. (2015) reported an erythromycin resistance rate of 40.2% (using CLSI breakpoints) among 
a collection of 500 clinical S. aureus isolates from various body sites.
87
  A number of studies 
have shown that macrolide resistance may be more prevalent among methicillin-resistant S. 
aureus (MRSA) isolates than methicillin-susceptible S. aureus (MSSA) isolates.  One study 
performed on a collection of S. aureus isolates from China (where macrolide resistance is 
highly prevalent among respiratory isolates) demonstrated resistance rates of 82.2% among a 
collection of 73 MRSA isolates and 63% among a collection of 403 methicillin-susceptible S. 
aureus MSSA isolates (both using CLSI breakpoints).
77
  Asbell et al. (2015) reported an 
azithromycin resistance rate of 63.3% (using CLSI breakpoints) among a mixed collection of 
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MRSA and MSSA strains containing 1169 isolates; when separated by methicillin resistance 
status, resistance rates were 93.3% among 493 MRSA isolates and 41.9% among 676 MSSA 
isolates.
88
 
2.3.3 Haemophilus influenzae 
Reported macrolide resistance rates among H. influenzae isolates must be interpreted with 
care.  By nature, most wild-type strains have macrolide minimum inhibitory concentrations 
(MIC) that are higher than what would be observed in susceptible isolates of other species 
such as S. pneumoniae, and the majority of these strains will fall above the susceptibility 
breakpoints defined by EUCAST (see Figures 2.5 and 2.6) and CLSI.  However, the MICs 
for most of these “non-susceptible” strains tend to fall only slightly above the susceptibility 
breakpoint, and will often fall below the resistance breakpoint (and will be defined as 
“intermediate”).  Therefore, stating that there is a low rate of susceptibility to macrolides 
among any group of H. influenzae isolates does not necessarily mean that those non-
susceptible isolates carry high level resistance to macrolides, and interpretation should always 
consider the MIC50 and MIC90 values of the collection where available. 
Jacobs et al. reported less than 1% of a global collection of 8523 H. influenzae isolates were 
susceptible to erythromycin and clarithromycin, and less than 2% were susceptible to 
azithromycin (using PK/PD breakpoints).
67
  However, in that particular study, clarithromycin 
resistance prevalence was less than 1% (using CLSI breakpoints), and susceptibility rates of 
79.6% and 99.5% (both using CLSI breakpoints) were reported for clarithromycin and 
azithromycin, respectively.  MIC90 values were 8 µg/mL, 16 µg/mL and 2 µg/mL for 
erythromycin, clarithromycin and azithromycin, respectively,
67
 suggesting that the majority 
of the isolates were inhibited by these antibiotics at relatively low concentrations and fell 
within or only slightly above the intermediate range.  Furthermore, 99.8% susceptibility rates 
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Figure 2.5: EUCAST azithromycin MIC distribution for Streptococcus pneumoniae (2014).  Two distinct groups of isolates (susceptible and 
resistant) are apparent. 
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Figure 2.6: EUCAST azithromycin MIC distribution for Haemophilus influenzae (2014).  Most isolates cluster in the intermediate range 
between the breakpoints. 
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against azithromycin and 89.4% susceptibility rates against clarithromycin (both using CLSI 
breakpoints) were reported for a collection of 2948 isolates cultured from various body sites 
via the PROTEKT study,
89
 and Peric et al. (2003) demonstrated that only 1.3% of collection 
of 6,382 H. influenzae isolates had an azithromycin MIC > 4 µg/mL (used to represent “high-
level resistance”), with only 2.5% having a clarithromycin MIC > 16 µg/mL.90  A number of 
recent studies have repeatedly demonstrated low rates of high-level macrolide resistance in 
H. influenzae
77,88,91
 even in situations where selective antibiotic pressure is present.
92
  
However, prevalence has been demonstrated to be higher in particular test groups: Cardines 
et al. (2012) observed an azithromycin resistance rate of 10.1% (using EUCAST breakpoints) 
in a group of 79 isolates from children with CF,
32
 while Roberts et al. (2011) found 27 out of 
a group of 106 isolates from CF patients on an azithromycin placebo-controlled trial were 
resistant to erythromycin and/or azithromycin (using BSAC interpretive criteria; 
erythromycin MIC > 8 µg/mL; azithromycin MIC > 4 µg/mL).
93
  Marchese et al. (2005) 
reported a clarithromycin resistance prevalence rate of 11.2% among clinical respiratory 
isolates collected in Italy during the year 2000 (breakpoints not described).
94
  Pfaller et al. 
(2012), reporting on antibiotic resistance trends in the USA as part of the AWARE 
Ceftaroline Surveillance Program, found that azithromycin non-susceptibility was uncommon 
among H. influenzae isolates (including both respiratory and bloodstream infection isolates), 
but that a slight increase in resistance occurred over the period of 2008-2010 (0.8% in 2008 
to 1.4% in 2010, using CLSI methodology).
75
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2.4 Overview of macrolide resistance mechanisms among key 
respiratory bacteria 
The issues surrounding the mechanisms behind macrolide resistance are complex and 
expansive, and a significant body of literature has been developed that describes both 
acquired genes and chromosomal alterations that are associated with resistance to macrolides.  
This section of the chapter will provide an overview of commonly encountered macrolide 
resistance mechanisms among respiratory isolates, including commonly encountered 
macrolide resistance genes and resistance-associated chromosomal mutations. 
2.4.1 Acquired macrolide resistance genes 
Macrolide resistance has long been attributed to acquired genes.  An online database of the 
currently identified MLSB resistance genes is maintained by Dr. Marilyn Roberts;
95
 this 
database is frequently updated and the genes listed within this database at this time are also 
listed in Tables 2.5, 2.6 and 2.7 of this chapter.  A large number of these genes have been 
described but can be separated into three broad groups based on their mechanism of action.  
The first group describes a collection of rRNA methylase-coding genes.  The genes in this 
group are called the erm genes and the methylases encoded by them act by altering the 
binding site of the macrolides to the ribosome to reduce macrolide binding affinity.  The 
second group describes genes that encode various efflux pumps with action against 
macrolides.  The mef genes are examples of genes contained within this group.  Finally, a 
third group of genes encode for enzymes that act directly on the macrolide to inhibit their 
action.  The focus of this chapter will primarily be placed on genes that are considered 
clinically important among macrolide-resistant respiratory isolates, namely the erm and mef 
groups. 
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2.4.1.1 erm and rRNA methylation 
The erm genes were among the first genes detected that were found to provide protection 
against macrolides.  These genes code for rRNA methyltransferases which add methyl groups 
to the 23S moiety of the 50S rRNA subunit, altering the binding site of the macrolide and 
inhibiting its actions through the prevention of efficient drug binding.
1
  The methyl groups 
are typically described as being added specifically at position A2058 within the 
peptidyltransferase centre; this numbering is based on E. coli positioning, but has also been 
applied to other organisms in some instances for uniformity of the nomenclature.
96
 
Roberts et al. (1999) made an attempt to standardise the erm nomenclature system,
97
 which 
was revised in 2008.
1
  The current system groups different erm genes based on their amino 
acid homology with previously described erm variants (a cut-off <80% homology is required 
to assign any variant as a new gene; otherwise, the gene is assigned a title based on its 
homology with the current groups).
1
  Currently, 38 different erm gene types had been 
described and listed by Roberts (see Table 2.5).
95
  The erm gene group is diverse and widely 
disseminated in Gram positive bacteria.
98
  While each erm gene has been more strongly 
associated with a particular genus, many are not limited to one species and have disseminated 
among other species.
1
  Of the many erm gene types, erm(A), erm(B), and erm(C) are among 
the most commonly encountered among Gram positive bacterial respiratory pathogens. 
The erm gene group is capable of producing high-level resistance to macrolides, lincosamides 
and streptogramin B, all of which are structurally distinct but bind to the same site in the 
bacterial ribosome (Chancey 2012).  This phenotype is referred to as the MLSB resistance 
phenotype.  Some erm genes do not produce resistance to the entire MLSB group however.  
Expression of erm genes may be inducible or constitutive; bacteria with inducibly-expressed 
variants produce an inactive form of methylase mRNA that becomes active in the presence 
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Table 2.5: List of currently identified* rRNA methylation genes and the genera in which they 
have been detected.
95
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**The cfr genes are not associated with macrolide resistance but are associated with resistance against other MLSB drugs including 
lincosamides. 
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of an inducer, while bacteria with constitutively-expressed variants produce active forms in 
the absence of an inducer.
99
  The expression status of an erm gene is related to the presence 
and structure of an attenuator upstream of the structural gene.
99
 
It is worth noting that only certain macrolides are capable of inducing expression of the erm 
genes, and that lincosamides and streptogramin B are generally not inducers of erm.
98
  In the 
case of macrolides, common structural elements of inducers include a 14- or 15-membered 
macrolide ring, a monosaccharide at the C-5 position of the macrolide ring, and cladinose at 
the C-3 position.
98
  It has been suggested that the C-3 cladinose is the key determinant of a 
macrolide being able to act as an inducer because the ketolides, generally reported to be non-
inducers, have the correct ring size and the C-5 monosaccharide, but lack the C-3 cladinose.  
However, several ketolides including cethromycin and telithromycin have been demonstrated 
to be inducers of erm,
100
 and previous reports of ketolides being non-inducers (based on their 
phenotypic antimicrobial activity) may be reflective of their potent antimicrobial activity 
irrespective of the presence of ribosomal methylation.
98
 
Constitutively expressed variants tend to produce the complete MLSB resistance 
phenotype.
101
  The resistance phenotype produced by inducible erm appears to be dependent 
on the specific erm gene variant, with some variants producing a variety of phenotypes in 
different isolates and species, and others producing a more predictable phenotype.
99
  In 
inducible variants, resistance to 16-membered macrolides, lincosamides and streptogramin B 
may not be present unless expression of the genes has been induced by 14- or 15-membered 
macrolides like erythromycin and azithromycin,
98
 but the use of non-inducing macrolides and 
other MLSB antibiotics in treating infections with bacteria carrying inducibly-expressed 
variants of erm still carries significant risk.  Mutants with constitutively-expressed variants 
can be selected easily in vitro, and this has also been reported in patients undergoing 
clindamycin therapy against inducibly-resistant S. aureus.
99
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While erm is the primary gene group that encodes rRNA methylase-mediated MLSB 
resistance, the cfr genes have also been identified as encoders of a similar mechanism.  These 
genes are associated with resistance against lincosamides and streptogramin A, but unlike the 
erm genes they are not associated with macrolide resistance.  One of these genes, simply 
referred to as cfr, has been identified in 6 genera including Staphylococcus, Bacillus and 
Escherichia.  This gene causes methylation at position A2503 of 23S rRNA that results in 
clindamycin and chloramphenicol resistance and has been detected on the plasmid pSCFS3.  
cfr(B) is chromosomally located and has been reported in the genera Clostridium and 
Enterococcus.
95
 
2.4.1.1.1 erm(A) 
The erm(A) gene has long been associated with S. aureus, particularly with MRSA,
99
 and has 
historically been widespread among staphylococci.
102
  erm(A) has been reported among at 
least nine different genera, including S. pyogenes
103
 and Enterococcus spp.,
104
 although it has 
not disseminated as widely as erm(B) or erm(C).
95
  Mazzariol et al. (2007) reported a 73.9% 
prevalence rate of erm(A) among a group of 69 S. pyogenes with an iMLSB phenotype.  On 
the other hand, the same group did no detect erm(A) among a group of 40 S. pyogenes with a 
cMLSB phenotype, nor did they find any incidence of erm(A) among a collection of 145 
erythromycin-resistant S. pneumoniae isolate regardless of whether they had an iMLSB 
phenotype or a cMLSB.
103
  Jensen et al. (1999) found that among a collection of 44 
erythromycin-resistant isolates of S. aureus of human origin, 10 were found to carry erm(A), 
three of which also carried erm(C).  The same group did not detect erm(A) among a 
collection of 17 Enterococcus faecium isolates of human origin.
105
 
Sequencing of erm(A) revealed that the gene codes for a 243-amino acid protein that is 
homologous to that produced by other erm variants, including erm(C).  Murphy (1985) 
reported that erm(A) was less closely related to erm(B).
106
  erm(A) is regulated by 
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translational attenuation, and is preceded by an attenuator structure that encodes two leader 
peptides.
98
  The erm(A) attenuator model in S. aureus has been studied and in this particular 
allele, the presence of an inducer results in stalled ribosome complexes forming on the 
cistrons of the leader peptides erm(A)L1 and erm(A)L2.  Stalling of erm(A)L1 results in 
translation of erm(A)L2, and stalling on erm(A)L2 allows for translation of the erm(A) 
gene.
107
  However, mutations that disrupt the attenuator structure can result in constitutive 
expression of erm(A) in some Gram positive species, including S. aureus, Staphylococcus 
epidermidis and Streptococcus agalactiae.
98,108
 
2.4.1.1.2 Mobile genetic elements carrying erm(A) 
The chromosomally-located 6691-bp element Tn554, detected in S. aureus, was among the 
earliest genetic elements described that was shown to carry erm(A).
106
  Tn554 is associated 
with inducible MLSB resistance and is integrated into the S. aureus chromosome at a 
particular insertion site, att554.
109,110
  Tn554 will almost always be inserted in a particular 
orientation.
110
  This element consists of 6 ORFs.  Three ORFs represent genes encoding 
functions essential for transposition, tnpA, tnpB, and tnpC.  tnpA and tnpB are thought to 
encode products that catalyze the recombination reaction while tnpC controls the efficiency 
of the reaction and determines the orientation of Tn544 in att554 (mutations in tnpC can 
result in Tn544 being inserted in the opposite direction of the chromosome).
111
  Two other 
ORFs were identified as spc (encoding resistance to spectinomycin) and erm(A).
110
 
Tn554 is widespread among isolates and is the best described erm(A)-carrying element, 
although composite elements with homology to Tn554 have also been detected.  For 
example, Tn6133, described in MRSA, is an 11,475-bp transposon that was found to consist 
of Tn554 with a 4-787-bp insertion, in which the streptogramin A-, pleuromutilin-, and 
lincosamide-resistance-encoding gene vga(E) was contained.
109
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2.4.1.1.3 erm(B) 
erm(B) was described in Streptococcus sanguinis (formerly Streptococcus sanguis) as early 
as 1978.
112
  The gene has since spread across many species worldwide
113
 and has been 
detected in more individual genera than any other erm gene currently listed in the Roberts 
database.
95
  In 2008, erm(B) was reported to be the most common macrolide resistance 
mechanism among erythromycin resistant S. pneumoniae isolates (55.0% globally)
114
 in most 
countries
76
 and particularly widespread among streptococcal species.
98,115
  Studies have 
continued to a report high incidence of erm(B) among macrolide-resistant clinical isolates of 
S. pneumoniae, often in the presence of mef.  Azadegan et al. (2015) reported an erm(B) 
prevalence rate of approximately 84% among a collection of 88 erythromycin- and 
clarithromycin-resistant clinical and normal flora S. pneumoniae isolates from Iran; all 
erm(B) carrying isolates were associated with a cMLSB phenotype, and 40% of the 88 
resistant isolates carried erm(B) and mef.
116
  Kohno et al. (2014) reported erm(B) in six out of 
eleven azithromycin-resistant clinical S. pneumoniae isolates from Japan, with 2 of these 
isolates also carrying mef(A).
117
  Mazzariol et al. (2007) reported that among a collection of 
119 erythromycin-resistant clinical isolates S. pneumoniae exhibiting an MLSB phenotype, all 
isolates carried erm(B) regardless of whether the phenotype was constitutively or inducibly 
expressed.  In addition, the same group also reported that among a collection of 40 S. 
pyogenes with a cMLSB phenotype, all carried erm(B), and among a collection of 69 S. 
pyogenes with an iMLSB phenotype, 26.1% carried erm(B).
103
  Jensen et al. (1999) reported 
that 100% of a group of 17 erythromycin-resistant E. faecium isolates of human origin carried 
erm(B), and did not detect any instances of erm(B) among a collection of 44 erythromycin-
resistant isolates of S. aureus of human origin.
105
 
The protein produced by erm(B) as reported by Horinouchi et al. (1983) was predicted to be 
246 amino acids in length; the same group stated that erm(B) likely shares a common origin 
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with other erm genes due to their sequence homology.
118
  The mechanism of erm(B) 
induction has not been as thoroughly studied as it has with erm(C).  Much like erm(A), 
erm(B) induction is also regulated by translational attenuation with stalling of erm(B) 
expression, but in this case there is only a single leader peptide sequence with no resemblance 
to that of erm(A) or erm(C).
98
  Expression of erm(B) can be inducible or constitutive; 
mutations in the leader peptide sequences have been demonstrated to allow for constitutive 
expression of erm(B) in S. pneumoniae, S. pyogenes and S. agalactiae.
98,103,108,119
  
Interestingly, the phenotype produced in bacteria by inducibly expressed variants of erm(B) 
can vary greatly compared to inducibly expressed variants of erm(A) or erm(C), which tend 
to fit the expected phenotypic profile of resistance to 14- and 15-membered macrolides but no 
resistance to 16-membered macrolides.
99
 
2.4.1.1.4 Mobile genetic elements carrying erm(B) 
The group of elements bearing erm(B) is more diverse than what is seen with erm(A).  
Among the earliest reported elements was pAM77, a plasmid isolated from an isolate of S. 
sanguinis with the MLSB phenotype and derived from dental plaque of a patient who had 
been on long-term erythromycin therapy.
112
  This plasmid, as well as the erm(B)-carrying 
plasmid pAMβ-1, has also been detected in E. faecalis.  Other plasmids capable of carrying 
erm(B) that have been described include pTE80 in Lactobacillus reuteri, pBT233 in Bacillus 
subtilis, pMD101 in S. pyogenes, pIP501 in S. agalactiae, pLEM3 in Lactobacillus 
fermentum, pIP1527 in E.coli, and pIP402 in Clostridium perfringens.
95,120-125
 
Among the most studied erm(B)-carrying elements is Tn917, first described in Enterococcus 
faecalis,
126,127
  and originally described on a multiresistance plasmid, pAD2, with no 
conjugative properties.
128
  Tn917 has since been shown to be incorporated into a variety of 
other conjugative elements.
115,129
  Sequencing of Tn917 revealed that the transposon contains 
5 ORFs, including erm(B) and the transposition-related genes tnpR and tnpA.
115
  Subsequent 
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to the description of Tn917, structures with similar sequences were described in S. 
pneumoniae.  Tn3872, a conjugative element,
115, 133
 is the result of the insertion of Tn917 into 
orf9 of the tet(M)-carrying Tn916, creating a linkage between erm(B) and tet(M).
130,131
  
Elements similar in structure to Tn3872 have since been found in S. pyogenes; Tn917 was 
also found in other isolates and may have been present on alternate conjugative 
elements.
115,132
  A composite element corresponding to Tn3872 has also been described in S. 
agalactiae.
133
 
Elements with Tn916-like features are important mediators of resistance among 
streptococci,
134
 and a number of other erm(B)-bearing transposons containing a Tn916-like 
element with a erm(B)/tet(M) linkage have been described.
115
  In some of these elements, the 
erm(B)-carrying element is a 2,874bp element consisting of 5 ORFs from orfP0 to orfP4 
(erm(B) is orfP2, the third ORF), and inserts into a different position of Tn916 than is seen in 
Tn3872 (position 3847 of published sequenced).
115
  In Tn6002, the erm(B) element is 
inserted alone.  This conjugative element
133, 135
 has been reported in S. pyogenes
132
 and S. 
pneumoniae.
132,135-137
  The conjugative
136
 Tn6003 can be distinguished from Tn6002 by the 
additional insertion of the MAS (macrolide-aminoglycoside-streptothricin) element, inserted 
between orfP0 and orfP1 within the erm(B) element.
115
  The insertion of MAS, which 
contains an additional erm(B) gene and its leader peptide, into Tn6003 may be related to a 
222-bp sequence, normally absent in Tn916, found on the left end of the erm(B) element and 
on the right end of the MAS element.
136
  Tn6003 is less commonly encountered than Tn6002, 
possibly due to the instability of the MAS element.
138
  Tn2010 is another erm(B)-carrying 
Tn916-like transposon that has been described in S. pneumoniae.  The element contains an 
insertion of a variant of mega (macrolide efflux genetic assembly), a mef(E)-carrying 
element, at position 17014 of the Tn6002 sequence.  It does not appear to be transferable by 
conjugation.
137,139
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The approximately 50kb element Tn1116 has been described in S. pyogenes.
132
  Tn1116 is 
the result of an insertion of an erm(B)-carrying element into the coding sequence of tet(M) 
within a defective variant of Tn5397, a Tn916-related, tet(M)-carrying element originally 
described in Clostridium difficile, in which the xis (excisase) and int (integrase) genes typical 
of Tn5397 are replaced with the tndX (resolvase) gene.
140
  The involvement of Tn5397 and 
the resulting truncated and silent
140
 tet(M) distinguishes Tn1116 from other Tn916-like 
elements.  Tn1116 has been shown to demonstrate homology with the S. pyogenes plasmid 
pSM19035
115,121
 and is easily transferred in intraspecific matings.
132
 
In S. aureus, erm(B) has been reported on the transposon Tn551.
141,142
  This approximately 
5.2kb element was detected on a set of plasmids derived from Japan in the 1960s that shared 
the same prototype, pI258, and isolates carrying this resistance determinant were shown to 
exhibit a cMLSB phenotype.
110,142
  This transposon encodes five putative proteins and has 
been reported to be extremely similar to Tn917 in terms of genetic organisation and 
nucleotide sequence, with the two transposons differing at just 11 positions along the entire 
sequence.
143
 
2.4.1.1.5 erm(C) 
erm(C) is among the most widely disseminated and clinically important determinants of the 
MLSB phenotype in Gram positive organisms.  erm(C) has been identified in at least 32 
different genera.
95
  erm(C) is particularly prevalent among staphylococci,
1,98,101
 and while 
erm(A) was historically considered the primary erm gene in S. aureus, erm(C) prevalence has 
been shown to exceed that of erm(A) in certain contexts.  Eady et al. (1993) reported that 
erm(C) was the predominant erm gene among a highly-diverse collection of erythromycin-
resistant Staphylococcus spp., which erm(C) prevalence at 51.2% among the human isolates 
included in the study.  By comparison, erm(A) prevalence was 8.1% among the same group 
of isolates and no instances of erm(B) were reported in the study.
144
  In addition, Westh et al. 
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(1995) found that erm(C) prevalence had risen among a collection of blood-derived 
erythromycin-resistant S. aureus isolates from Denmark collected over the period of 1959-
1988, being absent prior to 1971 but becoming the predominant erm gene from 1984 
onwards.  Prior to the detection of erm(C), erm(A) had been the predominant erm gene.
102
  In 
addition, Jensen et al. (1999) detected 36 instances of erm(C) among a collection of 44 
erythromycin-resistant isolates of S. aureus of human origin, compared to 10 instances of 
erm(A) in the same group of isolates (three of the isolates carried both erm(A) and 
erm(C)).
105
  erm(C) is not exclusive to staphylococci however, and the gene has also been 
reported in Streptococcus spp., Enterococcus spp. and a number of anaerobic species 
including Bacteroides spp..
95
 
The product of erm(C) is 244 amino acids in length.
145
  erm(C) can be constitutively or 
inducibly expressed depending on the presence of a complete attenuator.
144
  The erm(C) 
induction model is the best described model of erm induction.  It is known that erm(C) can be 
induced by 14- and 15-membered macrolides, and that expression is controlled by 
translational attenuation.
98,101
  Expression of erm(C) is also dependent on the presence and 
specific structure of the leader sequence,
101,146,147
 which contains a small open reading frame 
that encodes ErmCL, a 19-amino acid leader peptide.
98
  This leader sequence is separated 
from the structural gene by a 60-bp spacer region containing 2 pairs of inverted repeats rich 
in G/C content.  These inverted repeats are involved in the folding of the leader sequence in 
different conformations during both non-inducing and inducing conditions.
98
  When the 
inducer is absent, the first and second inverted repeats anneal with each other to form stem-
loop 1+2, while the third and fourth repeats anneal with each other to form stem-loop 3+4.  
The formation of stem-loop 3+4 sequesters the ribosomal binding site of erm(C) (RBS2), 
blocking the translation of the gene.
98
  When an inducer is introduced, the structure of the 
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stem-loops is disrupted and the second and third inverted repeats are allowed to anneal and 
form stem-loop 2+3.  This frees RBS2 and allows for erm(C) translation to occur. 
The formation of the active or inactive conformation is dependent on the translational status 
of the ribosome on the erm(C)L leader cistron.
98
  In the absence of an inducer, the ribosome 
unwinds stem-loop 1+2, thereby translating erm(C)L and dissociating from the transcript.  
The inactive conformation then forms via the refolding of stem-loop 1+2.
98,148
  When an 
inducer is bound to the nascent peptide exit tunnel (NPET) of the 50S ribosomal subunit, the 
ribosomal complex is stalled on erm(C)L.  This prevents the reformation of stem-loop 1+2 
and allows for erm(C) to be translated.
98
  Stalling of the ribosome on erm(C)L depends on 
how the proteins carrying the nascent peptide interact with ribosomal nucleotides as it travels 
through the NPET;
149
 the specific position of stalling in the presence of an inducer is dictated 
by the interactions between nucleotides near the peptidyl transferase center and carboxyl 
terminus of the nascent leader peptide.
98
 
2.4.1.1.6 Mobile genetic elements carrying erm(C) 
In staphylococci, a large number of small multi-copy plasmids carrying erm(C), typically 
ranging from 2.2-2.5kb in size but with a number of exceptions, have been described.  Many 
of these plasmids are capable of mobilization between different staphylococcal species, and 
also between staphylococcal species and B. subtilis.
101
  In S. aureus, the plasmid pE194 was 
among the earliest described plasmids capable of carrying erm(C).
147,150,151
  The nucleotide 
sequence of pE194, which contains 3728bp, was first deduced by Horinouchi et al. (1982), 
who were able to localize the determinants for MLSB resistance and plasmid replication 
within pE194 using site-specific cleavage with restriction enzymes.  The erm(C) gene was 
reported to be constitutively expressed in this case.
152
  A number of other plasmids carrying 
both inducible and constitutively expressed variants of erm(C) plasmids have since been 
identified.  Many of these plasmids carry resistance regions homologous to pE194 and likely 
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share a common evolutionary origin, although the replication regions of these plasmids may 
differ from pE194.
110
 
The naturally-occurring 2475bp plasmid pT48 of S. aureus confers the MLSB phenotype and 
was completely sequenced in 1988.  It was found to contain a region homologous to pE194 
that contained erm(C) and the leader peptide that allows for inducible expression.
141
  By 
contrast, the erm(C) gene found on the closely related plasmid pNE131 is constitutively 
expressed due to a deletion of the leader sequence that regulates translational attenuation of 
the gene.
141
  Constitutively expressed erm(C) variants in S. aureus have also been described 
on pJ74 and pA22 (2.5kb), attributable to leader sequence deletions,
141,153
 and on the 2.55kb 
pRJ5, attributable to a duplication within the leader region (Oliviera 1996).  erm(C)-carrying 
plasmids have also been detected in other staphylococci.  Examples include pPV141 found in 
Staphylococcus chromogenes
154
 and pPV142 found in Staphylococcus simulans (2.5kb, 
constitutively expressed, shares homology with pPV141),
155
 A variety of erm(C)-carrying 
plasmids identified in staphylococci derived from animal sources have also been described, 
including pSES4a from Staphylococcus haemolyticus (2.3kb, constitutively expressed), 
pSES5 from Staphylococcus hominis (2.4kb, inducibly expressed), and pSES6 from 
Staphylococcus equorum (4.0kb, constitutively expressed).
95,101
  The erm(C) variants on each 
of 3 animal-sourced plasmids listed above exhibited high degrees of homology with that of 
pE194, and the methylase produced by the erm(C) on pSES6 was indistinguishable from that 
of pE194.
101
 
In other species outside of staphylococci, other erm(C)-carrying plasmids have also been 
described.  Another naturally occurring erm(C)-carrying plasmid, pIM13, has been described 
in B. subtilis.
156,157
  The plasmid is a close relative to pE5, an inducible erm(C)-carrying 
plasmid that is native to S. aureus, and the erm(C) resistance determinant was found to be 
greater than 90% homologous to that of pE194.
157
  The erm(C) gene found on pIM13, which 
Chapter 2: General Introduction 
62 
 
likely arose from pE5, was constitutively expressed due to a deletion in the leader sequence 
that is present on pE5.
157
 
2.4.1.1.7 Other erm genes 
As mentioned previously, a large number of erm gene types have been described,
95
 although 
most of these genes have not been reported among Staphylococcus spp. and Streptococcus 
spp..  erm(F), erm(Q) and erm(T) have been reported among Streptococcus spp.,
95,97,158,159
 
while erm(F), erm(G), erm(Q), erm(T), erm(Y), erm(42), erm(43) and erm(44) have been 
reported among Staphylococcus spp..
1,95,158,160,161
  An erm(A)/erm(C) recombination product 
designated erm(33) has also been reported in Staphylococcus sciuri.
162
  erm(T) has been 
detected in inducibly resistant invasive S. pyogenes isolates, group D streptococci, E faecium 
and livestock-associated MRSA.
159,163,164
  While the erm(T)-carrying element has been shown 
to be chromosomal in nature in group D streptococci, it was shown to be carried on a 4,962 
bp plasmid referred to as pRW35 in invasive macrolide-resistant S. pyogenes isolates.
159
  In 
livestock-associated MRSA, the plasmid pKKS25 carries a constitutively expressed variant 
of erm(T); the erm(T)-bearing region of this plasmid shares >99% homology with that of  
pRW35.
164
  A number of other plasmids have also been described as carriers of erm(T) in 
Lactobacillus spp.,
165,166
 in which erm(T) was first reported.  erm(T)-carrying elements have 
been shown to be mobile from S. agalactiae donors to S. agalactiae and enterococcal 
recipients.
167
  erm(Y), a variant with around 80% nucleotide homology with erm(T) and 
leader peptide similarities with erm(C), has been detected among S. aureus clinical isolates 
on the plasmid pMS97 which also harbours the macrolide resistance genes msr(A) and 
mph(C).
161
  erm(F) is also found in human pathogenic bacteria and has been reported among 
25 different genera.
95
  The gene is commonly associated with Bacteroides spp. and other 
anaerobic species,
99
 but has been reported among clinical isolates of alpha-haemolytic 
streptococci, S. agalactiae, S. aureus and other Staphylococcus spp..
1,97,158
  In Bacteroides 
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fragilis, erm(F) has been detected on the plasmid pBF4,
168
 and transposons such as Tn4351
169
 
and Tn4551.
170
 
An erm(A) subclass variant designated erm(TR) and associated with macrolide resistance in 
streptococci has been described
171
 and should be noted here.  This gene, reportedly inducibly 
expressed
172
 but also reported in constitutively resistant isolates alongside other macrolide 
resistance genes,
173
 has been shown to be widely distributed among S. pyogenes.  One report 
on a global collection of erythromycin-resistant S. pyogenes isolates demonstrated an 11.3% 
prevalence rate of erm(TR),
174
 while another study reported an erm(TR) prevalence rate of 
30% among a collection of 60 erythromycin-resistant isolates with an iMLSB phenotype (no 
instances of erm(TR) were reported among a collection of 20 isolates with a cMLSB 
phenotype.
175
  erm(TR) has also been reported among alternate beta-haemolytic 
Streptococcus spp.
176,177
 as well as less frequently in S. pneumoniae.
178
  erm(TR) has been 
shown to be carried on a number of homologous conjugative elements via mating studies 
using S. pyogenes and other gram positive organisms as recipients.
115
  In S. pyogenes, 
erm(TR) has been demonstrated to be carried on ICE 10750-RD.2, a 49-kb integrative 
conjugative element (ICE) that is integrated into DNA restriction-modification 
methyltransferases-encoding hsdM.
179
  In S. pneumoniae, erm(TR) is carried on Tn1806.
178
  
Tn1806 is slightly larger in base length than ICE 10750-RD.2 but the two elements share 
significant homology, and Tn1806 is integrated in a site homologous to spr0790 and 
corresponding to hsdM.
115,178
 
2.4.1.2 mef and macrolide efflux 
Macrolide resistance has also been attributed to genes encoding efflux mechanisms (see 
Table 2.6).  Inducible efflux-mediated resistance was first observed in S. epidermidis and was 
attributed to an incomplete ABC transporter encoded by msr(A).
98,180
  A number of other  
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Table 2.6: List of currently identified* MLSB efflux-encoding genes and the genera in which 
they have been detected.
95
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**A number of other mef genes have been described in the literature, including mef(E) and mef(I), but these are not including within 
Roberts’ online database. 
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genes encoding macrolide efflux resistance mechanisms have since been described, including 
the mef gene.  The mef gene is predicted to encode a major facilitator family efflux pump.
98
  
Macrolide efflux encoded by the mef gene group is associated with low-level resistance, and 
typically with the M phenotype rather than the MLSB phenotype associated with erm-
mediated resistance (i.e. resistance to 14- and 15- membered macrolides but not to 16-
membered macrolides, lincosamides and streptogramin B).  At least 6 mef genes have been 
described,
95,115
 with mef(A) and mef(E) being the earliest mef genes reported.
181,182
 
A gene homologous to msr(A), an ATP-binding cassette-encoding gene associated with 
macrolide efflux in staphylococci,
183
 is frequently reported downstream of mef.  This gene is 
referred to as msr(D), but other names have historically been used to describe msr(D) 
depending on the mef gene variant (such as mel).  Studies have demonstrated that mef and 
msr(D) are co-transcribed and may act as a dual efflux system,
184
 inducible by 
erythromycin.
185
  Notably, it has been reported that msr(D) may be more important than mef 
in producing the M-phenotype,
186
 and a recent study found that msr(D) can almost 
compensate for mef(A) function in S. pyogenes when it has been knocked out, while mef(A) 
is unable to do the same for msr(D), indicating that of the two genes in the efflux system, in 
S. pyogenes at least, msr(D) may be the predominant determinant of macrolide efflux rather 
than mef(A).
187
 
2.4.1.2.1 mef classification and nomenclature 
Historically, some controversy has existed regarding the classification of the separate mef 
genes.  The reported mef variants exhibit significant DNA and protein sequence homology to 
one another, with mef(A) and mef(E) exhibiting >90% protein sequence homology,
185,188
 and 
some studies have shown that there is little difference in the phenotype produced by these 2 
genes.
103
  As a result, Roberts et al. (1999) put forth the argument that the separate mef genes 
types are in fact variants of the same gene, and that all of them should simply be referred to 
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as mef(A).  If it were necessary to distinguish the separate gene types, the gene would be 
referred to as a subtype of mef(A) (e.g. mef(A) subtype mef(E)).
97
  Currently, Roberts’ online 
database lists three separate mef gene types: mef(A), mef(B) and mef(C) (see Table 2.6).
95
 
Although many previously assumed that mef(A) and mef(E) were species specific, studies 
soon emerged where mef(A) was detected in community-acquired isolates S. pneumoniae 
after it was originally detected and described in S. pyogenes.
189,190
  In recent years it has been 
shown that the various mef genes have disseminated in markedly different ways via different 
mobile elements, and often in association with different resistance markers,
191
 and that there 
may even be differences in the activities of these genes in certain contexts.  For example, one 
study looking at mef(A) in S. pneumoniae found that isolates containing mef(A) had 
consistently higher minimum inhibitory concentrations (MICs) that isolates with mef(E).
192
  
Furthermore, the 2 genes have disemminated into different species over time; while both 
genes had been identified in 5 species of streptococci by 2005, mef(E) had also been 
identified in numerous streptococcal, staphylococcal, and enterococcal species in which 
mef(A) had not yet been described.
193
  These differences have lead to many researchers to 
continue to differentiate mef(A), mef(E) and the other mef genes, despite the 
recommendations of Roberts et al..
193
  For the purposes of this review, mef(A) and mef(E) 
will be considered separate genes. 
As a result of the confusion regarding mef nomenclature, care must be taken when 
interpreting prevalence data reported by surveillance studies on the different mef genes.  In 
some cases, these studies will report the prevalence of “mef(A)” within a particular group of 
isolates but it is not always clear if these studies are reporting only this particular mef variant 
or have simply grouped multiple mef variants together as “mef(A)” in accordance with the 
recommendations of Roberts. 
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2.4.1.2.2 mef(A) 
The mef(A) gene is among the most commonly encountered mef genes in macrolide-resistant 
Gram positive organisms and was first described by Clancy et al. (1996) in S. pyogenes.
181
  It 
has since been identified in a number of other Streptococcus spp., including S. pneumoniae, 
S. agalactiae and Streptococcus suis.
193-195
 With the increasing reliance on macrolide drugs 
over time, the number of isolates that have acquired this gene has increased.  In a 2008 study, 
mef(A) was reported as the second most common macrolide resistance mechanism among 
erythromycin resistant S. pneumoniae isolates after erm(B)
114
 although surveillance studies 
have also demonstrated that the prevalence of mef(A) may exceed that of erm(B) in certain 
countries, including Canada, USA and Greece.
196
  Bley et al. (2011) also found that mef(A) 
was the most common macrolide resistance determinant among S. pneumoniae (57.7% 
among 437 macrolide resistant invasive and non-invasive isolates from Germany) and the 
second most common macrolide resistance determinant (after erm(B)) among S. pyogenes 
(31.0% among 29 macrolide resistant invasive and non-invasive isolates from Germany).
194
  
Silva-Costa et al. detected mef(A) in 31.7% of a collection of 161 S. pyogenes isolates 
exhibiting the M-phenotype collected over the period of 2007-2013; 49.4% of a similar 
collection of 156 isolates collected over the period of 2004-2006 had been previously 
reported.
44,80
  Mazzariol et al. (2007) reported that 100% of a collection of 40 clinical isolates 
of S. pyogenes exhibiting the M phenotype carried mef(A), and that 69.2% of a collection of 
26 clinical isolates of S. pneumoniae exhibiting a similar phenotype also carried mef(A).
103
 
The mef(A)/msr(D) operon is inducible in S. pyogenes.  While the mechanism has not been 
widely reported, the mechanism for the homologous system mef(E)/msr(D) has been 
reported
98
 and it is likely that mef(A)/msr(D) is controlled by a transcriptional attenuator 
mechanism in a similar fashion. 
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2.4.1.2.3 Mobile genetic elements carrying mef(A) 
Tn1207.1 was among the earliest mef(A)-carrying elements to be described and was 
originally described in S. pneumoniae.  It is a chromosomal element (integrated into celB of 
the pneumococcal chromosome) and was considered to be a defective element due to the 
truncated appearance of the 5’ end of orf8.197  Of the 8 ORFs, mef(A) was the fourth and 
msr(D) was the fifth.  Orf2 was homologous to site-specific recombinases of Gram positive 
bacteria, while orf6, orf7, and orf8 were homologous to 3 ORFs of Tn5252, a conjugative 
transposon found in pneumococci. 
In S. pyogenes, Tn1207.1 is found as part of larger prophages, and it is currently understood 
that phage transfer plays a critical role in the dissemination of mef(A) in S. pyogenes.
198
  In 
recent years, evidence has suggested that transduction plays a role in the horizontal transfer 
of these prophages.
115,199
  The 52,491-bp prophage ɸ1207.3, in which Tn1207.1 forms the left 
end, was originally referred to as a conjugative transposon (Tn1207.3) before its true nature 
as a prophage was elucidated
200
 and has been shown to be transferable between streptococcal 
species, including S. pyogenes, S. pneumoniae and Streptococcus gordonii.
200,201
  The 
element contains 58 ORFs, including the ORFs of Tn1207.1.  ɸ1207.3 integrates at a single 
site within the bacterial chromosome of S. pyogenes, namely within the putative competence 
protein-encoding comEC (for which celB is the pneumococcal equivalent).
200
  ɸ1207.3 shares 
significant sequence homology with the 58,761-bp ɸ10394.4, another prophage found in S. 
pyogenes in which Tn1207.1 is integrated.
200,202,203
  ɸ1207.3 is identical to the right hand side 
of ɸ10394.4, the latter of which is also integrated into comEC, but ɸ10394.4 carries an 
additional left hand region approximately 6kb in length.
199,203
  Of the 2 elements, ɸ1207.3 is 
the more common among S. pyogenes isolates carrying the tetracycline-susceptible M-
phenotype.
204-206
  In addition, ɸ1207.3 has been detected in S. agalactiae,177 while ɸ10394.4 
has been detected in S. gordonii (viridans variants) and Streptococcus salivarius.
207
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In addition, alternate mef(A)-carrying elements in which tetracycline resistance determinant 
tet(O) is also carried have also been described in S. pyogenes.
198
  The most extensively 
described of these elements is the ~60 kb ɸm46.1,115,199 which is not integrated into the same 
chromosomal site as ɸ1207.3 and ɸ10394.4 but is instead integrated into rum, a coding 
region for an RNA uracil transferase.
200,204
  Particular regions of ɸ1207.3 outside of the 
Tn1207.1 segment share significant homology (>70%) with ɸm46.1, although overall the 
homology is not shared to the same degree as that with ɸ10394.4.200  It has been shown to be 
transferable by mating experiments with S. pyogenes as the recipient.
208
  ɸm46.1 is 
widespread among S. pyogenes, but while ɸm46.1 has not been detected in any other 
streptococcal species outside of S. pyogenes,
199
 it has been shown to be transferable to S. 
agalactiae, S. suis, and S. gordonii with negligible fitness cost, and in the case of S. suis, 
ɸm46.1 appeared to grant the species a noticeable fitness advantage.199  On the other hand, no 
transfer was demonstrated when S. pneumoniae, Streptococcus oralis, S. salivarius, and E. 
faecalis were the recipients.
199,208
 
2.4.1.2.4 mef(E) 
mef(E) was first reported in S. pneumoniae shortly after the first description of mef(A).
182
  
mef(E)  exhibits >90% homology to the mef(A) detected in Tn1207.1.
115
  As described 
previously, the distinction of mef(E) from mef(A), in spite of the high degree of homology, 
has been justified by many researchers in part by the distinct mobile genetic elements that 
encode these genes.  mef(E) has since been reported as being widespread among S. 
pneumoniae (with some isolates being detected with mef(E) and erm(B)) and has been 
detected in a variety of other species,
193
 including S. pyogenes and S. aureus.
115,192,209-211
 
A number of studies have investigated the prevalence of mef(E) among particular groups of 
macrolide resistant isolates.  In one study, from a collection of 99 erythromycin resistant S. 
pneumoniae isolates from healthy Polish children aged 3-5 years, eight carried mef(E) (all 
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alongside erm(B)).
212
  From a collection of 69 macrolide resistant S. pneumoniae isolates 
obtained via the PROTEKT study over the period of 1999-2000, all of which had previously 
been identified as both erm(B) and mef positive, 18 were found to carry mef(E) rather than 
mef(A).
213
  Among a collection of 70 Canadian paediatric multi-resistant S. pneumoniae 
isolates collected over the period of 1998-2004, 66.2% carried mef(E) and 8.5% carried 
mef(E) and erm(B).
214
  Jeric et al. (2007) detected mef(E) in nine MRSA isolates out of a 
small collection of 11 nosocomial isolates.
209
  Silva-Costa et al. detected mef(E) in a single 
isolate out of a collection of 161 S. pyogenes isolates exhibiting the M-phenotype collected 
over the period of 2007-2013; none had been detected in a collection of 156 isolates collected 
over the period of 2004-2006.
44,80
  Mazzariol et al. (2007) found that 30.8% of a collection of 
26 clinical isolates of S. pneumoniae exhibiting the M phenotype carried mef(E).
103
 
Induction of the mef(E)/msr(D) system is controlled at the level of transcription. It has been 
suggested that induction of mef(E) is controlled by transcriptional attenuation;
98,215
 a putative 
leader peptide encoded upstream of mef(E) shares similarities to the leader peptide of the 
transcriptionally-attenuated erm(K).
98
  mef(E)/msr(D) can be induced by the 16-membered 
macrolides tilmicosin and rosamicin,
215
 in addition to 14- and 15-membered macrolides.  
Given that none of telithromycin, tilmicosin or rosamicin contain a C3 cladinose, it has been 
suggested that cladinose is not necessary for mef(E)/msr(D) to be induced. 
It is worth noting that mef(E) can also be induced by the macrophage-borne antimicrobial 
peptide LL-37, possibly via a different pathway than macrolide-mediated induction, 
suggesting that induction may occur at the site of infection.
98
  This may imply that the degree 
of mef(E)-mediated resistance in bacterial isolates carrying this particular gene may be much 
higher in the clinical setting than would be suggested by in vitro MIC testing.
216
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2.4.1.2.5 Mobile genetic elements carrying mef(E) 
While mef(E) share a high degree of homology with mef(A), the elements one which it has 
been described differ significantly.  As described by Gay and Stephens (2001), the genetic 
element carrying mef(E) in S. pneumoniae is mega (macrolide efflux genetic assembly).
184
  It 
contains 5 ORFs that are closely related to the last 5 ORFs of the mef(A)-carrying Tn1207.1.  
The first of these 5 ORFs is mef(E) and the second ORF is msr(D) (previously referred to as 
mel).  There are a number of insertion sites that have been described within the genome of S. 
pneumoniae,
184
 with each site possibly being associated with different variants of mega.
115
 
In other instances of mef(E)-carrying S. pneumoniae, the mef(E)-carrying element was found 
to be a composite element where mega had been inserted in another transposon.  Examples of 
these composite transposons include Tn2009 and Tn2010, where mega is inserted within orf6 
of the tet(M)-carrying elements Tn916
217
 and Tn6002,
137,139
 respectively, and oriented in the 
opposite direction of tet(M).
115
  These elements provide a vehicle for the simultaneous 
transfer of tet(M), mef(E) and (in the case of Tn2010) erm(B).  Indeed, streptococcal isolates 
carrying both mef(E) and erm(B) together have been detected.  In both Tn2009 and Tn2010, 
mega was similar in composition to a mega variant reported in S. salivarius that contained an 
additional ORF (orf6) between orf4 and orf5.
218
  In vitro attempts at conjugated either 
element have been unsuccessful,
137
 although Tn2009 has been shown to be transformable.
217
 
2.4.1.2.6 Other mef genes 
Mosaic mef(A)/mef(E) variants of mef, in which the 5’ end is identical to mef(A) and the 3’ 
end is identical to mef(E), have been detected in S. pyogenes, and were shown to be 
consistently associated with tet(O).
191
  The element carrying this mosaic mef(A/E) was found 
to be a variant of ɸm46.1. 
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The mef(I) gene, detected in S. pneumoniae, S. pyogenes and group C streptococci, exhibits 
>90% homology to both mef(A) and mef(E).
186,219
  mef(I) is carried on a composite element 
named 5216IQ complex.  The complex consists of an element (IQ) inserted into a defective 
variant of Tn916, which is in turn inserted into a defective variant of Tn5252.  The resulting 
element (30505 bp) consists of two halves.  The left half (15316 bp) is formed from segments 
of Tn5252 and Tn916, in which the tet(M) is silent.  The right half (15115 bp) contains mef(I) 
adjacent to its own msr(D) variant, along with the chloramphenicol resistance gene catQ, 
marking the first time this gene was detected and linked with mef in S. pneumoniae.
220
  
Induction of mef(I) has not been demonstrated.
98
 
Finally, mef(O), mef(B), mef(C) and mef(G) are additional mef gene variants that have 
recently been described in streptococci, all associated with their own msr(D) variants.  mef(B)  
was initially described in S. agalactiae;
219
 the Roberts database does not list Streptococcus as 
an associated genera with erm(B) but does list Escherichia.
95
  mef(G) has been detected in S. 
agalactiae and Streptococcus dysgalactiae.
219,221
  The elements that carry these mef genes 
have not been characterized to the same extent as mef(I). 
2.4.1.2.7 Other acquired efflux genes 
Aside from the mef gene group, numerous other AMRGs coding for efflux mechanisms with 
action against MLSB antibiotics have been described, although many of them are less 
commonly encountered among common respiratory pathogens than mef.  Many of these 
mechanisms are not major facilitators like mef, but are instead ATP-binding transporters.
95
  
msr(A) was among the first of these described.  Originally reported in S. epidermidis, studies 
have commonly encountered this gene in macrolide resistant isolates of S. epidermidis,
222
 and 
it is also frequently reported in clinical isolates of S. aureus.
223
  In addition, msr(A) has been 
detected in Streptococcus spp., Corynebacterium spp. and Enterococcus spp. (Roberts 2008, 
Chancey 2012).
1,98
  msr(A) typically has action against erythromycin and streptogramin B, 
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but not against 16-membered macrolides or lincosamides.
95,98,224
  Due to similarities between 
the leader peptides of msr(A) and mef(E), it is believed that induction of msr(A) is controlled 
at transcription.
98
  A number of plasmids have been identified as carriers of msr(A), including 
the msr(A)-, erm(Y)- and mph(C)-bearing pMS97 detected in S. aureus
160,161
 and pUL5054 
detected in S. epidermidis.
95,183
  Other msr variants have also been described, including 
msr(C), msr(D) (found in a linkage with mef) and msr(E). 
Another macrolide efflux gene, car(A), results in efflux against carbomycin, an uncommonly 
used 16-membered macrolide with a similar range of activity to that of erythromycin.  Other 
ATP-binding transporter gene groups include lsa, vga and ole, though these tend to be more 
potent against particular lincosamides and streptogramin antibiotics rather than erythromycin 
and other macrolides.  lmr(A), like mef, is a major facilitator rather than an ATP-binding 
transporter, but is more potent against lincomycin than erythromycin.
1,95,97
 
2.4.1.3 Macrolide inactivation 
A third class of genes has been described that also have inhibitory activity against macrolides 
and other antibiotics classified under the MLSB group.  These genes code for enzymes that 
inhibit the drug by acting on them directly and deactivating them rather than by altering the 
macrolide binding site or by efflux action (see Table 2.7).  The mph genes encode a 
phosphorylase that inactivates macrolides through the introduction of a phosphate on the 2’-
hydroxyl group of the amino sugar.
225
  At least seven mph genes have been described.  They 
have typically been reported among in Gram negative bacteria,
95
 but they have also been 
reported in Gram positives and mph(C) in particular has been reported among S. epidermidis 
of human and animal origin.
222,226,227
  A recent study by Juda et al. (2016) detected mph(C) 
among erythromycin-resistant S. epidermidis respiratory isolates from lung cancer patients.  
Most instances of the genes were in combination with erm genes and/or msr(A); 2 isolates  
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Table 2.7: List of currently identified* MLSB inactivating enzyme-encoding genes and the 
genera in which they have been detected.
95
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with mph(C) alone presented with an MSB phenotype.
222
  The ere genes, of which ere(A) and 
ere(B) are described and which have also been historically associated with Gram negative 
organisms, code for esterase enzymes that hydrolyze the lactone ring of the macrocyclic 
nucleus.
225
  ere(A) has been reported among a slightly wider variety of species than ere(B).
95
  
Ere-like activity has been reported in clinical isolates of S. aureus for some time
228
 and both 
have been detected in S. aureus and coagulase-negative staphylococci from animal 
sources.
229
  ere primarily produces high-level resistance to erythromycin.  The mph and ere 
genes have typically been plasmid-borne,
95
 although mph(E) has also been reported 
chromosomally in P. multocida sourced from animals.
230
 
Other genes encoding deactivating genes have been described, but these have not been widely 
reported to have action against macrolides.  The lyase-encoding vgb(A) and vgb(B) are 
associated with streptogramin B resistance while the transferase-encoding lnu and vat genes 
are associated with lincomycin and streptogramin A resistance, respectively.  These genes 
have also been detected on plasmids.
95
 
2.4.2 Ribosomal binding site alterations associated with macrolide 
resistance 
In addition to AMRGs, a number of chromosomal mutations have also been associated with 
the development of macrolide resistance.  These mutations typically occur in regions 
associated with structural components of the bacterial ribosome, and the resulting changes to 
the ribosomal binding site of the macrolides ultimately reduce the binding affinity of the 
macrolide to the ribosome.  The most commonly described chromosomal alterations occur in 
genes coding for the L4 and L22 ribosomal protein genes, both of which code r-proteins that 
are components of the 50S subunit of the ribosome,
231
  and from mutations in the 23S rRNA 
segment of the 50S segment of the bacterial ribosome,
1
 the most common target for 
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antibiotics which act by inhibiting protein synthesis.  This is somewhat reminiscent of the 
effect of the erm gene group, although the resistance phenotype produced by these mutations 
will not necessarily be the same as that of erm.  These mutations have been shown to develop 
under antibiotic pressure
232
 and can be passed on to daughter cells, but generally cannot be 
passed on horizontally to different genera.
1
 
2.4.2.1 L4 and L22 
The presence of ribosomal protein alterations have been reported in macrolide resistant 
isolates for some time.  The proteins that have been the most consistently researched have 
been the L4 and L22 proteins, which lie within the peptide exit tunnel of the 50S subunit.  
Macrolides bind in a narrow part of this tunnel between the peptidyl transferase centre and a 
constriction in the tunnel near L4 and L22, with some macrolides and macrolide derivatives 
making contact with these proteins.
4
  As a result these proteins are believed to play a 
significant role in the binding of macrolides to the ribosomal binding site.
233
 
Alterations in these proteins can hinder the ability of macrolides to bind to the ribosome.  
Alterations in highly-conserved regions of these proteins as a result of mutations in the genes 
coding for them (including single base substitutions, insertions and deletions) have long been 
reported to be associated with macrolide resistance in a number of species including E. coli.
96
  
Chittum and Champney (1994) reported that an A to G substitution at the first position of 
codon 63 in the L4-encoding rplD resulted in a lysine to glutamic acid change in L4 in an 
erythromycin-resistant E. coli mutant, whereas a nine base pair deletion resulting in a three 
codon loss in the L22-encoding rplV resulted in an altered L22 in another erythromycin-
resistant E. coli mutant.
234
  Other Gram negative species in which L4 and/or L22 alterations 
have been reported and associated with macrolide resistance include Campylobacter spp. and 
Rickettsia spp..
1
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Among Gram positive organisms, L4 and/or L22 alterations have been reported in E. faecalis, 
B. subtilis, S. aureus and S. pyogenes.
1
  L4 and L22 alterations generated in pneumococci in 
vitro have been shown to be associated with resistance.  Tait-Kamradt et al. (2000) were able 
to generate two S. pneumoniae mutants bearing alterations in L4.  One mutant contained a 
C69D alteration, while the other mutant contained an INS 67SQ.  Both mutants saw an 
approximate 4-fold increase in MICs of 14-, 15- and 16-membered macrolides and 
streptogramin B compared to a susceptible isolate, but lincosamide and telithromycin MIC 
saw more modest increases.
232
  In addition, clinical strains isolated from Europe were found 
to carry a three amino acid substitution (69GTG71  TPS) in L4 and were associated with 
an MSB phenotype (resistance to macrolides and streptogramin B only).  Another strain from 
Canada with a similar phenotype carried an insertion of six amino acids (REKGTG) after 
position 71. The macrolide MICs for this Canadian isolate were not as high as the European 
isolates and the alteration appeared to have an impact on growth time, although the 
telithromycin MIC was higher.
235
  L22 alterations such as G95D, P99Q, A93E, P91S and 
G83E have been associated with resistance to streptogramin B and low levels of clindamycin 
and macrolides in S. pneumoniae.
236
 
2.4.2.2 23S 
Direct chromosomal alterations of the binding site of macrolides are also known to reduce the 
susceptibility of bacteria to macrolides.  23S rRNA alterations have been reported in a variety 
of Gram positive and Gram negative species, including but not limited to S. aureus, S. 
pyogenes, S. pneumoniae, E. coli, Neisseria gonorrhoeae and Campylobacter spp..
1
 
Among the most widely reported and investigated 23S rRNA alterations are those of A2058 
in domain V (using E.coli numbering), a nucleotide residue that serves as a common binding 
site for macrolides.  In S. pneumoniae, an A2058G alteration has been shown to be associated 
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with the MLSB phenotype in resistant isolates generated in vitro,
232
 and a similar effect was 
observed in Propionibacterium spp..
237
  A2058G has also been reported in a variety of other 
species,
238
 including E. coli (associated with resistance to erythromycin and lincosamides),
231
 
Mycobacterium spp. (associated with resistance to clarithromycin and occasionally 
azithromycin)
239,240
 and Helicobacter pylori (associated with the MLSB phenotype).
241,242
  
Other alterations of the wild-type A2058, including A2058C and A2058U, have also been 
associated with macrolide resistance in these species.
238
  Furthermore, alterations at adjacent 
positions such as G2057 and A2059 have also been observed and associated with macrolide 
resistance;
238
 in S. pneumoniae, an A2059G alteration was associated with an azithromycin 
MIC of >200 µg/mL, but was not associated with an increase in resistance against 
streptogramin B like that observed with A2058G.
232
  Clinical strains of S. pneumoniae with 
this alteration have also been detected and were associated with an ML phenotype (resistance 
to macrolides and lincosamides only).
235
  G2057 alterations reportedly confer resistance to 
14-membered macrolides in E. coli and Propionibacterium spp., but not to 16-membered 
macrolides.
238
 
C2611 is another common hotspot for erythromycin resistance-inducing alterations, and such 
alterations confer a similar phenotype to that resulting from G2057 alterations.
238
  Tait-
Kamradt et al. (2000) demonstrated an association with C2611A and C2611G and macrolide 
resistance in isolates of S. pneumoniae generated via macrolide passage in vitro,
232
 while 
Vannuffel et al. (1992) detected C2611U in erythromycin-resistant E. coli.
243
  Also in E. coli, 
a U754A alteration in domain II has been shown to be associated with low level 
erythromycin resistance,
244
 while an A752 deletion has been associated with erythromycin, 
azithromycin and clarithromycin MICs of >32 µg/mL in S. pneumoniae.
236
  Alterations 
within domain II have also been associated with erythromycin resistance in E. coli, with 
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particular three consecutive nucleotide group deletions (including CAU1321 and AUG1232) 
being sufficient to confer resistance.
245
 
Many species contain multiple copies of 23S.  For example, S. pneumoniae has been shown 
to carry four copies of 23S.
232
  Intriguingly, it has been demonstrated that it is not necessary 
for all of these 23S operons to carry a mutation for a macrolide resistance phenotype to 
develop.  For example, in Streptomyces ambofaciens, only one of its four copies is required to 
carry a mutation such as A2058G to produce erythromycin resistance,
246
 while it has been 
shown that only one copy is required to be altered in Helicobacter spp. and M. 
pneumoniae.
232
  In the study of Tait-Kamradt et al. (2000), the C2611G mutant (in which all 
four copies of 23S bore the alteration) was more resistant to 14- and 15-membered 
macrolides, as well as streptogramin B and telithromycin, than the C2611A mutant (in which 
three of the four copies bore the alteration), but it was not clear if the copy number was the 
determinant of this difference or if it was related to the specific amino acid difference.
235
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2.5 Macrolide resistance mechanisms in NTHi 
The mechanisms behind macrolide resistance in NTHi are not as well understood as in other 
species.  The current evidence suggests that macrolide resistance in NTHi is mediated 
primary by chromosomal factors with comparatively few reports of AMRGs.  In some 
studies, isolates exhibiting increased macrolide resistance lack any known chromosomal 
mutations or AMRGs, leaving the specific cause of the resistance in these cases unresolved.  
This section will examine the current evidence for both chromosomal mutations and AMRGs 
in macrolide-resistant NTHi. 
2.5.1 Chromosomal multi-drug efflux and AcrAB 
Among many species, inherent multi-drug efflux systems have been described.  In NTHi, 
such systems include those encoded by homologs of ydeA, yieO and norM, although the 
effect of many of these systems in NTHi has been reported to be minimal.
247
  The 
AcrA/AcrB/TolC homolog efflux system has been well described and is the primary H. 
influenzae efflux mechanism of this type.
247
  It was established years ago that the H. 
influenzae genome contains a three-gene complex that is homologous to the acrRAB complex 
(consisting of homologs of acrR (the regulatory gene controlling expression of the complex), 
acrA and acrB) found in E.coli.
248
  The AcrAB efflux complex (consisting of the outer 
membrane transporter TolC, the membrane fusion protein AcrA and the inner membrane 
transporter AcrB) is known to contribute to antibiotic efflux in E. coli,
249
 and Sanchez et al. 
(1997) were able to demonstrate that expression of the homologous system contributed to the 
baseline macrolide MIC levels typical of wild-type strains of H. influenzae, and that 
disruptions of the acrA and acrB homologs resulted in hyper-susceptibility to 
erythromycin.
250
  Peric et al. (2003) also reported that hyper-susceptible strains lacked any 
efflux mechanism such as that seen in hyper-resistant and base-line strains,
90
 indicating that 
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this efflux mechanism may be the reason that wild-type NTHi strains have base-line MICs 
that are higher than is observed in base-line Gram positive species.  Trepod et al. (2004) 
demonstrated that inactivation of the individual components of AcrAB resulted in increased 
susceptibility to erythromycin and other antibiotics in H. influenzae.
247
 
Given that MICs in isolates carrying the AcrAB system and similar systems are still relatively 
low compared to highly-resistant organisms, there has historically been some contention as to 
whether this kind of macrolide efflux is clinically relevant in H. influenzae.
37
  However, there 
is recent evidence that suggests that overexpression of acrB resulting from mutational 
changes can lead to high-level macrolide resistance.  In particular, Seyama et al. (2016) 
reported that all isolates among a small collection of respiratory NTHi isolates with high-
level clarithromycin resistance carried a frameshift mutation within acrR and exhibited 
increased transcription of acrB.  No isolates were found to carry erm(B) or mef(A), and all 
isolates tested negative for amino acid substitutions within the L4 and L22 ribosomal 
proteins.  In addition, transformation of the acrR variant into susceptible recipients resulted in 
the same increased acrB expression and clarithromycin MIC as the donor strain.
251
  This 
outcome indicates that not only can the AcrAB system cause high-level resistance in the 
absence of other known mechanisms, but that acrR may in fact play a significant role.  The 
authors also note that since the mutation sites within acrR varied among their isolates, acrR 
may act as a hotspot for such mutations.
251
 
2.5.2 Ribosomal mutations 
The presence of mutations in chromosomal genes coding for ribosomal structural components 
in macrolide-resistant NTHi isolates has been documented, and the presence of these 
chromosomal mutations has formed the basis of classification of NTHi isolates based on their 
resistance profile to macrolides.  The majority of isolates that form the base-line with respect 
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to macrolide susceptibility for this species lack chromosomal mutations in ribosomal 
structural elements associated with macrolide resistance, but do exhibit inherent macrolide 
efflux.  A small proportion of isolates lack this efflux mechanism and ribosomal alterations 
and are defined as hyper-susceptible isolates.  Finally, occasional highly macrolide-resistant 
isolates typically exhibit the inherent efflux but also carry at least one ribosomal 
alteration.
90,252
 
Peric et al. (2003) reported that 28 out of a collection of 31 H. influenzae isolates with high-
level macrolide resistance had alterations in L4, L22 or 23S rRNA (all in domain V).  Among 
the seven isolates with 23S rRNA alterations detected (five of which also carried L4 and/or 
L22 mutations), A2058G (based on E. coli numbering) was detected in two isolates (with one 
isolate carrying an additional G2160U), and the remaining isolates carried alterations within 
the 2160-2164 range of positions, including one isolate with a GGA2160-2162UAU 
alteration.  The majority of these isolates with 23S rRNA alterations, including both isolates 
with A2058G alterations, had azithromycin and/or clarithromycin MICs of >64 µg/mL.
90
  In 
a subsequent study including many of the same isolates as Peric et al. (2003), Bogdanovich et 
al. (2006) reported the presence of domain II 23S rRNA alterations among azithromycin- and 
clarithromycin-resistant isolates, with A654G, G884U and C894A being reported among 
multiple isolates.  Only one isolate carried a domain II alteration (A654G) with no other 
alterations; this isolate had MICs of >32 µg/mL against clarithromycin and 4 µg/mL against 
azithromycin.
252
  It is worth noting here that while NTHi is known to carry at least 6 copies 
of 23S rRNA, reports on the presence of 23S rRNA have typically not mentioned whether all 
copies carry the mutations listed here, or if only some of the copies have been altered with the 
other copies remaining unchanged.  Therefore, it is not currently clear whether there is a link 
between the number of copies carrying alterations and the emergence of macrolide resistance 
in NTHi. 
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In the study of Peric et al. (2003), seven isolates solely carried an L4 protein alteration.  One 
isolate bore an INS 63GT alteration, and the remaining six carried a single point mutation: 
K61Q (one isolate), T64K (one isolate), A69S (one isolate), T82I (one isolate) or G65D (two 
isolates).  Clarithromycin MICs ranged from 32 to >64 µg/mL for these isolates, and 
azithromycin MICs ranged from 8 to 64 µg/mL.  Eleven isolates carried a L22 protein 
mutation alone.  Two isolates carried a G91D substitution and exhibited clarithromycin and 
azithromycin MICs of 16 µg/mL and 8 µg/mL, respectively.  The remaining isolates bore 
amino acid insertions or substitutions; clarithromycin MICs ranged from 16 to >64 µg/mL, 
and azithromycin MICs ranged from 8 to >64 µg/mL.  Another eight isolates carried 
alterations in multiple sites.  Five of these isolates carried 23S rRNA alterations in positions 
2160-2164 (based on E. coli numbering).  A T64K alteration in L4 and a G91D alteration in 
L22 were paired together in five isolates; three of these five isolates also carried a C2164G 
alteration in 23S rRNA.  Of the remaining three isolates, one carried L4 and 23S rRNA 
alterations, one carried L22 and 23S rRNA alterations, and one carried L4 and L22 
alterations.  The MICs for the eight isolates with multiple alterations ranged from 32 to >64 
µg/mL against clarithromycin and from 8 to >64 µg/mL against azithromycin.
90
  In a more 
recent study assessing the effect of macrolide and quinolones on eradication of H. influenzae 
in COPD patients and resistance emergence in persistent H. influenzae isolates, Pettigrew et 
al. (2016) reported the emergence of a G91D alteration in L22 in persistent isolates derived 
from patients with COPD after undergoing macrolide therapy; L22 alterations were not 
detected in the same patients prior to undergoing macrolide therapy.  The persistent isolates 
that developed this L22 alteration exhibited 4-fold increases in azithromycin MIC values.  L4 
and 23S rRNA alterations were not detected among any isolates in the same study.
29
 
Note that the presence of alterations in certain ribosomal structural elements does not appear 
to ensure that high-level macrolide resistance will develop in NTHi.  Bogdanovich et al. 
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(2006) reported three isolates carrying an L4 alteration (two with K61Q and one with A69S) 
alongside multiple alterations of 23S rRNA in domain II (including A654G, G884U and 
C894A), all of which exhibited azithromycin MICs of ≤1µg/mL and clarithromycin MICs of 
8 µg/mL.
252
  Interestingly, Peric et al. (2004) reported the presence of L22 R88P alterations 
in both high-resistant and hyper-susceptible strains of NTHi.  Upon further investigation, it 
was found that the hyper-susceptible isolates carrying this mutation lacked the ability to 
pump macrolides via an efflux mechanism.  This suggested that particular alterations in L22 
may not be sufficient to cause high-level macrolide resistance in NTHi alone, and that it 
requires supplementation by an unaltered inherent efflux mechanism such as AcrAB/TolC to 
result in a resistance phenotype.
253
  This also reaffirms the importance of inherent efflux in 
the development of high-level macrolide resistance in NTHi. 
2.5.3 Acquired macrolide resistance genes in NTHi
†
 
Historically, AMRGs have not been widely associated with macrolide resistance in NTHi, 
and studies reporting on macrolide resistance mechanisms in NTHi have typically been 
unable to detect AMRGs among macrolide-resistant isolates.  In a study by Peric et al. (2004) 
involving 31 macrolide-resistant NTHi isolates, no isolate was found to carry mef(A), 
erm(A), erm(B), or ere(A).
253
  In a follow-up to that study including many of the same 
isolates and some new isolates, Bogdanovich et al. (2006) also failed to detect the presence of 
mef(A), erm(A), erm(B), or ere(A).
252
  More recently, Seyama et al. (2016) were not able to 
detect mef(A) or erm(B) among a smaller collection of 7 clarithromycin-resistant isolates, 
with resistance instead being attributed to increased transcription of the acrB gene as a result 
of alterations of the acrR regulatory gene,
251
 and Pettigrew et al. did not detect erm(A), 
                                                             
†FOOTNOTE: The content of the literature review is based on publications up to December 16th 2016 in 
account of a January 6th 2017 thesis submission date.  However, a very recent study – available in advance 
access online from December 20th 2016 – has reported the detection of an isolate of H. influenzae with 
mef(A).
254
  This will not be discussed in the literature review or Chapters 3-7, but is briefly discussed in the 
general discussion of Chapter 8. 
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erm(B), erm(C), erm(F) or mef(A) in any isolates (n = 200, or 100 persistent strain pairs) 
included in their study (MIC increases were either attributed to L22 alterations or the 
mechanism was not determined).
29
 
In recent years, there has been one report where AMRGs have been widely reported among 
NTHi isolates.  In a study by Roberts et al. (2011) regarding the prevalence of particular 
macrolide resistance genes among CF isolates of NTHi, the authors aimed to characterise the 
macrolide resistance mechanisms in NTHi isolates taken from CF patients enrolled in a 
placebo-controlled azithromycin trial.  Each isolate was tested for phenotypic macrolide 
resistance by E-test MIC, as well as for the presence of L4 and L22 mutations (23S rRNA 
was not investigated), and the erm(A), erm(B), erm(C), erm(F) and (undifferentiated) mef(A) 
genes.  The authors found that 25.5% of their strains were resistant to azithromycin and 
erythromycin (using BSAC interpretive criteria; erythromycin MIC > 8 µg/mL; azithromycin 
MIC > 4 µg/mL), and 73.6% were intermediate to both macrolides (using BSAC interpretive 
criteria; 1 µg/mL ≤ erythromycin MIC ≤ 8 µg/mL; 0.5 µg/mL ≤ azithromycin MIC ≤ 4 
µg/mL).  None of these resistant strains carried L4 or L22 mutations, but 93% of all the 
strains included in the study (regardless of phenotypic macrolide resistance profile) carried at 
least one of erm(B) (31% prevalence), erm(F) (29% prevalence) and mef(A) (74% 
prevalence).  The remaining isolates that were negative for these 3 genes were additionally 
tested for and found to carry at least one of erm(A) and erm(C), resulting in 100% of the 
isolates included in the study carrying at least one AMRG.  The author also note that erm(A) 
and erm(C) prevalence may have been underestimated as only a small number of the isolates 
in the study were tested for these genes.
93
 
Furthermore, the authors demonstrated that select donors were able to transfer these genes to 
H. influenzae Rd KW20 as well as E. faecalis JH2-2 via conjugation.  The H. influenzae 
transconjugants demonstrated an up to a 48-fold increase in erythromycin MIC and up to a 
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24-fold increase in azithromycin MIC compared to the recipient, while the E. faecalis 
transconjugants demonstrated a 16-fold increase in erythromycin MIC compared to the 
recipient.
93
  These findings suggested that these genes were associated with mobile genetic 
elements, and that NTHi could act as a donor and recipient of these genes.  Given that these 
genes are detectable among respiratory bacteria and P. aeruginosa, the authors speculated 
that selective pressure via continuous antibiotic exposure associated with CF therapy might 
facilitate the exchange of these AMRGs in vivo.
93
 
The ability to successfully transfer AMRGs to H. influenzae by conjugation was not a novel 
finding.  Chung et al. (1999) were able to transfer erm(F) to H. influenzae RD8 (erythromycin 
MIC = 1 µg/mL) from both Prevotella bivia and Haemophilus aphrophilus (since re-
classified as Aggregatibacter aphrophilus), with transconjugants exhibiting increased 
erythromycin MICs (64 µg/mL),
158
 while Luna et al. (2000) have previously described the 
transfer of mef from S. pneumoniae to H. influenzae RD8 (phenotype changes were not 
reported).
255
  However, this study represented the first report of erm(A), erm(C) and erm(F) 
among clinical NTHi, and the authors also state that this is the second report of mef(A) and 
erm(B) among NTHi isolated from CF patients.
93
  Furthermore, the authors of the study go 
on to state that there may be some correlation between the acquisition of these genes by 
NTHi and the development of macrolide resistance in NTHi.  This was based on the 
observation that 56% of the macrolide-resistant NTHi isolates in the study carried at least 2 
macrolide genes.  By comparison, 23% of the isolates that were defined as intermediate to 
macrolides carried at least 2 genes.
93
  However, it is worth noting that the MIC values of 
many of the isolates included in the study did not appear to be highly raised compared to a 
typical wild-type strain despite carrying at least one AMRG.  Many isolates carrying an erm 
gene were defined at “intermediate” according to the MIC results and did not demonstrate the 
high level resistance that would be typically be produced by these genes.  Out of 7 isolates in 
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the study that carried all of mef(A), erm(B) and erm(F), only 2 had MIC values falling above 
the resistance breakpoint, with the remaining defined as “intermediate”, and there was 1 
particular isolate that carried erm(B) and mef(A) simultaneously but was susceptible to 
erythromycin.
93
  The reason for these particular findings is not clear but suggests that there 
may be other factors involved that allow for these genes to grant macrolide resistance in 
NTHi. 
2.5.4 Acquired MLSB resistance genes in other Haemophilus spp. 
Haemophilus parainfluenzae is closely related to H. influenzae and an occasional 
opportunistic pathogen in humans.  H. parainfluenzae, which is differentiated from H. 
influenzae based on its lack of requirement on X factor (haemin) for growth, has been 
associated with a number of infections including urethritis and respiratory infections (in 
which macrolides may be prescribed).  Notably, it is a known cause of infective endocarditis 
and is included in the HACEK group of fastidious Gram-negative bacteria that can cause this 
disease.
256
  It has previously been demonstrated that H. influenzae and H. parainfluenzae are 
able to share mobile antibiotic resistance determinants with each other, and suggested that H. 
parainfluenzae may act as an important reservoir for antibiotic resistance genes and plasmids 
for H. influenzae.
37
 
Tinguely et al. (2013) reported the presence of multi-drug resistance in 2 separate isolates of 
H. parainfluenzae (both from urethral swabs of homosexual men, isolated 5 months apart).  
The isolates possessed identical phenotypic and genotype characteristics.  The isolates 
exhibited high-level resistance to erythromycin, azithromycin and clarithromycin (MIC > 256 
µg/mL for all 3 drugs) and were additionally resistant to a broad range of β-lactam antibiotics 
(but non-resistant to meropenem), ciprofloxacin and levofloxacin, tetracycline, and 
chloramphenicol.  The isolates were susceptible to cotrimoxazole and rifampin.  Analysis of 
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the isolates revealed that both carried mef(A) and an L4 mutation (A69S).  The authors did 
not detect any known macrolide resistance-associated alterations in L22 or 23S, and erm(A), 
erm(B), erm(C), erm(D) and erm(F) were not found.
257
  A subsequent report revealed that 
mef(A) was carried on the mega element.
258
 
The authors attribute the high-level resistance to macrolide in the isolates to the presence of 
mef(A) and the A69S alteration of L4.
257
  However, it is not certain how much each 
mechanism was contributing to the reported phenotype.  The mef genes typically produce a 
moderate increase in erythromycin MIC and are not normally associated with high-level 
resistance across all of erythromycin, azithromycin and clarithromycin.  Meanwhile, the role 
of macrolide resistance-associated chromosomal mutations have not been widely investigated 
in H. parainfluenzae, although in H. influenzae, the A69S was previous reported in an isolate 
with azithromycin and clarithromycin MICs of 32 µg/mL.
90
  On the other hand, A69S has 
also been reported (in parallel with multiple mutations in domain II of 23S) in an H. 
influenzae isolate with azithromycin and clarithromycin MICs of 0.5 µg/mL and 8 µg/mL, 
respectively.
252
  The high MICs observed here may be attributable to a combined effect 
between the L4 mutation and mef(A).  The combined effect of chromosomal mutations and 
AMRGs on phenotypic macrolide resistance has not been widely studied, although the 
previously discussed report of the inability of L22 to increase macrolide resistance in the 
absence of an underlying efflux (such as acrAB)
253
 does provide a precedent for the 
possibility of particular mechanisms having a greater effect on macrolide resistance when in 
the presence of another mechanism to supplement it. 
Haemophilus parasuis is the causative agent of Glässer’s disease in swine.  Chen et al. (2010) 
have reported the presence of the transferase-encoding lincosamide resistance gene lnu(C) in 
an isolate of H. parasuis exhibiting high MICs of lincomycin and clindamycin, but a low 
MIC of erythromycin.  lnu(C) was carried on a 6320bp-long plasmid referred to as pHN61; 
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transformation of this plasmid into susceptible isolates resulted in an increase in MICs of 
lincomycin (2 to 32 µg/mL) and clindamycin (2 to 16 µg/mL).
259
  pHN61 appeared to share 
little homology with plasmids previously reported in other H. parasuis at the time, but shared 
similarities with the multi-resistance plasmid pHB0503 found in Actinobacillus 
pleuropneumoniae,
260
 a respiratory pathogen also found in swine.  In addition, Yang et al. 
(2013) reported the presence of erm(T) in an isolate of H. parasuis which exhibited high-
level resistance against erythromycin and lincomycin.  This was the first time erm(T) had 
been reported in a Gram-negative organism.  The gene was carried on a 7577bp-long plasmid 
that additionally carried the blaROB-1 gene coding for β-lactam resistance.  The regions of this 
plasmid, referred to as pFS39, that surrounded erm(T) and blaROB-1 were similar to those of 
pHN61.  erm(T) was constitutively expressed in this instance due to a deletion of the leader 
peptide and IR-1.  Transformation of this plasmid into susceptible H. parasuis resulted in a 
64-fold increase in erythromycin MIC and a 16-fold increase in lincomycin MIC, along with 
MIC increases for penicillin, amoxicillin and cefaclor.
261
 
2.5.5 Acquired MLSB resistance genes in members of the family 
Pasteurellaceae 
Haemophilus spp. belong to the family Pasteurellaceae which includes a variety of closely 
related Gram negative rods that typically live as commensals in a number of mammal and 
bird species and generally survive poorly outside of this niche.  Other genera of this family 
include Pasteurella, Mannheimia and Actinobacillus.  Antibiotic resistance determinants, 
including those associated with macrolide resistance, have been documented in members of 
this family.
95
 
P. multocida is an animal commensal known for its multi-host associations.
262
  It can act as a 
pathogen in a number of species; in humans, it is associated with wound infections from dog 
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and cat bites, although P. multocida-mediated bacteraemia and meningitis can also develop.  
In recent years, multiresistant isolates of P. multocida derived from bovine respiratory 
infections have emerged, and many of these isolates also exhibit resistance to macrolides.  
Michael et al. (2012) have identified the presence of an integrative and conjugative element 
(ICE) which encodes 12 antibiotic resistance genes, designated ICEPmu1, in the chromosome 
of a representative P. multocida isolate.
263
  Many of these genes are not indigenous to 
Pasteurellaceae but had been previously reported among member of the family 
Enterobacteriaceae.
264
  Among those genes found on ICEPmu1 were the macrolide 
resistance genes erm(42), msr(E) and mph(E).  In a subsequent study, the same group were 
able to demonstrate conjugation of ICEPmu1 from the original representative isolate to 
another P. multocida, as well as to isolates of Mannheimia haemolytica and E. coli, with 
transfer of all resistance genes.
264
  It is currently unclear if ICEPmu1 can also be conjugated 
to H. influenzae, however. 
These three AMRGs are detectable among field isolates of P. multocida and M. haemolytica 
and can occur in different combinations that ultimately impact on the resistance phenotype.  
Desmolaize et al. (2011) reported three distinct phenotypes.  The first phenotype is the classic 
MLSB phenotype, in which high-level lincosamide resistance and low-to-moderate macrolide 
resistance is observed.  This is attributable to monomethylation of nucleotide A2058 of 23S 
rRNA.  Isolates with this phenotype carry erm(42) alone.  The second phenotype involves 
resistance against 14- and 15-membered macrolides (including tulathromycin, used to treat 
bovine respiratory disease (BRD)), but comparatively less resistance against lincosamides 
and 16-membered macrolides (including tilmicosin, also used for BRD).  This phenotype is 
attributable to the presence of msr(E)-mediated efflux and mph(E)-mediated phosphorylation 
of the antibiotics.  The third phenotype involves high-level resistance across the entire MLSB 
group; isolates with this phenotype carry all three genes.
265
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Members of the Pasteurellaceae are capable of exchanging genetic material via horizontal 
transfer.  Of particular note is that there is precedent for the possibility of Pasteurella spp. 
and Haemophilus spp. sharing resistance determinants.  The blaROB-1-carrying plasmid 
pB1000 was first described in H. parasuis in swine,
266
 and it (and its derivatives) was 
subsequently reported in animal-derived P. multocida isolates and in human clinical H. 
influenzae (including NTHi) isolates in Spain.
262,267
  Tristram et al. (2010) subsequently 
demonstrated that blaROB-1 is also carried on pB1000 in H. influenzae isolates outside of 
Spain.
268
  This not only suggests that pB1000 plays a significant role in the spread of this 
resistance gene (possibly via multi-host spread of P. multocida), but that the spread of 
resistance determinants between Pasteurella spp. and Haemophilus spp. on conjugative 
genetic elements may be a distinct possibility.  Given the previous detection of AMRG-
carrying conjugative elements such as ICEPmu1 in P. multocida, there is a real possibility of 
NTHi also acquiring genes such as erm(42), msr(E) and mph(E) and subsequently exhibiting 
macrolide resistance. 
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2.6 Chapter summary 
Macrolides have been used for decades for their antibiotic and anti-inflammatory properties, 
and they have a wide variety of applications in the clinical setting, including in the 
management of chronic respiratory conditions.  As a result of our increasing reliance on these 
antibiotics, however, the proportion of macrolide-resistant species has been increasing.  The 
prevalence of resistance reported among surveillance studies varies depending on the species, 
country of origin and the specific methodology used to define resistance, but regardless the 
prevalence continues to rise at an alarming rate in certain contexts and remains a significant 
threat. 
A vast amount of data has been presented regarding the mechanisms involved in macrolide 
resistance, with resistance being attributed to both chromosomal alterations, in particular 
ribosomal structural elements, and the acquisition of macrolide resistance genes.  Over 100 
AMRGs have been identified and code for a number of different mechanisms, including 
rRNA methyltransferases that alter the ribosomal binding site of macrolide (e.g. erm), other 
enzymes that deactivate the drug directly, and macrolide efflux systems (e.g. mef).  Many of 
the currently identified AMRGs are known to be carried on mobile genetic elements which 
has allowed for the horizontal transfer of these genes and their associated phenotype among 
isolates of different species.  This has contributed to the increasing prevalence of resistance 
among clinical isolates. 
While the mechanisms have been thoroughly studied in many species, the mechanisms of 
macrolide resistance in NTHi have only recently been investigated in depth.  There is sound 
evidence for the role of chromosomal mutations in macrolide-resistant NTHi isolates.  The 
role of AMRGs in NTHi is a contentious issue, but while these genes have not been widely 
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reported in this particular species, more recent evidence is suggesting that the occurrence of 
these genes in NTHi may be an emerging threat. 
There are a number of gaps in the literature regarding our basic understanding of the 
mechanisms behind macrolide resistance in NTHi, such that the specific aims of research 
studies presented in this thesis are to: 
 Investigate the prevalence of select acquired macrolide resistance genes commonly 
encountered among respiratory species (and previously reported in NTHi) (Chapter 4) 
and among animal pathogens closely related to NTHi (Chapter 7). 
 Investigate the presence of a wider range of AMRGs among NTHi by analysing 
previously-collated whole genome sequences (WGS) of NTHi (Chapter 5). 
 Investigate the phenotypic effect and expression of select AMRGs commonly 
encountered among respiratory species (Chapter 6). 
 Investigate the potential for NTHi to acquire AMRGs from closely-related animal 
pathogens such as P. multocida by assessing the conjugative potential of ICEPmu1 
between P. multocida and NTHi, and determine the stability of ICEPmu1 in NTHi 
(Chapter 7). 
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Chapter 3: General Methodologies and Materials 
3.1 Introduction 
While chapter-specific methodologies are provided subsequently in this thesis, the following 
section describes general methodologies used throughout this work, including media 
preparation, antibiotic resistance testing methods, and DNA and RNA extraction.  Where 
necessary, methodology descriptions in subsequent chapters will refer the reader back to this 
chapter. 
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3.2 Culture media and incubation conditions 
A number of different culture media were used throughout the work described in this thesis.  
These are outlined below. 
3.2.1 Blood agar 
Columbia agar (Oxoid) was reconstituted in distilled water and autoclaved in accordance with 
the manufacturer’s instructions.  The agar was cooled to 55°C and supplemented with 
defibrinated horse blood to a final concentration of 5% (v/v) before pouring.  If the addition 
of antibiotics was necessary, these were added alongside the blood. 
3.2.2 Chocolate agar 
Columbia agar (Oxoid) was reconstituted in distilled water and autoclaved in accordance with 
the manufacturer’s instructions.  The agar was cooled to 80°C and supplemented with 
defibrinated horse blood to a final concentration of 8% (v/v).  The agar was then cooled to 
55°C and supplemented with Vitox (Oxoid) at 1% (v/v) before pouring.  If the addition of 
antibiotics was necessary, these were added alongside the Vitox.  Chocolate agar was 
primarily used for the culture of NTHi and P. multocida.  These isolates were grown at 37°C 
overnight in a CO2-rich environment. 
3.2.3 Heart infusion broth 
Heart infusion broth (BHI) (Oxoid) was reconstituted in distilled water and autoclaved in 
accordance with the manufacturer’s instructions.  For the growth of NTHi, Vitox (Oxoid) at 
2% (v/v) and Haemophilus Test Medium (HTM) supplement (Oxoid) to a final concentration 
of 15 µg/mL NAD and haematin were added to the BHI prior to inoculation, to give 
supplemented BHI (sBHI).  If the addition of antibiotics was necessary, these were added 
alongside the Vitox and HTM supplement. 
Chapter 3: General Methods 
96 
 
For all study isolates, culture in sBHI was performed at 37°C overnight on a shaker (150 
rpm). 
3.2.4 LB agar and broth 
LB broth with agar (Lennox) (Sigma) was reconstituted in distilled water and autoclaved in 
accordance with the manufacturer’s instructions.  The agar was cooled to 55°C before 
pouring.  If the addition of antibiotics was necessary, these were added immediately before 
pouring. 
LB broth base (Lennox L Broth base) (Invitrogen by Life Technologies) was reconstituted in 
distilled water and autoclaved in accordance with the manufacturer’s instructions. 
3.2.5 Mueller-Hinton agar and broth 
Mueller-Hinton agar (Oxoid) was used for EUCAST susceptibility testing.  Mueller-Hinton 
agar (Oxoid) was reconstituted in distilled water and autoclaved in accordance with the 
manufacturer’s instructions.  The agar was cooled to 55°C before pouring.  For the growth of 
NTHi, defibrinated horse blood to a final concentration of 5% (v/v) and HTM supplement 
(Oxoid) to a final concentration of 20 µg/mL NAD were added was added to the agar 
immediately before pouring (MH-F agar). 
Mueller-Hinton broth (Oxoid) was reconstituted in distilled water and autoclaved in 
accordance with the manufacturer’s instructions.  HTM supplement (Oxoid) was added to the 
broth prior to inoculation.  The broth was additionally supplemented with 5% yeast extract 
(Oxoid). 
3.2.6 Antibiotic preparation for media 
Antibiotic supplementation was required for a number of experiments performed throughout 
this thesis, the majority of which were prepared fresh.  Table 3.1 lists the antibiotics used in  
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Table 3.1: Antibiotics used in the various media of this work, with corresponding solvents. 
Antibiotic Solvent 
Tetracycline Water 
Rifampicin Methanol 
Nalidixic Acid NaOH, 0.1M 
Cefotaxime Water 
Kanamycin Water 
Erythromycin Water 
Azithromycin Water 
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the various media used throughout this thesis and the solvents used to prepare each 
antibiotic.
269
  Water was used as a diluent for all of these antibiotics as required.  All 
antibiotic stock powders were manufactured by Sigma. 
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3.3 Antibiotic susceptibility testing 
A number of different methodologies were used to test for antibiotic susceptibility throughout 
this work; the specific method used for each experiment will be indicated in the subsequent 
chapters of this thesis. 
3.3.1 Etest 
Etests on H. influenzae strains were performed on MH-F agar, incubated at 37°C in 5% CO2 
for 24 hours using H. influenzae ATCC 49247 as a control.  EUCAST breakpoints were used 
for interpretation where relevant.
69
 
3.3.2 Broth microdilution 
In Chapters 6 and 7, MICs for study isolates were determined by broth microdilution in 
accordance with CLSI recommendations and methodology.
270
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3.4 PCR and DNA preparation 
PCR reactions were performed using the C1000 Touch Thermal Cycler (Bio-Rad).  Real-time 
PCR was performed with the CFX96 Real-Time System (Bio-Rad) using SYBR Green (Bio-
Rad) unless otherwise stated.  Primer sequences and annealing temperatures are described in 
subsequent chapters of this work. 
For all analyses, genomic DNA was extracted using the Isolate II Genomic DNA Kit 
(Bioline) in accordance with the manufacturer’s instructions. 
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3.5 Sanger sequencing and primer design 
Sanger Sequencing was performed on PCR-generated DNA products; agarose gel 
electrophoresis was used to confirm the presence of amplicons of the appropriate size.  The 
DNA was purified using the QIAquick PCR Purification Kit (Qiagen) in accordance with the 
manufacturer’s instructions.  DNA samples were quantified using agarose gel electrophoresis 
and were subsequently submitted to the Australian Genome Research Facility Ltd (AGRF) 
(Queensland, Australia) for sequencing.  Samples were sent off in a 1.5 mL tube with 
9.6pmol of the appropriate primer (2 tubes were sent off per sample, with one tube containing 
the forward primer and the other tube containing the reverse primer) and water to make the 
total volume up to 12 mL.  The amount of DNA product sent off was determined in 
accordance with the recommendations of the AGRF (see Table 3.2 for details). 
3.5.1 Sequence analysis 
The AGRF provides 4 separate files for each submitted tube: 
 sample.ab1: The raw chromatogram trace file 
 sample.seq: A text file of the sequence, as generated by the sequencing instruments 
 sample.fa: A trimmed FASTA formatted text file.  Reads are trimmed on the basis of 
the quality values assigned to the basecalls. 
 sample.bn: A BLAST file (GenBank) of the trimmed FASTA file. 
When files were received, the ab1 file was first inspected for quality using the Chromas 
(McCarthy 1996-1998) chromatogram viewer.  If the trace file was deemed satisfactory, the 
fa file for each sample was accessed with CLC Main Workbench 7.  For each sample 
submitted, the fa file for both submitted tubes (containing the forward and reverse primers) 
was opened with CLC Main Workbench 7 and Contig files were assembled to generate the 
complete sequence of the PCR product.  Any conflicts between the 2 trimmed sequences 
were resolved based on the ab1 trace files.  The identity of the assembled sequence was  
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Table 3.2: Recommended DNA Quantities for submission to the AGRF for sequencing. 
Template Recommended Quantity of DNA 
PCR Product 100-200 bp 3-8 ng 
PCR Product 200-400 bp 6-12 ng 
PCR Product 400-600 bp 12-18 ng 
PCR Product 600-800 bp 18-30 ng 
PCR Product >800 bp 30-75 ng 
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confirmed using Basic Local Alignment Search Tool (BLAST) through the National Center 
for Biotechnology Information (NCBI). 
If the aim of the sequencing was to detect sequence differences between the submitted 
samples and a reference sequence, a fasta file of the reference sequence was obtained from 
GenBank and opened with CLC Main Workbench 7.  Sample sequences were aligned with 
the reference sequence to detect the presence of any sequence variations. 
3.5.2 Primer design 
Primers were designed with CLC Main Workbench 7 using an appropriate nucleotide 
sequence as the template.  Primer quality and specificity was analysed using Primer BLAST 
through the NCBI. 
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3.6 RNA extraction and conversion to cDNA 
3.6.1 RNA extraction 
Cells were grown in sBHI, with appropriate antibiotics where necessary, until the bacteria 
had reached a point of mid-log phase growth (Abs650nm = 0.200-0.800).  After growth and 
prior to RNA isolation, RNA was stabilised by treating the cells with RNAprotect® Bacteria 
Reagent (Qiagen) in accordance with the manufacturer’s instructions.  After stabilisation, 
RNA was isolated from the cells using the RNeasy Mini Kit (Qiagen) in accordance with the 
manufacturer’s instructions.  Extractions were performed on the QIACUBE automated 
platform and included a DNase treatment step for the removal of potential contaminant 
genomic DNA in the samples.  Extracted RNA samples were stored at -80°C. 
3.6.2 RNA quality analysis and quantification 
RNA quality was analysed using the Experion
TM
 Automated Electrophoresis Station (Bio-
Rad) in accordance with the protocol outlined in the Experion
TM
 RNA StdSens Analysis Kit 
(Bio-Rad).  RNA concentrations were determined using the Qubit® 2.0 Fluorometer 
(Invitrogen by Life Sciences). 
3.6.3 Reverse transcription to cDNA 
RNA samples were reverse transcribed to cDNA using the iScript (Bioline) in accordance 
with the manufacturer’s instructions.  Prior to PCR analysis for measurement of expression, 
all cDNA samples were diluted 1/5 in RNase and DNase free molecular water.  Samples were 
stored at -20°C. 
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3.7 Conjugation 
Donor and recipient strains were grown overnight without shaking in 5.5 mL and 21.5 mL of 
BHI or sBHI (for H. influenzae).  After incubation, the donor and recipient cells were mixed 
in a donor:recipient of 1:5 (4 mL donor with 20 mL recipient).  This mixture was centrifuged 
at 3800 rpm for 10 minutes and the supernatant was discarded.  The pellet was resuspended 
in 30 mL of pre-warmed (37°C) BHI before being dispensed onto the centre of a dry pre-
warmed (37°C) suitable agar plate.  The pellet was allowed to dry on the plate for 30 
minutes; plates were subsequently incubated at 37°C for 6 hours in a suitable atmosphere. 
After incubation, the bacterial growth was harvested and suspended in 1 mL of cold saline.  
From this suspension, a dilution series (10
-1
 to 10
-8
) was prepared.  100 µL of the 10
-5
, 10
-6
 
and 10
-7
 dilutions were spread onto suitable non-selective agar plates.  100 µL of the 10
0
, 10
-1
 
and 10
-2
 dilutions were spread onto agar plates supplemented with antibiotics suitable for the 
selection of transconjugants.  In instances where it was necessary to calculate the conjugative 
transfer efficiency, 100 µL of the 10
-3
, 10
-4
 and 10
-5
 dilutions were spread onto agar plates 
supplemented with an antibiotic suitable for the selection of the donor strain, while 100 µL of 
the 10
-4
, 10
-5
 and 10
-6
 dilutions were spread onto agar plates supplemented with an antibiotic 
suitable for the selection of the recipient strain.  Transfer efficiency was calculated as the 
number of transconjugant cells per recipient cell. 
The specific antibiotics used throughout this work and the specific concentrations at which 
they were used are listed in Table 3.3. 
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Table 3.3: Antibiotics used for conjugation assays with corresponding concentrations. 
Antibiotic Concentration 
Tetracycline 15 µg/mL 
Rifampicin 50 µg/mL 
Nalidixic Acid 8 µg/mL 
Cefotaxime 1 µg/mL 
Kanamycin 30 µg/mL 
Streptomycin 500 µg/mL 
Ampicillin 4 µg/mL 
Erythromycin* 8 µg/mL, 16 µg/mL 
*Multiple concentrations (in different plates) were used for erythromycin. 
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3.8 Whole genome sequencing: quality control and assembly 
Whole genome sequencing was performed on select isolates as part of the work of Chapters 5 
and 7.  While the specific analytical methods used on these sequences are described in these 
chapters, all sequences underwent quality control checks and pre-processing regimes before 
the main analyses were performed.  These are detailed below. 
3.8.1 Quality check with FASTQC 
Sequences obtained from whole genome sequencing were uploaded to Galaxy/mGVL 0.10-2 
and analysed for quality using FastQC (Babraham Bioinformatics, Cambridge).  Quality was 
assessed through examination of the per base sequence quality report.  Quality was 
considered acceptable if the mean quality scores fell within the “good” range on the plot 
(represented by the green zones on the plot) (see Figure 3.1). 
3.8.2 Sequence manipulation 
Sequences were subsequently converted and trimmed using the FASTQ Groomer and 
Trimmomatic tools through Galaxy/mGVL 0.10-2.  When trimmed, sliding window trimming 
was used, using 4 bases to average across and an average quality of 20 as the threshold.  
Groomed and trimmed sequences were once again analysed for quality with FastQC as 
above. 
3.8.3 Sequence assembly 
Groomed and trimmed sequences which passed the quality checks were assembled using the 
SPAdes genome assembler in Galaxy, generating a single fasta file for each isolate. 
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Figure 3.1: Example per base sequence quality plot.  Mean is represented by the blue line.  The red lines represent the median quality values 
at each position.  The yellow box plots represent the inter-quartile range and the whiskers represent the 10% and 90% points.  Good quality 
is represented by the green area at the top of the plot; the red area represents poor quality. 
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Chapter 4: Acquired macrolide resistance genes in nontypeable 
Haemophilus influenzae? 
4.1 Introduction 
Macrolides such as erythromycin and azithromycin are antibiotics that target the 23S subunit 
of the bacterial ribosome and act as protein synthesis inhibitors.  Macrolides have been 
indicated for use in a number of conditions involving chronic respiratory bacterial infections, 
including chronic obstructive pulmonary disease (COPD).  Many of these infections can 
involve NTHi and this has resulted in the emergence of macrolide resistant NTHi isolates 
within communities. 
The activity of macrolides against NTHi isolates is limited in comparison to that against other 
species (azithromycin MICs typically cover the range of 0.25-4 µg/mL), although in vitro 
susceptibility of NTHi to macrolides is still relatively good.
252
  This higher baseline MIC 
range has been attributed to the presence of an intrinsic efflux pump that is homologous to the 
acrRAB complex found in E.coli.
250
  Additional high level resistance (azithromycin MICs 
typically ≥64 µg/mL) is relatively uncommon in NTHi but has increasingly been reported in 
some isolates.  These instances have typically been associated with L4 and L22 ribosomal 
protein mutations and 23S rRNA mutations.
90,252
 
A large range of acquired macrolide resistance genes (AMRGs) have been described in a 
wide variety of Gram-positive and Gram-negative bacteria.  These include various erm genes 
that code for rRNA methylases that alter the 23S rRNA binding site of the macrolide to 
inhibit macrolide binding; various mef or related genes that encode alternate efflux pumps; 
and various others genes encoding macrolide inactivating enzymes.
1
  These AMRGs have not 
been widely reported among NTHi isolates.  However, there has been one significant report 
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of macrolide resistance genes by Roberts et al..
93
  In that study, 106 isolates of NTHi from 
cystic fibrosis (CF) patients in a placebo-controlled trial of azithromycin were tested for the 
presence of erm(A), erm(B), erm(C), erm(F) and mef(A) by molecular methods.  All isolates, 
including those on placebo, were reported to have one or more of the acquired macrolide 
resistance genes, but there was no clear association between the presence of these genes and 
the azithromycin or erythromycin MICs.
93
  The only other report of an acquired macrolide 
resistance gene in Haemophilus spp. was mef(A) detected by microarray and sequencing in an 
isolate of Haemophilus parainfluenzae; in this case, macrolide MICs were >256 µg/mL.
257
 
The aim of this study was to determine whether the presence of these AMRGs is widespread 
in the broader NTHi population. 
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4.2 Methods and Materials 
4.2.1 Bacterial strains 
The isolate collection for this study consisted of 172 clinical respiratory isolates of NTHi 
identified by colony morphology, X and V factor dependence and a positive PCR for either 
fucK or hpd as previously described.
271
  Of these, 59 isolates were from CF patients, 27 
isolates were from a cohort of non-CF bronchiectasis patients with significant prior macrolide 
use,
272
 and the remaining 86 isolates were from a range of other patients.  All isolates were 
cultured on chocolate agar.  
4.2.2 Susceptibility testing 
Azithromycin MICs were determined using Etest on MH-F media (see Chapter 3) and 
incubated at 37°C in 5% CO2 for 24 h using H. influenzae ATCC 49247 as a control. 
EUCAST breakpoints (susceptible, ≤0.12 µg/mL; resistant, >4 µg/mL) were used for 
interpretation.
69
 
4.2.3 Detection of acquired macrolide resistance genes 
Genomic DNA extracted using the ISOLATE II kit (Bioline, NSW, Australia) was used as 
template for PCR.  All isolates were initially tested for the presence of the genes using locked 
nucleic acid dual-labelled hydrolysis probes (Sigma–Aldrich, NSW, Australia) in two 
quadruplex reactions for erm(A), erm(B) and erm(C) in reaction 1 and erm(F), mef(A) and 
mef(E) in reaction 2, with both reactions also including a 16S rRNA amplification control.  
Reaction conditions were as follows: iQ Multiplex Powermix (Bio-Rad, NSW, Australia) 
with probe and primers at final concentrations of 0.25 and 0.5 mM, respectively, over 30 
cycles with an annealing temperature of 60°C.  Primer sequences are given in Table 4.1. 
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Table 4.1: Probes and primers for detection of acquired macrolide resistance genes. 
Primer or probe Sequence
a 
Position
b 
GenBank accession
c 
16S probe ttcCtcCacAtcTctacgc 697–715 L42023 
16S F ATTTCAGACTGGGTAACTAGAG 634–655  
16S R GTCAGTACATTCCCAAGGG 735–753  
ermA probe tcaCttGacAtaAgcctcc 184–202 X03216 
ermA F ACAAGACAACGTAATAGAAATCG 90–112  
ermA R CTTTTATATTCTCAGAGGGGTTTAC 214–238  
ermB probe ccgCcaTacCacAgat 528–543 M11180 
ermB F TCATCCTAAACCAAAAGTAAACAG 486–509  
ermB R TTAGTAAACAGTTGACGATATTCTC 599–623  
ermC probe agcAaaCccGtaTtccac 379–396 NC001395 
ermC F AGTACAGATATAATACGCAAAATTG 319–343  
ermC R ATGCCAATGAGCGTTTTG 413–430  
ermF probe cacCgcCaaCtgTcaa 512–527 AF219231 
ermF F TTGAAACTTGTCTATGAGGTAGG 472–494  
ermF R CTCTAACAGACAGGAAATAAATGC 595–618  
mefA probe tagTaaGcaCcgAaccag 260–277 U70055 
mefA F GGATCGTCATGATAGGAAGAAG 204–225  
mefA R CAGGTAGCTCCATATAGAATGC 283–304  
mefE probe tctCagAacCacAactcct 630–648 U83667 
mefE F CCTAAGCTGGGTAATCAAGTG 571–591  
mefE R CTAAGAGTAATAAGGCAAACAATCC 658–682  
aSequences are given 5′ to 3′ and, for probes, capital letters indicate locked nucleotides. 
bNumbering based on ORF, except for 16S, which is based on a 1539 bp sequence. 
cReference sequences used for primer design. 
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Subsequently, the isolates were retested for the same genes (excluding mef(E)) using the 
primers and annealing temperatures described by Roberts et al.,
93
 but on a real-time PCR 
platform using SYBR Green (Bio-Rad, NSW, Australia).  Positives were checked on an 
agarose gel and amplicons of an appropriate size were sequenced using the respective 
amplification primers.  The primer sequences are given in Table 4.2. 
The control material was as follows: clinical isolates for mef(E), mef(A), erm(A) and erm(B) 
with gene identity confirmed by sequencing; pE194 for erm(C); and an erm(F) amplicon 
kindly provided by Zhongtang Yu (Department of Animal Sciences, Ohio State University, 
Columbus, OH, USA). 
4.2.4 Detection of L4, L22 and 23S rRNA mutations 
Any isolates exhibiting high-level macrolide resistance (azithromycin MIC > 64 µg/mL) 
underwent sequencing of the L4 and L22 protein genes and the 23S rRNA gene for the 
detection of macrolide resistance-associated mutations as previously described.
90
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Table 4.2: Primers used for detection of acquired macrolide resistance genes.* 
Primer Sequence (5’ – 3’) 
ermA-F GAA ATY GGR TCA GGA AAA GG 
ermA-R AAY AGY AAA CCY AAA GCT C 
ermB-F GAT ACC GTT TAC GAA ATT GG 
ermB-R GAA TCG AGA CTT GAG TGT GC 
ermC-F TCA AAA CAT AAT ATA GAT AAA 
ermC-R GCT AAT ATT GTT TAA ATC GTC AAT 
ermF-F CGA CAC AGC TTT GGT TGA AC 
ermF-R GGA CCT ACC TCA TAG ACA AG 
mefA-MF6 GGA CCT GCC ATT GGT GTG 
mefA-MF4 ACC GAT TCT ATC AGC AAA G 
            * As described by Roberts et al., 2011 
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4.3 Results and Discussion 
The azithromycin MICs ranged from 0.09 to >256 µg/mL, with MIC50 and MIC90 values of 
1.5 and 3 µg/mL, respectively.  Two (1.2%) isolates were susceptible, 163 (94.8%) 
intermediate and 7 (4%) resistant according to EUCAST breakpoints (susceptible, ≤0.12 
µg/mL; resistant, >4 µg/mL) (see Figure 4.1).
93
 
Of the resistant isolates, five were low level (6–16 µg/mL) and were not further investigated, 
but two, isolates Ci115 and M3, had azithromycin MICs of >256 µg/mL and were further 
investigated by sequencing of the L4 and L22 ribosomal protein and 23S rRNA genes.  One 
strain, isolate M3, had an A2058 mutation in the 23S rRNA gene and the other, isolate Ci115, 
had C2611T and R88P mutations in the 23S rRNA and L22 ribosomal protein genes, 
respectively, all of which have been previously associated with macrolide resistance (see 
Figures 4.2 and 4.3).
90,273,274
  M3 carried additional alterations in 23S rRNA (see Table 4.3), 
although the significance of these alterations in regards to macrolide resistance in unclear.  
No alterations were detected in the L4 ribosomal protein in either isolate. 
None of the acquired macrolide resistance genes erm(A), erm(B), erm(C), erm(F), mef(A) or 
mef(E) were detected in any of the isolates.  The absence of the acquired macrolide resistance 
genes tested for in our isolates is in stark contrast to the findings of Roberts et al.,
93
 where at 
least one gene was detected in each of their 106 isolates, two different genes were detected in 
28 isolates and three different genes were detected in 7 isolates. This difference cannot be 
readily explained. Admittedly, only a small proportion of our isolates (27/172) came from a 
known background of high cohort macrolide exposure, but the Roberts et al.
93
 study found 
the acquired macrolide resistance genes in isolates from both placebo and macrolide 
treatment groups, so recent macrolide use was not a prerequisite for the presence of the 
genes. 
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Figure 4.1: Distribution of azithromycin MICs of the isolates included in this study.  The green arrow indicates the susceptible breakpoint 
and the red arrow indicates the resistant breakpoint.  The majority of MICs fall within the intermediate breakpoint range (EUCAST 
breakpoints) and roughly follows a normal distribution, a finding typical of H. influenzae. 
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Figure 4.2: Sequence of L22 of H. influenzae Rd KW20 and Ci115.  Matching residues are shown with dots.  Ci115 carried a R88P 
alteration which has previously been associated with decreased macrolide susceptibility.  
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Figure 4.3: Sequence of 23S rRNA of H. influenzae Rd KW20, Ci115 and M3.  Matching residues are shown with dots.  Ci115 carried a 
C2611U alteration and M3 carried an A2058G alteration, both of which have previously been associated with decreased macrolide 
susceptibility.  Additional alterations in 23S rRNA from Rd KW20 were also apparent but the relevance of these is not known. 
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Table 4.3: Complete list of L4, L22 and 23S rRNA alterations detected in Ci115 and M3. 
Isolate L4 alterations L22 alterations 23S rRNA alterations 
Ci115 None R88P C2611U 
M3 None None 
A2058G, C2128A, U2132A, G2141C, C2150G, G2160U, 
G2162A, A2163U, G2207U, A2208G, A2211G, U2216C 
 
 
 
 
 
 
 
 
 
 
 
Similarly, the isolates from the Roberts et al.
93
 study were more resistant than ours, with 
27/106 (25%) resistant, but again the acquired macrolide resistance genes were detected 
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across all isolates irrespective of MIC, including erm(B) and mef(A) in the single susceptible 
isolate. 
To investigate technical differences, we retested our isolates using the primers used in the 
Roberts et al.
93
 study and found 21 isolates to be presumptively positive for mef(A) and 6 for 
erm(A).  The azithromycin MIC range for these isolates was 0.125 to 256 µg/mL with MIC50 
and MIC90 values of 1.5 and 4 µg/mL, respectively. In the additional investigation detailed 
below, these positive PCR results were found to be false positives. 
The amplicons from the mef(A) and erm(A) primers were difficult to distinguish from the 942 
and 332 bp amplicons of the respective positive controls on gel electrophoresis (see Figures 
4.4 and 4.5).  They were subsequently sequenced and identified using a BLASTn search.  The 
false positive mef(A) amplicon was found to span nucleotides 588138–589053 (916 bp) 
encompassing the transcription accessory protein (TAP) and adjacent to the DNA gyrase B 
gene (gyrB) in H. influenzae Rd KW20 (GenBank accession L42023).  The false positive 
erm(A) amplicon was found to span nucleotides 32743–32383 (361 bp) encompassing the rod 
shape-determining protein (ROD), also in H. influenzae Rd KW20.  Similar sequences are 
found in Genbank sequences from other strains of H. influenzae.  Close examination of the 
ends of these sequences revealed significant degrees of similarity to the primers, particularly 
at the 3′ end.  The degree of similarity differed depending on the particular strain and this is 
briefly illustrated in Table 4.4. 
These observations raise the question as to why all of our isolates did not give false positives 
with these PCRs, given that these genes are part of the core genome of H. influenzae.  When 
we examined the relevant regions of GenBank sequences for these genes in other strains of H. 
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Figure 4.4: Electrophoresis gel of amplicons produced by the Roberts primers for the detection of mef(A).  The false positive amplicons 
(indicated by the red box) were difficult to distinguish from a true positive amplicon (indicated by the green box) by gel electrophoresis 
alone due to their similar size. 
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Figure 4.5: Electrophoresis gel of amplicons produced by the Roberts primers for the detection of erm(A).  The false positive amplicons 
(indicated by the red box) were difficult to distinguish from a true positive amplicon (indicated by the green box) by gel electrophoresis 
alone due to their similar size. 
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Table 4.4: Example sequences showing deduced primer binding sites for false positive 
amplicons. 
er
m
(A
) 
Details Sequence 
Rd* 32743-23  TGGTGGATTAAGCGGAAAAGG 
KR494
#
 1558106-126 TGGTGGATTAAGCGGAAAAGG 
Primer ermA-F (5’ -3’)    GAAATYGGRTCAGGAAAAGG 
  
Rd 32401-383 (complimentary) TTCAAAACCAAATGACTAC 
KR494 1557730 to 1557746 (complimentary) CTCGAAACCAAATGACTAC 
Primer ermA-R (3’ – 5’) CTCGAAAYCCAAAYGAYAA 
   
m
ef
(A
) 
Rd 588138-56 TTTAGTGCATCAGGCAAAG 
KR494 216063-216080 TTTAACGCATCAGCAAAG 
Primer mefA-MF4 (5’-3’) ACCGATTCTATCAGCAAAG 
  
Rd 589037-53 (complimentary) GTGGTTACCGAAAGCCA 
KR494 216961-216977 (complimentary) GTGGTTACCGAAAACCA 
Primer mefA-MF6 (3’-5’) GTGTGGTTACCGTCCAGG 
*H. influenzae Rd (GenBank accession L42023) and # H. influenzae KR494 (Genbank accession CP005967) 
 
 
 
 
 
 
 
 
 
 
 
influenzae, some sequence variation that could affect primer binding was evident.  In 
addition, our false positive reactions had Ct values of between 24 and 27 cycles compared 
with 15–20 cycles for the positive controls, so it would not be unexpected for small variations 
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in nucleotide sequence or DNA quality across our test isolates to result in inconsistent 
amplification of these chromosomal targets.  No further analysis was performed on the 
erm(A) false positive amplicons, but in an attempt to determine why only some of our 
isolates were producing false positive amplicons using the Roberts mef primers, we designed 
a number of primer sets to investigate the presence of any genome variations between isolates 
producing the false positive amplicon and isolates that produced correctly negative results.  
Firstly, we designed primers around 200 bp outside of where the false positive binding was 
occurring.  These primers were designed to show any sequence differences in the region 
generating the false positive amplicons that may have affected the binding affinity of the 
Roberts primers.  We also designed primers amplifying both gyrB (an ORF which flanks the 
region covered by the false positive amplicon) and TAP to determine if one or both of these 
genes were missing in our true negative isolates, and to further confirm the presence of any 
sequence differences in these genes between false positive isolates and true negative isolates.  
Finally, we designed primers to amplify the region bridging gyrB and TAP.  The aim here 
was to determine if gyrB and TAP were within the same proximity of each other in false 
positive isolates, and if the proximity was different for true negative isolates.  The primers 
were designed to bind within the last 300 bp of gyrB and the first 300 bp of TAP, and would 
only produce an amplicon if gyrB and TAP were within close proximity of each other; 
furthermore, any amplicon size differences would indicate differences in the region between 
these genes and might explain isolate differences using the Roberts primers.  All of these 
primer sequences are listed in Table 4.5. 
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Table 4.5: Primer sequences for the investigation of the false positive binding of the Roberts 
mef primers. 
Primer Sequence Purpose 
F-FPMefA TCC ACC ACT TCA AAT AAC 
Amplification and sequencing of entire false positive amplicon 
R-FPMefA GTC CGT TTA TTC AGC TTC 
F-GyrB GGA TCT TTT TCT TGG CAG T 
Amplification of gyrB 
R-GyrB GGT TTG GTG GCG ATT ATT 
F-TAP GTG TGG ATA AAT GGT GGT 
Amplification of TAP 
R-TAP GAA AAA GCG GAA GAA GAA G 
F-bridge CCG TTT TGG CGA TGC TTT TC 
Amplification of the region bridging gyrB and TAP 
R-bridge CGT GGA AAT ATG CAG CGA GA 
 
 
 
 
 
 
 
 
 
 
 
For our investigations, we selected 5 isolates that produced the false positive amplicon with 
the Roberts mef primers and 5 isolates that did not produce this amplicon.  Testing of these 10 
isolates revealed that all of them carried gyrB and TAP, suggested that the discrepancy was 
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not caused by the absence of one or both of these genes in the true negative isolates.  In 
addition, we performed agarose gel electrophoresis on the amplicons produced by the gyrB 
and TAP primers, as well as the amplicon produced by the bridge primers.  The amplicons for 
all 3 primer sets were shown to be of the expected size regardless of whether the isolate being 
tested was a false positive amplicon producer or a true negative isolate.  This indicated that 
the discrepancy was not due to a large scale insertion or deletion in gyrB or TAP, and that the 
length of the bridging region between these genes was similar enough to be indistinguishable 
on an agarose gel.  We subsequently submitted the same 10 isolates for sequencing using the 
false positive amplicon primers described in Table 4.5.  However, analysis of the sequences 
did not reveal any sequence differences between the false positive isolates and the true 
negative isolates that would explain why the amplicon was being produced with some 
isolates and not others. 
In addition to the sequencing analysis described above, we also ran an annealing temperature 
gradient with the Roberts mef primers using two false positive isolates and two true negative 
isolates.  The temperature gradient covered the range of 50-60°C and the PCR was continued 
for 40 cycles.  At higher temperatures, the Ct values of the true negative isolates exceeded 30 
cycles, and the Ct value did not drop below 30 cycles until an annealing temperature of 52°C.  
By contrast, the Ct values of the false positive isolates fell below 30 cycles at temperatures as 
high as 60°C.  The Ct values of a false positive isolate (CF21) and a true negative isolate 
(CF11) are listed in Table 4.6 to demonstrate this contrast. 
The various CF21 and CF11 amplicons were run on an agarose electrophoresis gel (see 
Figure 4.6).  For CF11, an amplicon of similar size to the false positive amplicon produced 
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Table 4.6: Ct values of CF21 (false positive isolate) and CF11 (true negative isolate) from the 
temperature gradient using the Roberts’ mef primers. 
Annealing Temperature (°C) CF21 Ct Values CF11 Ct Values 
60.0 24.54 36.94 
59.6 23.66 35.41 
58.3 23.26 34.76 
56.4 21.84 31.43 
53.9 20.87 30.20 
52.1 20.46 26.90 
50.8 19.69 25.34 
50.0 19.01 23.72 
 
 
 
 
 
 
 
 
 
 
by CF21 could be visualised across all temperatures, although at higher temperatures the 
amplicon was very faint.  Given that no apparent sequence alterations in the region covered 
by the false positive amplicon (including in gyrB and TAP) were detected, it is therefore 
likely that the “true negative” isolates are capable of producing the same false positive 
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amplicon as the previously described false positive isolates.  Given that the PCR used for the 
Roberts mef primers was originally run at 30 cycles using an annealing temperature of 56°C, 
it is unsurprising that these isolates were not detected during the original assays.  It is still 
unclear why only some isolates produced this amplicon at the annealing temperature of 56°C, 
although it may perhaps be attributable to subtle variations in DNA concentration or quality 
between the starting extracted DNA material for each individual isolate. 
In any case, the emergence of false positive amplicons using the Roberts mef and erm(A) 
primers in our study makes it interesting to speculate as to whether some of the positive 
results in the Roberts et al.
93
 study, particularly for mef(A) and erm(A), could have been 
similar false positives.  This might explain the large number of positives and the absence of 
associated raised macrolide MICs.  However, although none of the amplicons in that study 
was confirmed by sequencing, they were confirmed using hybridization probes. 
In conclusion, our study shows that acquired macrolide resistance genes are not widespread 
in NTHi and the high prevalence of these genes previously reported might be unique to the 
specific circumstances of that study.  We also demonstrate that the use of primers in 
organisms other than those for which the primers were initially designed and evaluated can 
produce false positive amplification not easily detected without confirmatory tests such as 
sequencing. 
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Figure 4.6: Electrophoresis gel of amplicons produced during temperature gradient with the Roberts primers for the detection of mef. 
 
 
 
4.4 Further developments 
The experimental work presented within this chapter was performed during the period of 
January 2014 – December 2014.  The experimental design and result interpretation were 
guided by information we had at the time the work was performed; this included the 
          50°C        50.8°C     52.1°C      53.9°C     56.4°C     58.3°C     59.5°C      60°C 
CF22 
CF11 
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information presented by Roberts et al., as well as personal communications with Dr. Roberts 
regarding the design of the primers used in her manuscript. 
The work presented here was peer reviewed and published in the Journal of Antimicrobial 
Chemotherapy in 2015.
275
  Since the publication of this work, Roberts et al. have published a 
comment on our manuscript in response to some of our findings and interpretations.
276
  
Notably, Roberts et al. point out that the primers that we stated that they used in their original 
study were not the primers they actually used, but were a different set of primers from an 
unaffiliated study, and that therefore we are unable to speculate about the possibility of the 
presence of false positives among the positive findings reported in the study.  Our group have 
also published a response to this comment.
277
  The responses of Roberts et al. and our group 
can be found in Appendix 1. 
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Chapter 5: Utilisation of whole genome sequencing techniques in 
the investigation of acquired macrolide resistance genes in 
Haemophilus influenzae 
5.1 Introduction 
The use of whole genome sequencing is becoming more common as an alternative to other 
techniques for DNA analysis such as Sanger sequencing.  Whole genome sequencing 
techniques can be utilised for the investigation of antibiotic resistance in bacteria and is more 
affordable than ever.  Such techniques offer a number of analytical advantages over other 
techniques used to investigate resistance.  For example, in addition to its use in characterising 
isolates for the presence of known resistance markers, whole genome sequencing can also be 
useful for detecting unknown potential contributors to resistance in isolates, assuming one 
has good knowledge of functional motifs.  This can be particularly useful for resistant isolates 
that lack other previously described resistance determinants.  In addition, whole genome 
sequencing also provides a more practical method to screen isolates for the presence of 
multiple resistance genes and determinants simultaneously. 
The work described in this chapter encompasses a number of projects, but the overall aim 
was to utilise whole genome sequencing techniques to further investigate macrolide 
resistance determinants in NTHi.  Firstly, we aimed to find further evidence of the presence 
of AMRGs in a range of NTHi isolates, including the isolates exhibiting high-level macrolide 
resistance detected in Chapter 4 (Ci115 and M3).  This involved whole genome sequencing 
these isolates and screening them for the presence of a larger set of specific AMRGs, 
including each of the genes investigated in Chapter 4, using the previously described 
SPANDx pipeline.
278
  We were additionally interested to see if we could detect these genes in 
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a wider range of NTHi isolates of unknown macrolide resistance phenotype, given that the 
study of Roberts et al. (2011) found AMRGs in isolates with a variety of resistance 
phenotypes,
93
 and as such we expanded the analysis to include further isolates for which 
whole genome sequences are publically available.
279
  
To supplement the above analysis, we also aimed to detect AMRGs in Ci115 and M3 by 
submitting these sequences to the Comprehensive Antibiotic Resistance Database (CARD).
280
  
Doing this would provide another avenue to screen for the presence of AMRGs in these 
isolates, including those not included in the initial SPANDx analysis.  The sequences were 
also submitted to the Resistance Gene Identifier (RGI) within CARD
280
 as an additional step 
in detecting macrolide resistance markers in Ci115 and M3. 
While the main focus of this thesis is on the potential presence and role of AMRGs in NTHi, 
we initially decided to further investigate the cause of the macrolide resistance phenotype in 
Ci115 and M3 by extracting the sequences of the L4 and L22 ribosomal protein and 23S 
rRNA genes from the whole genome sequence output and analysing these for known 
mutations associated with macrolide resistance.  While we had previously performed these 
analyses in Chapter 4 via Sanger sequencing, performing these additional analyses still had 
some value.  Firstly, repeating analyses on L4, L22 and 23S rRNA served as a kind of control 
for quality of the analyses of the whole genome sequences in general, in the sense that it 
would be expected that alterations detected from the Sanger sequences in Chapter 4 would 
also be detected from the whole genome sequences in this chapter.  Any conflicts found 
between the two approaches may imply errors in the analyses that would warrant further 
investigation, and may compromise any further work performed on the whole genome 
sequences related to AMRGs.  In addition, analysis of the whole genome sequences could 
provide further information regarding the role of 23S rRNA in macrolide resistance.  The 
primers used in Chapter 4 were designed to amplify domain V only and do not provide 
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coverage of domain II; whole genome sequencing can be used to provide this information.  
Furthermore, whole genome sequencing can also be used to determine how many of the 6 
operons of 23S rRNA found in H. influenzae carry particular alterations (i.e. the dosage).  In 
addition, very recent evidence not available at the time the work of Chapter 4 was completed 
has indicated that that alterations in the regulatory gene (acrR) of the acrAB system can result 
in overexpression of acrB and may play a role in macrolide resistance.
251
  As such, we 
decided to use whole genome sequencing to attempt to detect alterations in this gene in our 
resistant isolates that could also be contributing to the resistant phenotype. 
Finally, we attempted to detect the presence of any unknown contributors to macrolide 
resistance in Ci115 and M3 with transformation experiments on susceptible recipients using 
genomic DNA extracted from these isolates.  This involved selecting and whole genome 
sequencing azithromycin-resistant transformants and comparing them to the sequences of the 
donors and recipients to determine whether specific sequences or snps had transferred across 
that may be contributing to macrolide resistance. 
 
 
 
 
 
 
 
Chapter 5: AMRGs and WGS 
135 
 
5.2 Methods and Materials 
5.2.1 Bacterial strains and genomes 
The primary strains of interest were 2 respiratory NTHi isolates (Ci115 and M3) that had 
previously been found to exhibit high-level macrolide resistance (azithromycin MIC ≥ 256 
µg/mL) in Chapter 4 of this work.  Sanger sequencing of both isolates in Chapter 4 had 
previously revealed that isolate M3 carried an A2058 mutation in the 23S rRNA gene and 
that isolate Ci115 carried C2611U and R88P mutations in the 23S rRNA and L22 ribosomal 
protein genes, respectively. 
For the in silico AMRG search (see below), we chose to look more broadly for the presence 
of these genes in a wider collection of NTHi WGSs of unknown macrolide resistance 
phenotype.  The strains included in this analysis were derived from the “De Chiara 
collection”, for which whole genome sequences are publically available.279  The complete set 
of genomes included in this study is listed in Table 5.1. 
For transformation assays, the recipient strains were NTHi strain 86-028NP and H. influenzae 
Rd KW20. 
5.2.2 Transformation assays 
The transformation assays performed in this study were adapted from the methodology 
previously described by Ubukata et al. (2001)
281
 and are described below. 
5.2.2.1 Preparation of genomic DNA 
Genomic DNA of Ci115 and M3 was prepared as previously described in Chapter 3. 
 5.2.2.2 Growth and washing of recipient cells 
Recipient cells were grown overnight on chocolate agar and a heavy suspension (equivalent 
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Table 5.1: Complete list of genomes included in this study.  
#* Strain** #* Strain** #* Strain** 
1 Ci115 32 Hi1621 63 Hi805 
2 M3 33 Hi1622 64 Hi88 
3 DC7331102 34 Hi1623 65 Hi968 
4 Hi1008 35 Hi1630 66 Hi973 
5 Hi11 36 Hi167 67 Hi981 
6 Hi1124 37 Hi17 68 HiPittII 
7 Hi1158 38 Hi176 69 HiR2846 
8 Hi1180 39 Hi177 70 HiR3021 
9 Hi1200 40 Hi199 71 RM600672 
10 Hi1207 41 Hi2019 72 RM601173 
11 Hi1231 42 Hi206 73 RM601974 
12 Hi1233 43 Hi24 74 RM603375 
13 Hi1247 44 Hi264 75 RM605177 
14 Hi1268 45 Hi285 76 RM701878 
15 Hi1363 46 Hi375 77 RM702879 
16 Hi1500 47 Hi398 78 RM702980 
17 Hi1513 48 Hi432 79 RM706883 
18 Hi1549 49 Hi443 80 RM712284 
19 Hi1553 50 Hi477 81 RM730885 
20 Hi1556 51 Hi486 82 RM730986 
21 Hi1557 52 Hi492 83 RM734787 
22 Hi1558 53 Hi525 84 RM744888 
23 Hi1559 54 Hi609 85 RM745989 
24 Hi1560 55 Hi639 86 RM746590 
25 Hi1566 56 Hi658 87 RM747791 
26 Hi1568 57 Hi667 88 RM749092 
27 Hi16 58 Hi709 89 RM761793 
28 Hi1606 59 Hi723 90 RM763794 
29 Hi1607 60 Hi740 91 RM787695 
30 Hi1619 61 Hi787 92 86-028NP 
31 Hi162 62 Hi794 
  
*Each genome was assigned a number for convenience (for referring to specific strains later in the study). 
**Ci115 and M3 are respiratory strains with high-level macrolide resistance that were isolated during the study described in Chapter 4.  The 
remaining sequences were sourced from the De Chiara collection.
279
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to McFarland standard of 2.0) of each strain was prepared in 2.5 mL saline.  This was added 
to 100 mL of sBHI and incubated in air at 37°C on a shaker (180 rpm) until reaching early- to 
mid-log phase growth (represented by an absorbance of approximately 0.5 at 650 nm).  The 
cells were chilled on ice for 30 minutes and subsequently split into two 50 mL Falcon tubes.  
Cells were centrifuged at 4200 g and 4°C for 20 min, and the supernatant was discarded.  
Cells were then resuspended and washed four times in 50 mL cold PSG buffer (15% glycerol, 
272 mM sucrose, 2.43 mM K2HPO4, 0.57 mM KH2PO4) using the same centrifugation 
conditions as above, and recombining the cells into 1 Falcon tube after the second wash.  
After the final wash, cells were resuspended in 1 mL of cold PSG. 
5.2.2.3 Transformation of NTHi 86-028NP and Haemophilus influenzae Rd 
KW20 
Transformation of the washed recipient cells was performed by electroporation using the Bio-
Rad MicroPulser
TM
.  40 µL of cells was combined and mixed gently with 5 µL of donor 
genomic DNA in a cold 1.5 mL microfuge tube and incubated on ice for 1 minute.  The 
mixture was then transferred to a chilled 2 mm cuvette and pulsed using the EC2 setting of 
the MicroPulser (V=2.5kV, time constant = 5 ms). 
5.2.2.4 Growth of transformants 
Transformed cells were flushed from the cuvette using pre-warmed sBHI.  The cells were 
then incubated in 1 mL pre-warmed sBHI in air at 37°C on a shaker (180 rpm) for 4 hours.   
After growth, cells were plated out (100 µL in varying dilutions) onto chocolate agar 
supplemented with 16 µg/mL azithromycin.  To ensure the agar was suitably selective and 
that the probability of random mutants emerging was low, donor and recipient cells were also 
cultured using these plates.  In addition, donor and recipient cells were suspended in saline to 
a 0.5 McF standard; donor suspensions were diluted with recipient suspensions (in varying 
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dilutions) and these were cultured on the agar to ensure that transformants could be isolated 
from a mix with non-resistant cells. 
After growth, potential transformants were procured for further examination. 
5.2.2.5 Antibiotic susceptibility testing 
Azithromycin MICs of transformants were determined using Etest on MH-F agar (refer to 
Chapter 3 for further information) and incubated at 378C in 5% CO2 for 24 h using H. 
influenzae ATCC 49247 as a control. 
5.2.3 Whole genome sequencing 
Isolates of interest were submitted to the Ramaciotti Centre for Genomics (University of New 
South Wales, Australia) for whole genome sequencing.  Isolates submitted were M3 and 
Ci115, NTHi 86-028NP, and select transformants (see Table 5.2 for list of transformants 
submitted). 
5.2.4 Sequence quality check and assembly 
Sequences obtained from whole genome sequencing were uploaded to Galaxy/mGVL 0.10-2 
and analysed for quality and assembled as previously described in Chapter 3 of this thesis.  
The NTHi 86-028NP contained 237 separate Contigs ranging from 56 to 245848 nucleotides 
in length, the Ci115 file contained 334 separate Contigs ranging from 56 to 257287 
nucleotides in length, and the M3 file contained 250 Contigs ranging from 56 to 225265 
nucleotides in length. 
5.2.5 Extraction of acrR and the L4 and L22 gene sequences 
Each assembled sequence was submitted to Rapid Detection using Subsystem Technology 
(RAST, http://rast.nmpdr.org/) for annotation, and sequences for L4, L22 and acrR were 
extracted from the resulting excel spreadsheet outputs.  Each extracted sequence was saved as  
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Table 5.2: List of recovered transformants with azithromycin MIC values. 
Transformant Donor Recipient Azithromycin MIC (µg/mL) 
CA1 Ci115 NTHi 86-028NP 64 
CA3 Ci115 NTHi 86-028NP 32 
CA4 Ci115 H. influenzae Rd KW20 96 
CA6 Ci115 H. influenzae Rd KW20 24 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: AMRGs and WGS 
140 
 
a fasta file and imported into CLC Main Workbench 7.  The sequences of M3 and Ci115 
were assembled against the sequences of NTHi 86-028NP to generate a Contig file for the 
detection of sequence variations.  All sequences were translated to proteins and the protein 
sequences of Ci115 and M3 were aligned against the protein sequence of NTHi 86-028NP to 
detect alterations in protein sequence and length. 
5.2.6 Extraction of 23S rRNA sequences 
The assembled sequences of M3 and Ci115 were mapped to the NTHi 86-028NP 23S 
sequence (NC_007146) using the Burrows-Wheeler-Aligner optimised for long reads (BWA-
MEM) in Galaxy.  The resulting bam and bai files were retrieved and the bam file was 
opened with the Integrative Genomics Viewer (IGV) to visualise alterations in the 23S 
sequence.  The dosage of each alteration was estimated by checking the percentage of 23S 
reads containing the alteration (see Table 5.3). 
5.2.7 In silico AMRG search 
A panel of known acquired MLSB resistance genes was developed (see Table 5.4).  The 
selection of genes for this analysis was guided by the list of recognised genes in the Roberts 
database.
95
 
The analysis was performed using the SPANDx pipeline (Sarovich 2014).
278
  The nucleic 
acid sequences of genomes of interest were converted to amino acid sequences and the 
tBLASTn algorithm was used to assess amino acid identity as previously described and 
recommended by Derek Sarovich (Sarovich et al. 2016).
282
  A BLAST score ratio of 0.70 was 
used as a cut-off; genes with scores below this cut-off were considered absent from the 
WGSs. 
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Table 5.3: Extrapolation between read % output from IGV and copy number. 
Approximate % of reads carrying alteration Number of copies carrying alteration 
16-17% 1 
33-34% 2 
50% 3 
66-67% 4 
83-84% 5 
100% 6 
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Table 5.4: List of genes included in the AMRG screen. 
erm Efflux Deactivation 
Gene Genbank # Gene Genbank # Gene Genbank # 
erm(A) X03216 car(A) M80346 ere(A) M11277 
erm(B) EF450709 lmr(A) X59926 ere(B) A15097 
erm(C) V01278 lsa(B) AJ579365 lnu(A) M14039 
erm(D) M29832 lsa(C) HM990671 lnu(B) AJ238249 
erm(E) X51891 lsa(E) AF408195 lnu(C) AY928180 
erm(F) M14730 mef(A) U70055 lnu(D) EF452177 
erm(G) M15332 mef(E) AF376746 lnu(E) KF287643 
erm(H) M16503 msr(A) X52085 lnu(F) EU118119 
erm(N) X97721 msr(C) AY004350 mph(A) D16251 
erm(O) M74717 msr(D) AF227521 mph(B) D85892 
erm(Q) L22689 msr(E) FR751518 mph(C) AB013298 
erm(R) AY623658 ole(B) L36601 mph(E) FR751518 
erm(S) M19269 ole(C) L06249 mph(F) AM260957 
erm(T) M64090 sal(A) KC693025 vat(A) L07778 
erm(V) U59450 srm(B) X63451 vat(B) U19459 
erm(W) 286053 tlr(C) M57437 vat(C) AF015628 
erm(X) M36726 vga(A) M90056 vat(D) L12033 
erm(Y) AB014481 vga(B) U82085 vat(E) AF139725 
erm(31) AF079138 vga(C) NC_013034 vgb(A) M20129 
erm(32) AJ009971 vga(D) GQ205627 vgb(B) AF015628 
erm(33) AJ313523 vga(E) FR772051   
erm(34) AY234334     
erm(35) AF319779     
erm(36) AF462611     
erm(37) Z74025     
erm(38) AY154657     
erm(39) AY487229     
erm(40) AY570506     
erm(41) EU177504     
erm(42) FR734406     
erm(43) HE650138     
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5.2.8 AMRG search in CARD 
To more thoroughly search for AMRGs in our resistant isolates, the WGSs of Ci115 and M3 
were submitted to CARD.
280
  A BLASTn search was performed on the Contigs against the 
complete database of resistance genes.  Only Contigs that were ≥250 nucleotides in length 
were included in this analysis; 97 Contigs from Ci115 and 60 Contigs from M3 were 
ultimately submitted using this criterion.  In addition, fasta files for both isolates were 
submitted to the Resistance Gene Identifier (RGI) in CARD
280
 for annotation to detect any 
other predicted macrolide resistance-associated gene products. 
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5.3 Results and Discussion 
Analysis of the L4 and L22 sequences extracted from the whole genome sequencing output 
for isolates Ci115 and M3 confirmed the findings reported in Chapter 4.  Ci115 carried an 
R88P alteration in L22 while M3 had no alterations in L22.  Neither of these isolates carried 
alterations in L4.  Analysis of acrR (see Figure 5.1) in M3 revealed a complete gene that also 
bore a number of nucleotide substitutions.  The acrR gene in Ci115 lacked these 
substitutions, but bore an INS 504A alteration that resulted in a frame shift and the generation 
of an early stop codon.  The resulting protein was 170 amino acids in length, representing an 
incomplete protein (complete protein is 188 amino acids in length).  It is not entirely clear 
how much these variations contribute to macrolide resistance in this instance.  Seyama et al. 
(2016a)
251
 have very recently reported that insertions and deletions within acrR resulting in 
the generation of an incomplete protein can resulting in overexpression of acrB, which in turn 
results in increased clarithromycin resistance (but with a comparatively smaller effect on 
azithromycin resistance).  While the 504A insertion seen in Ci115 was not reported in the 
Seyama et al. study,
251
 the varied nature of the insertions and deletions reported in that study 
indicate that acrR serves as a hotspot for the development of macrolide resistance and it is 
possible that INS 504A in acrR may also be a contributing factor here.  However, it is not 
possible to quantify its effect on phenotype in Ci115 given that this strain also carries other 
alterations associated with macrolide resistance, and further work would be required to 
transform this altered acrR variant into another H. influenzae strain in isolation to observe its 
effect in isolation.  In the Seyama et al. study,
251
 a clarithromycin-susceptible isolate was 
reported to have a complete acrR protein with multiple substitutions (using H. influenzae Rd 
KW20 as the reference) much like M3, although the specific alterations were not reported.  
We therefore speculate that the variations observed in acrR in M3 are unlikely to be having 
an effect on macrolide resistance. 
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Figure 5.1: Sequences of acrR of Ci115 and M3 aligned against NTHi 86-028NP.  Matching residues are shown with dots. 
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Alterations detected in 23S rRNA of Ci115 and M3 are summarised in Table 5.5.  All 
alterations detected in Chapter 4 were also detected here (highlighted in yellow in Table 5.5), 
including the known macrolide resistance-associated alterations C2611U in Ci115, and 
A2058G and G2160U in M3.  Interestingly, while all 6 operons of 23S rRNA carried the 
C2611U alteration in Ci115,  it appeared that only 5 of the 6 operons of 23S rRNA carried 
the A2058G alteration in M3, indicating that it is not necessary for all operons to carry the 
A2058G alteration for azithromycin resistance to develop in a strain of NTHi.  To our 
knowledge, this is the first time that any attempt has been made to examine the dosage in 23S 
rRNA in H. influenzae in the context of decreased macrolide susceptibility.  However, further 
work would be required to demonstrate the precise effect of dosage of various 23S rRNA 
mutations on macrolide resistance in NTHi, in isolation from other alterations also known to 
be associated with macrolide resistance. 
A number of other alterations to the 23S rRNA that had not been detected in Chapter 4 were 
also found.  Both isolates carried a number of alterations in domain II (these had not been 
previously investigated in Chapter 4 and are highlighted in green in Table 5.5), but neither 
isolate bore an alteration at position 754, a known ribosomal mutation hotspot in the 
development of macrolide resistance,
274
 and the remaining alterations fall outside the range 
covered by hairpin 35.  M3 additionally carried alterations at positions 2216 and 2579 in 
domain V (highlighted in orange in Table 5.5) although these too have not been previously 
reported to be associated with resistance.  The significance of these alterations in regards to 
macrolide resistance is unclear and beyond the scope of this work. 
Attempts to transform NTHi 86-028NP and H. influenzae Rd KW20 with genomic DNA 
from Ci115 resulted in the generation of only a small number of colonies (2 from 
experiments using NTHi 86-028NP as the recipient and 2 using H. influenzae Rd KW20) and 
these were subsequently investigated using whole genome sequencing.  None of the colonies  
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Table 5.5: Complete list of 23S rRNA alterations* detected in Ci115 and M3. 
Ci115 M3 
23S rRNA 
alteration** 
Number of 
operons with 
alteration 
23S rRNA 
alteration** 
Number of 
operons with 
alteration 
23S rRNA 
alteration** 
Number of 
operons with 
alteration 
23S rRNA 
alteration** 
Number of 
operons with 
alteration 
U538A 6/6 C93U 5/6 U1165G 6/6 C1736U 6/6 
C539A 6/6 A198C 6/6 U1210A 6/6 C1865A 6/6 
A690G 1/6 C503U 6/6 A1218C 6/6 C1870A 6/6 
A819G 1/6 G509A 6/6 U1229G 6/6 A2058G 5/6 
G1087C 6/6 U544A 6/6 A1230G 6/6 C2128A 6/6 
C1088A 6/6 C545A 6/6 C1290U 3/6 U2132A 6/6 
A1090G 6/6 U546G 6/6 C1506U 5/6 G2141C 6/6 
G1106A 6/6 G1098A 3/6 U1507A 5/6 C2150G 6/6 
G1146C 6/6 G1106U 6/6 U1514A 5/6 G2160U 6/6 
U1150C 6/6 G1145C 3/6 C1710U 6/6 G2162A 6/6 
U1153A 6/6 
G1146C*** 3/6 
G1711U 6/6 A2163U 6/6 
G1146A*** 3/6 
A1159G 6/6 U1147C 6/6 G1712A 6/6 G2207U 6/6 
U1165G 6/6 U1150C 3/6 A1730U 6/6 A2208G 6/6 
U1210A 6/6 U1153A 3/6 G1731A 6/6 A2211G 6/6 
A1218C 6/6 A1159G 3/6 G1735A 6/6 U2216C 6/6 
A1229G 6/6     U2579A 6/6 
A1230G 6/6       
A1542G 1/6       
C2611U 6/6       
*Alterations compared to NTHI 86-028NP. 
**Alterations previously recorded in Chapter 4 are highlighted in red text. 
*** G1146 of M3 was altered in all copies of 23S rRNA; 3 copies bore G1146C and 3 copies bore G1146A. 
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recovered from this experiment had azithromycin MIC values as high as the original donor 
(≥256 µg/mL), with MICs falling in the range of 24-96 µg/mL (see Table 5.2).  At this point 
of the analysis, this indicated that either the recovered isolates were random mutants rather 
than true transformants, or that the macrolide resistance observed in Ci115 may be 
multifactorial and that all contributors to the resistance were not transferred to any 
transformant.  Multiple attempts at transformation using genomic DNA from M3, each 
involving changes in conditions such as the concentration of selective agent used in the 
growth media and the volume of DNA used in the reaction, were not successful.  This may be 
because the specific alterations in M3 that are contributing to macrolide resistance are simply 
unable to be transformed into our recipients using our methodology, or because the 
alterations are incapable of increasing macrolide resistance on their own and would need to 
be transformed in unison to see the effect (the odds of transferring everything that is 
contributing to macrolide resistance is low).  We used multilocus sequence typing to 
characterise the donors and recipients by extracting the loci adk, atpG, frdB, mdh, pgi and 
recA, as previously described,
283
 from the spreadsheets previously generated for these 
organisms by RAST.  This was used to generate a phylogenetic bootstrap cladogram (see 
Figure 5.2) in the Molecular Evolutionary Genetics Analysis (MEGA) software package
284
 
with the donors and recipients along with commercially available strains of known identity.  
M3 appeared to be more phylogenetically distinct from the recipients than Ci115 was and this 
may have also contributed to the inability for our recipients to be successfully transformed 
with genomic DNA from M3, although there is little precedent for phylogenetic relationships 
affecting transformation efficiency and it would be necessary to attempt transformation with 
genomic DNA of isolates that are phylogenetically closely related to M3 to further 
investigate this possibility. 
For CA1 (AZ MIC = 64 µg/mL) and CA3 (AZ MIC = 32 µg/mL), the isolates derived from  
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Figure 5.2: Phylogenetic cladogram of donors and recipients alongside commercial strains.  M3 appeared to be genetically distinct from 
Ci115 and the recipients.  Note that L62 represents 86-028NP in this figure. 
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experiments using Ci115 as the donor and NTHi 86-028NP as the recipient, we observed that 
neither isolate received any components of 23S from Ci115 (see Figure 5.3).  CA1 did not 
have any changes in L4 or L22, but appeared to receive a 36kb-sized segment of DNA from 
Ci115 (see Figure 5.4).  This transformation generated a large number of single nucleotide 
polymorphisms (snps) in CA1 across multiple genes, including a cluster of fts genes (see 
Table A2.1 in Appendix 2).  It is not immediately clear how these snps would affect 
macrolide resistance as they have not occurred in regions known to affect macrolide 
susceptibility.  While determining the exact role of these snps is beyond the scope of this 
study, it does raise questions as to how or if this particular segment of DNA is contributing to 
the high macrolide resistance phenotype in Ci115, especially in relation to the effect of the 
previously observed C2611U alteration in 23S and the R88P alteration in L22 of Ci115.    
CA3 carried a DEL 299CTA in the L22 gene that resulted in an in-frame deletion of 
threonine at position 100 of the L22 protein.  CA3 was also observed to carry a snp in nth, an 
endonuclease coding gene, which was also seen in CA1 (see Table A2.1 in Appendix 2), 
although this is unlikely to be contributing to the macrolide resistance seen in CA3.  No other 
changes were observed compared to the reference, indicating that the L22 alteration is the 
most likely cause of the macrolide resistance in CA3.  However, as the specific change 
observed in CA3 was not seen in Ci115, it is most likely not a transferred deletion but rather 
a random mutational change in this specific transformant. 
Neither CA4 (AZ MIC = 96 µg/mL) nor CA6 (AZ MIC = 24 µg/mL), the isolates derived 
from experiments using Ci115 as the donor and H. influenzae Rd KW20 as the recipient, 
carried any alterations in 23S.  Both transformants appeared to exhibit a large degree of 
sequence variation compared to the recipient strain and the vast majority of snps were 
detected in both transformants (see Tables A2.2a-d in Appendix 2 for complete list of  
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Figure 5.3: Comparison of 23S of CA1, CA3 and NTHi 86-028NP, each compared to a reference 23S sequence.  Each sequence carried the 
same snps compared to the reference, indicating that there was no variation between the sequences and that no components of Ci115 were 
transferred to the recipient. 
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Figure 5.4: Snp density plot of CA1, CA3 and NTHi 86-028NP (a).  CA1 received a 36kb-sized segment of DNA from Ci115 that CA3 did 
not receive.  A close-up view of this sequence (b) demonstrates numerous snps compared to the recipient. 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
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alterations), including the macrolide resistance-associated R88P alterations in L22 originally 
detected in Ci115 (corresponding nucleotide alteration is highlighted in yellow in Table 
A2.2b).  This finding indicates that the presence of R88P alone is not necessarily sufficient to 
cause the high-level macrolide resistance observed in the donor, although it may still be one 
of several contributors.  The snps observed in CA4 and CA6 are distinct from those observed 
in CA1.  A number of identical insertions and deletions in both transformants were also 
apparent (see Tables A2.3a-b in Appendix 2).  CA4 appeared to recombine to a greater extent 
than CA6, with CA4 bearing 3 additional clusters of snps that CA6 lacked (see Tables A2.4a-
c in Appendix 2), located within the same 1.1 Mbp region (see Figure 5.5), as well as 4 
additions insertions or deletions (see Table A2.5 in Appendix 2).  These additional 
recombination events in CA4 are interesting to note with consideration of the fact that CA4 
had a higher azithromycin MIC than CA6, although it is not clear how these additional 
components that CA4 carried affect macrolide resistance. 
Overall, these transformation studies have failed to demonstrate any single transferable 
genetic feature to account for the high azithromycin MIC in Ci115 or M3.  The only slightly 
raised azithromycin MICs in the transformants are primarily of academic interest and cannot 
be easily explained by the findings reported here, although the findings hint at a number of 
novel potential hotspots with involvement in macrolide resistance.  While further 
investigating this possibility is beyond the scope of the present study, future studies 
attempting to identify unknown markers of resistance in Ci115 could utilise the very recently 
described technique of Transformed Recombinant Enrichment Profiling (TREP), which 
would involve using genomic DNA from Ci115 to generate a large pool of recombinants of a 
suitable recipient (such as H. influenzae Rd KW20), enriching those recombinants with 
increased resistance to macrolides, and then deep sequencing the enriched pool of 
recombinants to identify potential loci that are contributing to this resistance.  This has  
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Figure 5.5:Snp density plot of CA4 and CA6 (a).  A close-up view of this sequence (b) reveals that CA4 received three additional segments 
of DNA from Ci115 that CA6 did not receive. 
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previously been used to identify loci responsible for invasion in H. influenzae
285
 and could 
potentially be applied here.  In any case, the fact that the C2611U alteration of 23S observed 
in Ci115 was not transferred to any transformants and those transformants subsequently 
exhibited MICs that were lower than Ci115 further supports the finding of multi-copy 23S 
mutations being the primary mechanism of resistance in Ci115.  However, the findings 
reported here may be indicative of a multifactorial aetiology for the high-level macrolide 
resistance in Ci115, with resistance resulting from an accumulation of factors of which only 
some were demonstrated to be transferable. 
The BLAST score output given by the SPANDx pipeline used to screen for the presence of 
select AMRGs in the NTHi WGSs (n=92) included in this study is summarised in Tables 
A2.6a-g, A2.7a-g and A2.8a-g in Appendix 2.  For each gene included in this study, these 
scores were ≤0.21 for all WGSs, indicating that these genes were not present in this particular 
selection of isolates.  The BLASTn analysis performed on Ci115 and M3 in CARD also 
failed to detect any known AMRGs in these isolates.  When the fasta files for these isolates 
were submitted to RGI in CARD, the output for both analyse produced a single match that 
was annotated as a “macrolide resistance gene”.  The match given was for CRP (see Figure 
5.6 for output), an inherent catabolite regulatory protein that has previously been implicated 
as a regulator of the MdtEF multi-drug efflux pump in E. coli.
286
  Deletion of crp in E. coli 
has previously been reported to increase resistance to erythromycin and azithromycin,
286
 but 
CRP appears to be unaltered in Ci115 and M3 compared to NTHi 86-028NP (see Figure 5.7)  
and is unlikely to be contributing to the high-level macrolide resistance observed here.  In any 
case, no known AMRGs were detected in Ci115 and M3 using RGI either.  Our inability to 
detect these genes using the SPANDx system or CARD further supports the idea that the 
macrolide resistance observed in these isolates is not due to the acquisition of AMRGs but to 
the presence of alterations in 23S and other chromosomal components.  Furthermore, the fact  
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Figure 5.6: RGI output for Ci115 and M3. 
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Figure 5.7: Sequences of CRP of Ci115 and M3 aligned against NTHi 86-028NP. 
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that these genes (including the 6 genes investigated in Chapter 4) were not detected among 
any of the other isolates included in this study further indicates that AMRGs are currently not 
widespread among NTHi isolates. 
It is important to note that the genomes included in this study were not necessarily closed 
genomes.  The genomes were assembled from reads of varying size, but there was 
insufficient overlap present across these reads to generate a closed genome.  This raises a 
number of issues when attempting to analyse these genomes for the presence of resistance 
markers.  Firstly, this can result in gaps in the assembled sequences that may have caused 
important features to be missed during the analysis.  In addition, this makes it difficult to 
handle segments for which there are multiple copies, such as 23S rRNA, which were 
assembled together as one segment.  In this instance, dosage of particular mutations could 
still be estimated through the extrapolation of the output in IGV stating the percentage of 
reads carrying the alteration, but it was not possible to state which copy of 23S carried a 
particular mutation in situations where dosage was not complete. 
It is important to stress that the work described here represents preliminary studies in regards 
to how whole genome sequencing could be utilised in the investigation of macrolide 
resistance in NTHi.  While the findings of this study regarding chromosomal alterations do 
raise some interesting questions regarding macrolide resistance mechanisms, further work 
would be required to establish the exact role the numerous alterations observed within the 
transformants generated in this study have in causing resistance to macrolides in NTHi, as 
well as to establish the importance of 23S rRNA dosage in H. influenzae.  However, based on 
the whole genome sequencing and analyses we have completed in this chapter, we conclude 
once again that resistance to macrolides in NTHi can primarily be attributed to alterations in 
specific chromosomal components rather than through the acquisition of macrolide resistance 
genes, and that AMRGs are not currently widespread among NTHi isolates.
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Chapter 6: Phenotypic effect of expression of select acquired 
macrolide resistance genes in Haemophilus influenzae 
6.1 Introduction 
Most isolates of H. influenzae exhibit low-level intrinsic non-susceptibility to macrolide 
antibiotics, attributable to the presence of an inherent efflux mechanism analogous to the 
acrAB system in E. coli.  Despite this, there is increasing interest in utilising macrolides for 
respiratory infections where NTHi may be involved.
25,29
  While the efficacy of these agents in 
treating infections with wild-type NTHi has already been questioned in some instances,
29,274
 
the potential for NTHi to acquire high-level macrolide resistance in response to macrolide 
therapy may further undermine the utility of these agents. 
High-level macrolide resistance in NTHi has historically been attributed to chromosomal 
alterations of the bacterial ribosome structure that inhibit macrolide binding, including 
alterations in 23S rRNA, and the L4 and L22 ribosomal proteins.  In contrast, acquired 
macrolide resistance genes (AMRGs) have not been widely reported among NTHi isolates 
and a number of studies investigating macrolide resistance in H. influenzae have failed to 
detect these genes.
29,251-253
  In the single study where AMRGs have been reported in NTHi, 
the effect of these genes on phenotypic resistance was inconsistent.
93
  In that study, among a 
collection of 106 NTHi isolates from children with cystic fibrosis enrolled in a placebo-
controlled azithromycin trial, all isolates had at least one of the AMRGs erm(A), erm(B), 
erm(C), erm(F) and mef(A).  However, only 27 of these were phenotypically resistant to 
macrolides, with the remaining isolates either intermediate (n=78) or susceptible (n=1).  In 
addition, some of these NTHi isolates were able to conjugatively transfer some or all of their 
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AMRGs to H. influenzae Rd KW20 or E. faecalis JH2-2 recipients with an associated 
moderate to large increase in erythromycin and azithromycin MICs.
93
 
While the findings of this study are remarkable and may suggest a possible role for AMRGs 
in producing a macrolide resistance phenotype in NTHi, the variable macrolide resistance 
phenotype observed in the AMRG-carrying NTHi isolates reported in that study raises 
questions about the ability of these genes to confer high-level macrolide resistance in NTHi.  
Therefore, the aim of this study was to investigate and clarify the expression and phenotypic 
effect of select AMRGs in H. influenzae.  A range of approaches were taken to generate 
AMRG-positive H. influenzae, including conjugative transfer from wild-type Gram positive 
donors, and cloning with and without associated regulatory regions. 
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6.2 Methods and Materials 
6.2.1 Bacterial strains 
The complete list of donor isolates used in this study can be found in Table 6.1.  All were 
Gram positive organisms of human origin that were defined as erythromycin resistant using 
EUCAST methodology and interpretive criteria (for staphylococci, MIC > 2 µg/mL; for 
streptococci, MIC > 0.5 µg/mL) and that carried at least one of erm(A), erm(B), erm(C), 
mef(A) and mef(E).  Locked nucleic acid dual-labelled hydrolysis probes (Sigma-Aldrich, 
NSW, Australia) were used to detect the presence of these genes in each of the donor isolates 
as previously described in Chapter 4 of this thesis.  All seven donor isolates were used for 
conjugation assays, while isolates U37 (erm(A)), U200 (erm(B)), U387 (erm(C)), A22 
(mef(A)) and A7 (mef(E)) were additionally selected for use in cloning studies.  D tests for 
the detection of inducible clindamycin resistance were performed on all erm–carrying cloning 
study strains as previously described
287
 (see Table 6.1).  
For conjugation assays, H. influenzae Rd KW20 was used as the recipient.  Both H. 
influenzae Rd KW20 and E. coli JM109 were used during the cloning assays (see below for 
further details). 
6.2.2 Conjugation of AMRGs into Haemophilus influenzae Rd KW20 
To confirm that our selected H. influenzae Rd KW20 strain was receptive, mating 
experiments were performed to transfer ICEHin1056 from a previously generated H. 
influenzae Rd KW20 transconjugant (donor) to a separate streptomycin-resistant H. 
influenzae Rd KW20 mutant (recipient).  The donor and recipient were mixed in a ratio of 1:5 
and transconjugants were grown on chocolate agar supplemented with streptomycin (500 
µg/mL) and ampicillin (4 µg/mL). 
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Table 6.1: Donor sources of AMRGs used in this study. 
Isolate ID Species Gene of Interest D test AZ MIC (µg/mL) ERY MIC (µg/mL) 
U37* MRSA erm(A) + ≥64 ≥64 
A20 S. pneumoniae erm(B) ND ND ≥1 
U200* S. pneumoniae erm(B)/mef(E) - ≥64 ≥64 
U387* S. aureus erm(C) + ≥64 ≥64 
A22* S. pyogenes mef(A) ND 32 4 
A7 Group G Streptococcus mef(E) ND ≥64 16 
A10* S. pneumoniae mef(E) ND ND ≥1 
AZ, azithromycin; ERY, erythromycin; ND, not determined  
*Source of genes for cloning studies.  Note that U200 carries both erm(B) and mef(E), but only erm(B) was cloned from this isolate. 
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To transfer each of the AMRGs of interest to H. influenzae Rd KW20, mating experiments 
were performed using the Gram positive isolates listed in Table 6.1 as donors and the 
streptomycin-resistant H. influenzae Rd KW20 mutant as the recipient.  The donor and 
recipient were mixed in ratios of 1:1, 1:5 and 1:10; transconjugants were grown on chocolate 
agar with streptomycin (500 µg/mL) and erythromycin (8 µg/mL and 16 µg/mL).  Refer to 
Chapter 3 for further information. 
6.2.3 Cloning and transformation of AMRGs into Haemophilus influenzae 
Rd KW20 
Cloning into H. influenzae is complicated by the absence of suitable vectors, as most 
commercial vectors are designed for use in E. coli and do not replicate in H. influenzae. This 
laboratory has frequently used the shuttle vector pLS88 and we have previously observed 
significant run-off transcription of open reading frames (ribosome binding site present but 
promoters absent) cloned into the EcoRI restriction site. We sought to confirm this and 
determine the importance of cloning orientation by cloning blaTEM-1 (where effect of 
expression on phenotype is known) as a prelude to cloning the acquired macrolide resistance 
genes. 
6.2.3.1 Cloning of blaTEM-1 and AMRGs into Escherichia coli JM109 
The kanamycin resistance-marked plasmid pLS88 was extracted from a previously generated 
pLS88-carrying E. coli in accordance with the protocol outlined in the QIAGEN Plasmid 
Mini Kit (QIAGEN, Hilden, Germany).  The plasmid was digested with EcoRI (Promega) at 
37°C for 3 hours, followed by an incubation of 65°C for 15 minutes to deactivate the enzyme.  
Subsequently, the plasmid was digested with alkaline phosphatase (AP) (Promega, calf 
intestinal) at 37°C for 3 hours to prevent re-ligation. 
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To prepare the blaTEM-1 insert for cloning, pGEM-3Z (Promega) was used as a template for 
PCR using EcoRI-tailed blaTEM-1 primers as listed in Table 6.2.  To prepare the AMRGs for 
cloning into pLS88, genomic DNA was extracted from each of the selected donor isolates.  
Using the genomic DNA as a template, the inserts were generated by PCR using the EcoRI-
tailed gene specific primers listed in Table 6.2.  In all instances, primers were designed such 
that the amplicon included the RBS.  Sequencing was performed to confirm the identity of 
the AMRG inserts, using the primers listed in Table 6.3.  The AMRGs and blaTEM-1 were 
digested with EcoRI as above. 
To construct the recombinant plasmids, the digested amplicons were ligated with the 
linearised phosphatase-treated plasmid using T4 DNA ligase (Promega).  Maps of these 
vectors (excluding blaTEM-1) are shown in Appendix 3 of this thesis.  These constructed 
plasmids were combined with commercially prepared E. coli JM109 recipient cells 
(Promega) and incubated on ice for 30 minutes.  The cell-plasmid mixture was then heat-
shocked at 42°C for 20 seconds before being returned to ice for 2 minutes.  The heat-shocked 
cells were suspended in 450 µL SOC media (Bioline) and grown at 37°C for 80 minutes 
before being plated on LB media supplemented with kanamycin (30 µg/mL). 
The presence of respective AMRGs in the resulting E. coli clones were confirmed using 
locked nucleic acid dual-labelled hydrolysis probes as previously described in Chapter 4 and 
the presence of blaTEM-1 confirmed by PCR (blaTEM-F, 5’-GAAGACGAAAGGGCCTCGTG-
3’; blaTEM-R, 5’-GGTCTGACAGTTACCAATGC-3’) as previously described.
288
  The inserts 
in the clones were amplified using primers designed for the amplification of regions flanking 
the insertion site of pLS88 (pLS88seq-F, 5’-GACTTCATCCGCACACAC-3’; pLS88seq-R, 
5’-CAGGCAACCAGTCAGAAT-3’); amplicons were submitted to the Australian Genome 
Research Facility for sequencing (as previously described in Chapter 3 of this thesis) to 
confirm that the cloned genes were complete. 
Chapter 6: AMRG expression 
165 
 
 
 
 
 
 
 
Table 6.2: Primers used for the preparation of blaTEM-1 and AMRG inserts into pLS88. 
Gene/Region* 
With 
promoter? 
Description of PCR 
Annealing 
Temp. (°C) 
Primer Name Primer Sequence (5’ – 3’) 
blaTEM-1 No 
Preparation of blaTEM-1 
insert 
55 
TEM-CL-F GCGCGAATTCAAAAAGGAAGAGTATG 
TEM-CL-R GCGCGAATTCACCTAGATCCTT 
erm(A) No 
Preparation of erm(A) 
insert 
ermA-CLNG-F GCGCGAATTCTGAACGCTTAATGTCAGTTCATT 
ermA-CLNG-R GCGCGAATTCGCGTCCTCTTGTGAAATTAGAGA 
erm(A) Yes 
Preparation of erm(A) 
insert 
57 
ermA-clprF GCGCGAATTCATCGTAATCTTCTGCAACCT 
ermA-clprR GCGCGAATTCAGCGTCCTCTTGTGAAAT 
erm(B) No 
Preparation of erm(B) 
insert 
55 
ermB-CLNG-F GCGCGAATTCTTTATAGATGTAATCACTTCAGGA 
ermB-CLNG-R GCGCGAATTCCCAAATTTACAAAAGCGACTCA 
erm(B) Yes 
Preparation of erm(B) 
insert 
51 
ermB-clprF GCGCGAATTCAGAGTGTGTTGATAGTG 
ermB-clprR GCGCGAATTCGAATTATTTCCTCCCGT 
erm(C) No 
Preparation of erm(C) 
insert 
55 
ermC-CLNG-F GCGCGAATTCCAAATTAAAGAGGGTTATAATGAACG 
ermC-CLNG-R GCGCGAATTCTGCAGTTTATGCATCCCTTA 
erm(C) Yes 
Preparation of erm(C) 
insert 
54 
ermC-clprF GCGCGAATTCGCTCTACGACCAAAACTA 
ermC-clprR GCGCGAATTCGCAGTTTATGCATCCCTT 
mef(A)/mef(E) No 
Preparation of 
mef(A)/mef(E) insert 
55 
mef-CLNG-F GCGCGAATTCTCAAGCAAAAATAATATGCAGGAGA 
mef-CLNG-R GCGCGAATTCCAGGAAGAGTTACATGAAAATAAGA 
mef(A)/mef(E) Yes 
Preparation of 
mef(A)/mef(E) insert 
54 
mefE-clprF GCGCGAATTCCAGACCAAAAGCCACATT 
mefE-clprR GCGCGAATTCGCGATTTTAGCAGGAAGA 
*The mef primers were used for mef(A) and mef(E). 
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Table 6.3: Primers used to sequence inserts after preparation. 
Primer Sequence (5’ – 3’) 
ermA-106f
289
 GAA ATY GGR TCA GGA AAA GG 
ermA-437r
289
 AAY AGY AAA CCY AAA GCT C 
ermB-91f
289
 GAT ACC GTT TAC GAA ATT GG 
ermB-454r
289
 GAA TCG AGA CTT GAG TGT GC 
ermC-43f
289
 TCA AAA CAT AAT ATA GAT AAA 
ermC-684r
289
 GCT AAT ATT GTT TAA ATC GTC AAT 
mefA-MF6
290
 GGA CCT GCC ATT GGT GTG 
mefA-MF4
290
 ACC GAT TCT ATC AGC AAA G 
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6.2.3.2 Electroporation of Haemophilus influenzae recipient cells 
H. influenzae Rd KW20 cells were grown to an optical density at 650 nm (OD650) of 0.5 in 
Heart Infusion Broth (Oxoid) supplemented with Vitox (Oxoid) and 15 µg/mL NAD and 
haematin (Oxoid) at 37°C on a shaker. 
Cells were subsequently chilled for 30 minutes and washed 5 times with PSG buffer (15% 
glycerol, 272 mM sucrose, 2.43 mM K2HPO4, 0.57 mM KH2PO4) at 4°C.  Following washes, 
cells were resuspended in 1 mL cold PSG buffer.  The plasmids carrying the AMRGs or 
blaTEM-1 were introduced into the washed cells by electroporation.  Cells were electroporated 
in 2 mm cuvettes using the Bio-Rad MicroPulser
TM
 set on the EC2 setting of the MicroPulser 
(voltage of 2.5kV and time constant of approximately 5 ms).  Electroporated cells were 
suspended in sBHI and incubated at 37°C on a shaker for 4 hours.  Transformants were plated 
on chocolate agar supplemented with kanamycin (30 µg/mL) and grown overnight in 37°C in 
CO2.  Transformants were confirmed using locked nucleic acid dual-labelled hydrolysis 
probes as previously described in Chapter 4. 
6.2.3.3 Determination of insert orientation 
Primers for the amplification of regions flanking the insertion site (listed in section 6.2.3.1) 
were designed to determine and subsequently confirm the inserts were in the correct 
orientation for expression.  To determine which orientation was “correct”, select  blaTEM-1-
carrying H. influenzae transformants first underwent ampicillin disc diffusion susceptibility 
testing in accordance with the recommendations of EUCAST
291
 alongside an untransformed 
control to create 2 groups of transformants: one group of resistant transformants and one 
group of susceptible transformants.  To determine the insert direction of these groups of 
transformants, 2 separate PCR reactions were performed on each transformant. One reaction 
used pLS88seq-F and TEM-CL-F, and the other reaction used pLS88seq-F and TEM-CL-R; 
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our rationale was that only one of these reactions should result in an amplicon depending on 
the direction.  These PCRs revealed that resistant transformants produced an amplicon with 
the reaction involving TEM-CL-R only, while the susceptible transformants produced an 
amplicon with the reaction involving TEM-CL-F only. 
These results were used to develop a screening method to the determination of the orientation 
of the inserts in the AMRG-carrying transformants (without natural promoters only).  This 
screen involved testing select transformants as above, but substituting the TEM primers for 
the corresponding AMRG primers listed in Table 6.3.  Transformants that produced an 
amplicon with the corresponding reverse primers only were deemed to carry the insert in the 
correct orientation for expression. 
6.2.4 Macrolide susceptibility testing and D tests 
Erythromycin and azithromycin MICs for the transformants were determined by broth 
microdilution as previously described in Chapter 3.  D tests were performed on all erm 
“native promoter” transformants as previously described.287 
6.2.5 Expression analysis 
To prepare transformants for RNA extractions, isolates were grown overnight on chocolate 
agar supplemented with kanamycin (30 µg/mL) to maintain the plasmid.  The overnight 
growth was subcultured to 10 mL of sBHI supplemented with kanamycin (30 µg/mL) and 
incubated in air at 37°C on a shaker (180 rpm) until reaching early- to mid-log phase growth 
(represented by an absorbance of approximately 0.5 at 650 nm).  In addition, for those 
transformants with AMRGs cloned with natural promoters, broths were prepared as above 
but with the addition of erythromycin at a level of 0.125 of the previously determined MIC 
for each transformant. 
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After reaching log-phase growth, cells were chilled on ice for 30 minutes before RNA 
extractions were performed on all AMRG-carrying H. influenzae transformants as previously 
described in Chapter 3.  DNA was quantified using the locked nucleic acid dual-labelled 
hydrolysis probes (Sigma-Aldrich, NSW, Australia) previously described in Chapter 4 of this 
thesis.  gyrA was selected as the housekeeping gene for all transformants (F primer, 5’-
TCCAATCATCTATCACCC-3’; R primer, 5’-TTACATCACCCACAACAC-3’; probe, 5’-
TGCACGCCCAACGATAACC-3’).  All samples were run in parallel with a no-RT control 
to ensure no contamination with genomic DNA was present.  ΔCT values for each 
transformant were calculated using the formula ΔCT  = 2-(CT(GOI)-CT(gyrA)). 
Comparisons of ΔCT values were performed using unpaired t-tests.  Firstly, ΔCT values 
produced by each of the 5 AMRG-carrying transformants (with no natural promoter and no 
erythromycin exposure) were compared to ΔCT of untransformed H. influenzae Rd KW20 to 
determine if any increase in the mRNA change was statistically significant.  Comparisons 
were also performed between each of the 5 AMRG-carrying transformants to determine if the 
amount of expression was consistent across all transformants.  Secondly, for each of the five 
AMRGs, ΔCT comparisons were performed between transformants with their own natural 
promoters and transformants without their own natural promoters.  Finally, for each 
transformant with their natural promoters, ΔCT comparisons were performed between 
transformants grown in broth without erythromycin exposure and transformants grown with 
erythromycin exposure.  A p-value of 0.05 was used as a cut-off for significance for all tests. 
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6.3 Results and Discussion 
The aim of this study was to investigate the effect of expression of select acquired macrolide 
resistance genes in H. influenzae.  Initially, we attempted to naturally transfer these genes to 
H. influenzae Rd KW20 by conjugation.  We were able to efficiently transfer ICEHin1056 
into our designated recipient by conjugation, demonstrating that the strain was receptive and 
that our conjugation protocol was appropriate.  However, our attempts at transferring 
AMRGs from the Gram positive donors were not successful in generating transconjugants 
using the method described above. 
This is in contrast to the Roberts et al. (2011) study, in which these genes were successfully 
transferred from NTHi donors to both H. influenzae and E. faecalis recipients with an 
associated increase in macrolide MICs.  In reviewing the findings of Roberts et al., we noted 
a number of issues with the way in which transconjugants were detected and analysed.  While 
Roberts et al. were able to confirm the presence of the various AMRGs of interest in the 
transconjugants generated in that study, none of the transconjugants were analysed for the 
presence of macrolide resistance-associated L4 or L22 mutations, or 23S rRNA alterations.  
In the work described in Chapter 5 of this thesis, we were able to generate spontaneous 
macrolide resistant mutants of H. influenzae Rd KW20 by selection on media supplemented 
with macrolides (azithromycin, 16 µg/mL); this resistance was associated with a DEL 
299CTA in the L22 gene.  In addition, the range of conjugation efficiencies reported in the 
Roberts study (2.5x10
-10
 transconjugants/recipient – 3.7x10-7 transconjugants/recipient) are 
not drastically different from previously reported macrolide resistance-associated L4, L22 
and 23S rRNA mutation frequencies in H. influenzae mutants placed under selective pressure 
with inhibitory levels of azithromycin and clarithromycin.
273
  Given that the azithromycin 
MIC values observed in such mutants have been shown to be at around the same level as that 
observed in the transconjugants generated in the Roberts study (depending on the mutation 
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type),
93,273
 we feel that it may have been valuable for Roberts et al. to analyse all 
transconjugants for the presence of L4, L22 and 23S rRNA alterations to determine that these 
were not contributing to the raised MICs observed in the transconjugants and further support 
the conclusion that the AMRGs could act as a resistance determinant in NTHi. 
In designing our conjugation experiments, we were not certain of how great an extent the 
erythromycin MIC would change in H. influenzae as a result of acquiring these genes, and as 
such it was difficult to determine the appropriate erythromycin concentration in our selective 
plates.  Roberts et al. used a concentration of 5 µg/mL for the selection of H. influenzae 
transconjugants,
93
 but we found that our particular H. influenzae Rd KW20 recipient strain 
was not inhibited at this concentration and therefore used concentrations of 8 and 16 µg/mL 
instead.  Given that some of the transconjugants obtained in the Roberts et al. study had 
erythromycin MICs as low as 12 µg/mL,
93
 it is possible that 8 µg/mL may have been too high 
to allow for transconjugants to grow effectively on our media.  For future studies, it may be 
more appropriate to select a different recipient strain that is more easily inhibited at lower 
concentrations of erythromycin to increase the chance of recovering transconjugants. 
It is worth noting that the range of AMRG donor isolates we had access to and the range of 
donors used by Roberts et al. represent a key difference between the two studies.  When 
attempting to conjugatively transfer AMRGs to H. influenzae Rd KW20, we were unable to 
attempt to replicate the works of Roberts et al. (2011) because we did not have access to any 
wild-type NTHi isolates with AMRGs.  We instead used select AMRG-carrying Gram 
positive organisms such as S. aureus and various streptococci as donors for these 
experiments.  The use of these species as donors was deemed appropriate in this case because 
these species are both known to be involved in respiratory infections and common carriers of 
the particular AMRGs included in this study.  These species can additionally coexist with 
NTHi within the same respiratory niche, creating a significant opportunity for the natural 
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transfer of these AMRGs to NTHi; indeed, Roberts et al. put forth the possibility of the 
occurrence of AMRG transfer between species coexisting in the lungs or oral cavity
93
, and 
Luna et al. had previously been able to demonstrate conjugative transfer of mef from S. 
pneumoniae to H. influenzae.
255
  We therefore felt that demonstrating AMRG transfer from 
these Gram positive donors to H. influenzae would be especially relevant in assessing the 
potential for these genes to emerge as threats in NTHi.  Ultimately we were unable to 
demonstrate conjugative transfer using these donors.  It is worth noting that the main 
precedent for this natural transfer of AMRGs from Gram positive respiratory organisms to 
NTHi is the Roberts study, and there is otherwise little experimental evidence available for 
such transfer given that these genes are not widely seen in NTHi despite the species sharing a 
niche with Gram positive AMRG carriers.  Given that this transfer would need to cross a 
significant taxonomic barrier, it may simply be that these genes very rarely transfer to NTHi 
despite the aforementioned opportunities in which it could occur, and that it may only occur 
under very specific circumstances involving selective pressure from macrolide maintenance 
therapy observed in the Roberts study. 
As we were not able to generate AMRG-carrying H. influenzae transconjugants, we instead 
decided to clone the genes into a shuttle vector and use this construct to transform H. 
influenzae Rd KW20.  Out initial requirement was to observe the macrolide resistance effect 
of the expression of AMRGs in H. influenzae, and given the complexity of the regulatory 
regions of many AMRGs, our first option was to clone the AMRGs without native promoters 
such that they would be expressed from run-off transcription from the plasmid itself.  The 
calculated ΔCT values for each of these “no native promoter” transformants were statistically 
significantly increased compared to that of the untransformed H. influenzae Rd KW20 
control (erm(A), p=0.0047; erm(B), p=0.0031; erm(C), p<0.0001; mef(A), p=0.0037; mef(E), 
p=0.0018; see Figure 6.1), for which no amplification occurred using the AMRG locked  
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Figure 6.1: ΔCT values (mRNA Fold Change (relative to gyrA)) for each of the 5 transformants (“no native promoter”) and untransformed 
H. influenzae Rd KW20.  Note that each transformant only amplified with the primer set corresponding to the gene of interest; the columns 
represent expression of the gene of interest for each transformant only.  Untransformed H. influenzae Rd KW20 produced no amplification 
with any primer set.  Expression of each AMRG was statistically significantly increased compared to the untransformed H. influenzae Rd 
KW20. 
*, p<0.01; **, p<0.001; ***, p<0.0001. 
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nucleic acid dual-labelled hydrolysis probes, indicating that all genes were being expressed in 
H. influenzae.  Interestingly, when the ΔCT values of each transformant were compared to 
one another, the ΔCT values differed significantly (see Table 6.4 and Figure 6.2), indicating 
that the level of expression of each gene was not constant across the transformants despite 
being cloned into the same site on the same plasmid.  These results were confirmed by a 
repeat experiment, using the same transformants but fresh RNA isolation, cDNA generation 
and quantification, and are not easily explained. 
The MIC results for the “no native promoter” transformants are listed in Table 6.5.  Of the 
erm genes included in this study, the erm(A) transformant (erythromycin MIC = 16 µg/mL, 
azithromycin MIC = 4 µg/mL) did not appear to have a large increase in MIC compared to 
the untransformed H. influenzae Rd KW20 strain (erythromycin MIC = 8, azithromycin MIC 
= 4).  By comparison, the erm(B) (erythromycin MIC = 64 µg/mL, azithromycin MIC = 32 
µg/mL) and erm(C) (erythromycin MIC > 64 µg/mL, azithromycin MIC > 64 µg/mL) 
transformants had much larger MIC increases.  This is reflected by the differences in ΔCT 
values for these transformants, with the erm(A) transformant having significantly lower 
expression than that of the other erm transformants.  By contrast, the MIC values for the 
mef(A) and mef(E) were unchanged from the untransformed H. influenzae Rd KW20 strain.  
This is despite the expression analyses demonstrating expression of these genes was even 
higher than that of the erm genes.  These observations may reflect different efficiencies of the 
respective enzyme products of the genes. 
In the Roberts study (in which mef(A) and mef(E) were not differentiated), mef(A) was 
successfully transferred by conjugation and resulted in the generation of transconjugants 
exhibiting moderate erythromycin and azithromycin MIC increases in the order of 2- to 24 
fold and 5- to 15-fold, respectively.
93
  It is therefore interesting to note that our mef(A) and 
mef(E) transformants did not exhibit any increase in MICs of these antibiotics.  As previously  
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Table 6.4: Transconjugant pair ΔCT comparisons. 
 p-values* 
Vs. Rd KW20 erm(A) Rd KW20 erm(B) Rd KW20 erm(C) Rd KW20 mef(A) Rd KW20 mef(E) 
Rd KW20 erm(A)  0.0464 0.0023 0.0046 0.0038 
Rd KW20 erm(B)   0.0073 0.0051 0.0058 
Rd KW20 erm(C)    0.0063 0.0129 
Rd KW20 mef(A)     0.0099 
Rd KW20 mef(E)      
     *A p-value of 0.05 was used as the significance cut-off 
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Figure 6.2: ΔCT values (mRNA Fold Change (relative to gyrA)) for each of the 5 transformants (“no native promoter”).  Each level of 
expression of each AMRG was statistically significantly different when compared to one another. 
*, p<0.01; **, p<0.001; ***, p<0.0001. 
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Table 6.5: Erythromycin and azithromycin MIC results for untransformed H. influenzae Rd 
KW20 and each transformant (“no native promoter”). 
Strain 
MIC (µg/mL) 
AZ ERY 
H. influenzae Rd KW20 (no insert) 4 8 
H. influenzae Rd KW20 (erm(A)) 4 16 
H. influenzae Rd KW20 (erm(B)) 32 64 
H. influenzae Rd KW20 (erm(C)) >64 >64 
H. influenzae Rd KW20 (mef(A)) 4 8 
H. influenzae Rd KW20 (mef(E)) 4 8 
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discussed, Roberts et al. did not analyse these transconjugants for alternate resistance 
mechanisms such as L4, L22 and 23S rRNA alterations.
93
  If these transconjugants did have 
an alternate mechanism or mutation that had developed in the background during 
conjugation, it may be that this is contributing to the phenotype (either in combination with 
the effect of mef or as the sole contributor).  During our study, we used media supplemented 
with kanamycin to select for transformants rather than a macrolide; given that our  
transformants were not exposed to the same selective pressure present in the Roberts study to 
select background mutants, it is probable that our transformants lack this additional 
mechanism required for mef to have an effect on the macrolide resistance phenotype.  This 
may also explain difference between our study and the observations of Tinguely et al. (2011), 
in which isolates of H. parainfluenzae exhibiting high-level macrolide resistance were found 
to carry mef(A) but also bore the macrolide resistance-associated L4 alteration A69S that may 
have also contributed to the phenotype in those particular isolates. 
Another explanation for our observations is that our study did not account for the role of 
msr(D), an msr(A) homolog found downstream of the mef gene.  Previous studies have 
indicated that mef and msr(D) are co-transcribed as a inducible dual efflux system,
184,185
 and 
that msr(D) may be critical for the development of the M phenotype.
186,187
  The inserts 
prepared for the clones generated in this study did not cover the range including msr(D).  
Given that the isolates of H. influenzae and H. parainfluenzae mef genes detected by Roberts 
et al. and Tinguely et al., respectively, were naturally occurring and likely carried msr(D) 
alongside mef, the presence of msr(D) in those isolates (and subsequently generated 
transconjugants) may have also contributed to the difference in the phenotype in our 
transformants.  While the role of msr(D) is beyond the scope of this particular study, there is 
merit in investigating the role of msr(D), both standalone and in unison with mef, in the 
development of macrolide resistance in NTHi. 
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After this initial experiment, we then attempted to clone each of these AMRGs with their 
respective native promoters to determine if any change in phenotype and expression level 
was apparent.  ΔCT values were obtained for each of these new “native promoter” 
transformants and compared to the corresponding “no native promoter” transformants 
obtained in the first experiment.  Of the 5 genes included in this study, the level of expression 
of the erm(B) and mef(E) transformants did not appear to be statistically significantly 
different between the two pairs (erm(B), p=0.6186; mef(E), p=0.3746; see Figure 6.3).  When 
the erythromycin and azithromycin MICs were determined for the erm(B) and mef(E) “native 
promoter” transformants, no significant changes in the MICs were apparent compared to the 
corresponding “no native promoter” transformants (see Table 6.6), which is consistent with 
the findings of the expression analyses.  On the other hand, the erm(C) and mef(A) “no native 
promoter” transformants produced a significantly lower ΔCT than the corresponding “no 
native promoter” transformant (erm(C), p=0.0013; mef(A), p=0.0049; see Figure 6.3).  In the 
case of the erm(C) transformant, this drop in expression resulted in a corresponding decrease 
in erythromycin and azithromycin MICs compared to its paired “no native promoter” 
transformant (see Table 6.6), so we can conclude that this drop in expression was sufficient to 
result in a less resistant phenotype in H. influenzae.  No changes in erythromycin and 
azithromycin MICs were observed in the mef(A) transformant.  Given that the expression 
observed in the mef(A) “no native promoter” transformant was found not to be sufficient to 
increase the MICs in H. influenzae, this particular observation is not unexpected. 
The erm(A) “native promoter” transformant produced a significantly higher ΔCT than its 
corresponding “no native promoter” transformant (erm(A), p=0.0097; see Figure 6.3).  In 
addition, a corresponding and significant increase in erythromycin and azithromycin MICs of 
the erm(A) “native promoter” transformant was observed (see Table 6.6).  From this, we can 
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Figure 6.3: ΔCT values (mRNA Fold Change (relative to gyrA)) for each of the 5 transformants (“no native promoter” vs. “native 
promoter”).  A, all genes; B, erm(A); C, erm(B); D, erm(C); E, mef(A); F, mef(E). 
*, p<0.01; **, p<0.001; ***, p<0.0001. 
 
A) 
C) D) 
E) F) 
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Table 6.6: Erythromycin and azithromycin MIC results for each transformant (“native 
promoter”). 
Strain 
MIC (µg/mL) 
AZ ERY 
H. influenzae Rd KW20 (erm(A)) >64 >64 
H. influenzae Rd KW20 (erm(B)) >64 >64 
H. influenzae Rd KW20 (erm(C)) 4 16 
H. influenzae Rd KW20 (mef(A)) 4 8 
H. influenzae Rd KW20 (mef(E)) 4 8 
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say that this increase in expression was enough to generate a resistant phenotype.  It is 
interesting to note that the level of expression of erm(A) required for the development of 
macrolide resistance appears to be greater than the level of expression of erm(B) and erm(C) 
required to give a similar outcome.  As referred to previously, this may indicate that erm(B) 
and erm(C) produce greater efficiency in modifying the macrolide binding target site, 
although further investigations would be required to establish this.  It should be noted here 
that while this study involved the analysis of gene expression through cDNA measurements, 
no measurements of protein levels were made.  Given that there may be potential for post-
transcriptional regulation of these resistance genes, it would be valuable to additionally 
analysis protein levels to see if the differences in the various erm genes attributable to factors 
other than gene expression.  In any case, expression of all erm genes of interest and 
subsequent development of macrolide resistance in H. influenzae has been demonstrated 
across these two studies. 
As previously discussed in this thesis, AMRGs can be inducibly or constitutively expressed 
depending on the structure of the promoter, and among our collection of donors, the erm(A) 
and erm(C) donors (U37 and U387, see Table 6.1) were found to be inducibly resistant to 
clindamycin by D test.  The erm(B) (U200) donor was constitutively resistant to clindamycin 
by comparison.  To see if this profile was retained by the “native promoter” transformants, 
we performed D tests on each of these erm gene transformants, using untransformed H. 
influenzae Rd KW20 as a control.  No evidence of induction was found in any of these 
transformants.  The erm(C) transformant D test profile was identical to the untransformed H. 
influenzae Rd KW20 control, suggestive of no reduced MLSB antibiotic susceptibility.  Given 
that the previous expression analyses had shown that the “native promoter” erm(C) 
transformant had reduced expression of erm(C) (see Figure 6.3) and that the erythromycin 
and azithromycin MICs were not increased significantly compared to the untransformed  
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control (see Table 6.6), the D test results is not surprising.  The D test results for the erm(A) 
and erm(B) transformants indicated that the genes were being constitutively expressed (no 
zones of inhibition, see Table 6.7).  In the case of erm(A), this change from inducible 
phenotype (in the original donor) to constitutive phenotype (in the transformant) may be 
reflective of the high degree of expression of erm(A) observed in the transformant in the 
absence of the inducer (see Figure 6.3). 
It is important to note that the D test performed here is primarily designed for use for the 
detection of inducible clindamycin resistance in S. aureus and other Gram positive cocci, and 
it is not optimised for use in H. influenzae.  When performing the tests here, the 
transformants were tested on chocolate agar and grown overnight in a CO2 environment, and 
it is not clear what impact these factors have on the performance of the test.  In addition, the 
erythromycin and clindamycin discs were placed 15 mm apart in accordance with previously 
described methodologies but it is not known if this is the optimal spacing for this species.  
Given there is precedent for the importance of proper disc spacing in antibiotic resistance 
testing of H. influenzae, namely in regards to disc spacing issues presented in the detection of 
extended-spectrum β-lactamases (ESBLs) in H. influenzae through adjacent positioning of 
cephalosporin and augmentin discs,
292
 we felt an alternative method for testing the effect of 
inducers on the expression of the AMRGs in our “native promoter” transformants was 
warranted.  Therefore, we decided to repeat the expression analysis on the “native promoter” 
transformants (including the mef transformants), but with growth of the transformants in 
broth supplemented with a sub-inhibitory dose of erythromycin, a known inducing agent of 
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these genes, to see if expression would be increased in any of our transformants under these 
conditions.  When performing these assays, we chose to supplement our growth media with 
erythromycin set at a concentration of 0.125 of the erythromycin MIC of the transformant of 
interest, and we should note here that little information is available on what would be an  
 
 
 
 
 
Table 6.7: D test results for erm transformants (“native promoter”). 
Strain E15 zone size* (mm) DA2 zone size* (mm) D Test Interpretation 
H. influenzae Rd KW20 12 10 - 
H. influenzae Rd KW20 (erm(A)) 0 0 - (constitutive) 
H. influenzae Rd KW20 (erm(B)) 0 0 - (constitutive) 
H. influenzae Rd KW20 (erm(C)) 12 11 - 
* Diameter of inhibition around disc 
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appropriate concentration of erythromycin for this kind of investigation in H. influenzae and 
that the selection of this particular concentration was somewhat arbitrary.  One previous 
study investigating induction of AMRGs in S. pneumoniae used concentrations of inducer set 
at 0.1-0.2 of the MIC of the strain,
293
 so the selection of 0.125 in the present study has some 
precedent, but to further investigate the effect of inducers on the expression of AMRGs in H. 
influenzae, there may be some merit in performing the expression analyses using a range of 
different concentrations of the inducer to determine if the effect changes depending on this 
variable. 
ΔCT values were obtained for each transformant and compared to the corresponding ΔCT 
from the “native promoter” transformants grown without the inducer.  The ΔCT values for 
erm(A), erm(C) and mef(E) appeared to be increased after growth with the presence of 
erythromycin, with a slight drop for mef(A) and little difference for erm(B).  However, for 
each of the 5 genes, these differences did not appear to be statistically significantly different 
(erm(A), p=0.0736; erm(B), p=0.8586; erm(C), p=0.4693; mef(A), p=0.4597; mef(E), 
p=0.3483; see Figure 6.4).  Based on the findings of this study we are unable to conclude that 
the inducer has truly had an effect on the expression of these AMRGs in H. influenzae, and as 
such we have not been able to demonstrate potential inducible clindamycin resistance in our 
transformants. 
To summarise this chapter, we reiterate that the main aim of this chapter was to investigate 
the phenotypic effect of expression of select AMRGs in H. influenzae, using a number of 
different approaches.  Through cloning of these genes into a shuttle vector and subsequent 
transformation of these vectors into H. influenzae Rd KW20, our findings indicate that 
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expression of each of erm(A), erm(B) and erm(C) can result in a macrolide resistant 
phenotype in H. influenzae, with the latter two being potentially more efficient than erm(A) 
in this regard.  On the other hand, expression of mef(A) and mef(E) did not 
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Figure 6.4: ΔCT values (mRNA Fold Change (relative to gyrA)) for each of the 5 transformants (“native promoter”; “no erythromycin” vs. 
“erythromycin” ).  A, all genes; B, erm(A); C, erm(B); D, erm(C); E, mef(A); F, mef(E). 
*, p<0.01; **, p<0.001; ***, p<0.0001. 
 
A) B) 
C) D) 
E) F) 
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appear to have an effect on the macrolide resistance phenotype in this species on their own.  
Given that Roberts et al. (2011) have previously demonstrated that isolates acquiring mef can 
develop macrolide resistance, our findings indicate that these genes may only produce an 
effect in combination with another mechanism, such as underlying chromosomal mutations, 
or msr(D).  Further work is required to establish just how these different resistance 
mechanisms interact with one another. 
It is still unclear how much of a threat these particular AMRGs pose to future treatment 
regimes of diseases involving NTHi.  While we have been able to demonstrate a resulting 
high-level resistance phenotype through expression of erm(A), erm(B) and erm(C) in the 
present study, we were unable to demonstrate conjugative transfer of these erm or mef genes 
to H. influenzae and have yet to find these genes in wild-type strains of NTHi.  The study of 
Roberts et al. (2011) remains the only study in which these genes have been reported in wild-
type strains of NTHi, and while the authors of that study were able to demonstrate 
conjugative transfer of mef(A), erm(F) and erm(A), the MICs in resulting transconjugants 
was only moderately increased and cannot definitively be attributed to the presence of these 
genes alone.
93
  The potential role of these and other AMRGs in NTHi may warrant further 
monitoring in the future due to the potential for the acquisition and expression of these genes 
to cause reduced macrolide susceptibility, but based on the information we have currently 
acquired, we conclude that AMRGs are not a widespread threat among NTHi isolates and 
that chromosomal alterations remain the main contributor to high-level macrolide resistance 
acquisition in this species. 
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Chapter 7: Conjugative transfer of select acquired macrolide 
resistance genes from Pasteurella multocida to Haemophilus 
influenzae 
7.1 Introduction 
The bacterial family Pasteurellaceae covers a range of gram negative bacteria that typically 
act as upper respiratory commensals in a variety of mammal and bird species.  Genera 
included within this family include Haemophilus, Pasteurella and Mannheimia.  Members of 
this family have been shown to be capable of exchanging genetic material and this has 
facilitated the exchange of antibiotic resistance determinants. 
A number of acquired macrolide resistance genes (AMRGs) have been detected among 
animal commensals that have been implicated as opportunistic pathogens, such as 
Mannheimia and Pasteurella.  In particular, the ARMGs erm(42), msr(E) and mph(E) have 
previously been reported among field isolates of Pasteurella multocida and Mannheimia 
haemolytica and have been associated with resistance to 14-, 15- and 16-membered 
macrolides (and closely related antibiotics such as tulathromycin).  The resulting phenotype 
appears to depend on whether the genes exist alone or are present in particular combinations 
with one another.  Isolates carrying erm(42) alone typically produce moderate resistance to 
macrolides and high-level resistance to lincosamides, while isolates carrying msr(E) and 
mph(E) produce resistance against 14- and 15-membered macrolides and tulathromycin, but 
comparatively less resistance against lincosamides and 16-membered macrolides.  In 
addition, isolates simultaneously carrying all three and exhibiting high-level resistance to 
MLSB antibiotics have also been reported.
265
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Recently, a mobile, multiresistance integrative conjugative element (ICE), designated 
ICEPmu1,
263,264
 has been described in a bovine Pasteurella multocida isolate and was found 
to carry a large number of resistance determinants, including erm(42), msr(E) and mph(E).  
The structure of ICEPmu1, reportedly the first ICE in this species, has been deduced.  
ICEPmu1, 82214 bp in size and harbouring 88 reading frames, contains a core set of genes 
that are involved in excision, integration and conjugative transfer, and that demonstrate a 
great degree of similarity with alternative ICEs found in the bovine respiratory pathogens M. 
haemolytica and Haemophilus somni.  The ICE carries 12 resistance genes organised into 2 
separate resistance regions (see Figure 7.1) located 42526 bp apart.  These regions exhibit 
extensive similarities with transposons, plasmids and other elements previously identified in 
different species, indicating that they came about as a result of a series of integration and 
recombination events in which insertion sequences have played a significant role.  The first 
region, 15711 bp in size, contains erm(42), along with resistance markers against kanamycin 
and neomycin (aphA1), streptomycin (strA and strB), sulfonamides (sul2), and 
chloramphenicol and florfenicol (floR).  The second region, 9789 bp in size, contains msr(E) 
and mph(E) in addition to resistance markers against gentamicin (aadB), spectinomycin and 
streptomycin (aadA25), ampicillin (blaOXA-2) and tetracycline (tet(H)).  Conjugative 
experiments have shown that ICEPmu1 is an active element that can be transferred to other P. 
multocida isolates as well as to M. haemolytica and Escherichia coli.  Increases in MICs of 
the above antibiotics, including against clindamycin, tilmicosin and tulathromycin, were 
observed in resulting transconjugants.  In all of these experiments, ICEPmu1 was integrated 
into a tRNA
Leu
 site;
264
 this site has also been recognised as a common integration site for 
resistance elements in H. influenzae, particularly β-lactamase-harbouring genomic islands 
such as ICEHin1056.
294,295
 
It has previously been demonstrated that Pasteurella and Haemophilus are capable of sharing  
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 Figure 7.1
263
: The resistance regions of ICEPmu1.  Resistance region 1 (left image) contains erm(42) while resistance region 2 (right image) 
contains msr(E) and mph(E). 
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resistance determinants.  For example, the blaROB-1-carrying plasmid pB1000, first described 
in H. parasuis in swine
266
 and subsequently reported in animal-derived P. multocida isolates, 
has also been reported in human clinical H. influenzae isolates in Spain and Australia.
262,268
  
Indeed, previous reports have demonstrated that approximately 5% of β-lactamase positive H. 
influenzae strains carry a blaROB-1-type β-lactamase worldwide
268
 (with the majority found in 
the United States and Mexico),
296
 and evidence suggests that the majority of these blaROB-1-
type β-lactamases in H. influenzae are carried on pB1000-related elements.262,266,268  Given 
the previous detection of AMRG-carrying conjugative elements such as ICEPmu1 in P. 
multocida, there is precedent for the possible transfer of AMRG-bearing mobile elements and 
the associated phenotypic resistance from P. multocida to NTHi.  The aim of this study was 
to look for evidence of the AMRGs erm(42), msr(E) and mph(E) in wild-type strains of NTHi 
and demonstrate in vitro conjugative transfer of these AMRGs on ICEPmu1 from P. 
multocida to H. influenzae, and to investigate the phenotypic effect of these genes in H. 
influenzae. 
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7.2 Methods and Materials 
7.2.1 Detection of erm(42), msr(E) and mph(E) in clinical isolates of 
Haemophilus influenzae 
Before commencing the main component of this study, we screened a number of NTHi 
isolates for the presence of erm(42), msr(E) and mph(E) to detect any evidence of transfer of 
these genes to NTHi from Pasteurella and other genera that act as reservoirs for these genes.  
The isolate collection included in this screen consisted of 145 clinical respiratory isolates of 
NTHi identified by colony morphology, X and V factor dependence and a positive PCR for 
either fucK or hpd as previously described.
297
  Of these, 59 isolates were from CF patients, 
and the remaining 86 isolates were from a range of other patients.  The previously determined 
azithromycin MICs of this collection ranged from 0.09->256 µg/mL, with MIC50 and MIC90 
values of 1 µg/mL and 3 µg/mL, respectively.  All isolates were cultured on chocolate agar. 
A previously described multiplex PCR system was used for the detection of erm(42), msr(E) 
and mph(E).
298
  Primers used in this reaction can be found in Table 7.1. 
7.2.2 Conjugation of ICEPmu1 to Haemophilus influenzae Rd KW20 
To transfer ICEPmu1 to H. influenzae, mating experiments were performed using P. 
multocida strain 36950 (GenBank accession CP003022.1),
263
 a bovine-derived P. multocida 
isolate carrying ICEPmu1, as the donor and a previously generated nalidixic-resistant isolate 
of H. influenzae Rd KW20 as the recipient.  The donor and recipient were mixed in a ratio of 
1:5 and transconjugants were grown on chocolate agar with tetracycline (15 µg/mL) and 
nalidixic acid (8 µg/mL).  Transfer efficiency was calculated as the number of transconjugant 
CFUs per recipient CFU.  Refer to Chapter 3 for further information. 
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Table 7.1: Primers used for the detection of erm(42), msr(E) and mph(E) in H. influenzae. 
Gene/Region Description of PCR Annealing Temp. (°C) Primer Name Primer Sequence 
erm(42) Detection of erm(42) 
59 
p64
298
 TGCACCATCTTACAAGGAGT 
p66
298
 CATGCCTGTCTTCAAGGTTT 
mph(E) Detection of mph(E) 
p67
298
 ATGCCCAGCATATAAATCGC 
p68
298
 ATATGGACAAAGATAGCCCG 
msr(E) Detection of msr(E) 
p70
298
 TATAGCGACTTTAGCGCCAA 
p71
298
 GCCGTAGAATATGAGCTGAT 
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7.2.3 Characterisation of ICEPmu1 in transconjugants 
To confirm the identity of any transconjugants as ICEPmu1-carrying H. influenzae, PCRs 
specific for Haemophilus spp. (P6) and P. multocida (kmt-1), as well as PCRs for the 
detection of the integrase and relaxase genes of ICEPmu1 were performed.  Further 
information and primer sequences are provided in Table 7.2.  Isolates identified as ICEPmu1-
carrying H. influenzae underwent further PCR testing to determine which elements of 
ICEPmu1 were transferred.  PCRs were run for the detection of the individual resistance 
genes (including erm(42), msr(E) and mph(E)) as well as for the detection of linkages 
between particular elements of ICEPmu1.  Further details and primer sequences are provided 
in Tables 7.3 and 7.4. 
7.2.4 Antibiotic resistance testing 
MICs of ICEPmu1-relevant antibiotics were determined by broth microdilution, as previously 
described in Chapter 3, on any ICEPmu1-carrying H. influenzae isolates (as confirmed by 
PCR).  Antibiotics included in the panel were gentamicin, neomycin, tetracycline, tilmicosin, 
tulathromycin, chloramphenicol, florfenicol, streptomycin, ampicillin, erythromycin, 
clindamycin, spectinomycin, kanamycin and sulfamethoxazole. 
7.2.5 Retention of transfer functions of ICEPmu1 in Haemophilus 
influenzae 
To demonstrate that the transfer functions of ICEPmu1 were retained in H. influenzae, mating 
experiments were performed using an H. influenzae Rd KW20 carrying ICEPmu1 previously 
generated by conjugation assay with P. multocida 36950 as a donor and a separate 
rifampicin-resistant and nalidixic-susceptible H. influenzae Rd KW20 as a recipient.  The 
donor and recipient were mixed in a ratio of 1:10 and transconjugants were grown on 
chocolate agar with kanamycin (30 µg/mL) and rifampicin (50 µg/mL).  Transfer efficiency  
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Table 7.2: Primers used for the detection of ICEPmu1-carrying H. influenzae. 
Gene/Region Description of PCR Annealing Temp. (°C) Primer Name Primer Sequence 
kmt-1 P. multocida-specific 55 
KMT1SP6
299
 GCTGTAAACGAACTCGCCAC 
KMT1T7
299 ATCCGCTATTTACCCAGTGG 
P6 Haemophilus spp.-specific 54 
P6-fwd
300
 ACGATGCTGCAGGCAATGGT 
P6-rv
300
 CATCAGTATTACCTTCTACTAAT 
ICE_2051 Detection of the relaxase gene of ICEPmu1 60 
ICE-relaxase-fw
264
 CTGGTTCAACGTCCTGTCAA 
ICE-relaxase-rv
264
 ATCGTTGCAATTTCCTGTCC 
ICE_2052 Detection of the integrase gene of ICEPmu1 60 
ICE-integrase2052-fw* TGGCGTAATCAAATTGTTGG 
ICE-integrase2052-rv* AGCTGATTTTGGCTCATTGG 
*Primers are unpublished 
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Table 7.3: Primers used for the characterisation of resistance region 1. 
Gene/Region Description of PCR Annealing Temp. (°C) Primer Name Primer Sequence 
aphA1 
Detection of the kanamycin and neomycin 
resistance gene aphA1 
62 
aph(3')I-B
301,302 GGCAAGATCCTGGTATCGGTCTGC 
aph(3')I-F
301,302
 AACGTCTTGCTCGAGGCCGCG 
aphA1/strA Detection of the genetic linkage of strA and aphA1 55 
str1
303 TGACTGGTTGCCTGTCAGAGG 
strA/strB 
Detection of the genetic linkage of the streptomycin 
resistance genes strA and strB 
55 
strB-R
304 GGATCGTAGAACATATTGGC 
ICE_3 Detection of the genetic linkage of strA and ISCR21 59 
ICE_past3-fw* GCAAACAAACGGGTCAACTT 
str2
303
 CCAGTTGTCTTCGGCGTTAGCA 
sul2/strA Detection of the genetic linkage of sul2 and strA 57 
sul1
303 ACAGTTTCTCCGATGGAGGCC 
sul2 Detection of the sulfonamide resistance gene sul2 67 
sul2
303
 CTCGTGTGTGCGGATGAAGTC 
 
ICE_4 
Detection of the genetic linkage of ISCR21and floR 
 
56 
ICE_past4-fw* CTGTGACCAAAAACGGACCT 
ICE_past4-rv* CGGTAGGATGAAGGTGAGGA 
floR Detection of the florfenicol resistance gene floR 55 
floR-STOP
305
 CGGTTAGACGACTGGCGACT 
floR-START
305
 AGGGTTGATTCGTCATGACCA 
floR/erm(42) Detection of the genetic linkage of floR and erm(42) 55 
erm(42)-fw
230
 ACGTTGCACTTGGTTTGACA 
erm(42) 
Detection of the macrolide-lincosamide resistance 
gene erm(42) 
55 
Pm36950-erm-fw* ATCTGCAAAGCCGTTAATGC 
Pm36950-erm-rv* ATCCTTGCTTACCATGTTCG 
ICE_5 
Detection of the genetic linkage of ISCR2 and 
ISApl1 
60 
ICE_past5-fw* TACCGAAGCCCAGAGTCAAC 
ICE_past5-rv* ACGTAGCTCCAGCACCATTT 
*Primers are unpublished 
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Table 7.4: Primers used for the characterisation of resistance region 2. 
Gene/Region Description of PCR Annealing Temp. (°C) Primer Name Primer Sequence 
ICE_1 Detection of the genetic linkage of tetR and IS26 55 
ICE_past1-fw* TTCACGCTCTTTTTGGCTTT 
ICE_past1-rv* ACCTTTGATGGTGGCGTAAG 
aadB Detection of the gentamicin resistance gene aadB 57 
ant(2'')-I-B
301,306 TATCGCGACCTGAAAGCGGC 
ant(2'')-I-F
301,306 GGGCGCGTCATGGAGGAGTT 
aadB- blaoxa-2 Detection of the genetic linkage of aadB and blaOXA-2 57 
blaoxa-2-rev
307 CCACTCAACCCATCCTACCC 
blaoxa-2 
Detection of genes coding for beta-lactamases of OXA-
2 group 
60 
blaoxa-2-fw
307 AAGAAACGCTACTCGCCTGC 
ICE_6 Detection of the genetic linkage of blaOXA-2 and msr(E) 58 
Pm36950-mel-rv* CTGCCGTAATCGGGAACTTA 
msr(E) 
Detection of the macrolide resistance gene msr(E) 
 
57 
Pm36950-mel-fw* TATCTCGCCTTGGTGTTTCC 
aadA25 
Detection of variants of the streptomycin and 
spectinomycin resistance gene aadA 
60 
ant(3')I-F
301,308 GTGGATGGCGGCCTGAAGCC 
ant(3')I-B
301,308 ATTGCCCAGTCGGCAGCG 
mph(E) Detection of the macrolide resistance gene mph(E) 57 
Pm36950-mph-rv* GGGTGAAATCTGCCCATAGA 
Pm36950-mph-fw* ATCACTTGCTGAAGCACACG 
ICE_7 Detection of the genetic linkage of mph(E) and tet(H) 57 
tet(H)-2
309 TCCCAATAAGCGACGCT 
tet(H) Detection of the tetracycline resistance gene tet(H) 55 
tet(H)-1
309
 ATACTGCTGATCACCGT 
msr(E)-mph(E) Detection of the genetic linkage of msr(E) and mph(E) 55 
msr(E)-fw
230 TACCGGAACAACGTGATTGA 
mph(E)-rv
230 GAAGGGTTACGCCAGTACCA 
ICE_2 Detection of the genetic linkage of IS26 and tnp 59 
ICE_past2-fw* CAACGTGAAGAAGTGGCAGA 
ICE_past2-rv* ACCGCCTGATCCAGTACATC 
*Primers are unpublished 
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was calculated as previously stated.  PCR was used to confirm transfer as described above.  
To confirm CFUs as true transconjugants and not simply rifampicin-resistant mutant donors, 
isolates were tested for rifampicin and nalidixic acid resistance by disk diffusion in 
accordance with CDS methodology, using the donor and recipient as controls.  
Transconjugants were confirmed by matching their rifampicin and nalidixic acid resistance 
profiles with that of the recipient. 
Additional mating experiments were also performed using 2 rifampicin-resistant NTHi strains 
(H. influenzae NCTC 4560, and a separate clinical isolate (Ci6)) as recipients in an attempt to 
demonstrate conjugative transfer of ICEPmu1 to different strains of H. influenzae.  A range 
of donor:recipient ratios (1:1, 1:5 and 1:10) across different experiments were used. 
7.2.6 Determination of insertion point of ICEPmu1 into Haemophilus 
influenzae 
To establish the insertion point of ICEPmu1 into the H. influenzae genome, we designed 
primers for the amplification of tRNA
Leu
 sites, the expected insertion site of ICEPmu1.  Four 
primer sets (see Table 7.5 for sequences) were used to amplify separate tRNA
Leu
 sites in H. 
influenzae Rd KW20 (as indicated on reference sequence NC_000907.1 on GenBank).  
Primers were designed using Primer-BLAST (National Center for Biotechnology 
Information, USA); H. influenzae Rd KW20 (GenBank accession NC_000907.1) was used as 
the reference template.  Our donor P. multocida (with ICEPmu1) and recipient H. influenzae 
Rd KW20 strains were used as negative and positive controls for these PCR reactions, 
respectively. 
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Table 7.5: Primers for the determination of the insertion point of ICEPmu1 in H. influenzae. 
Gene/Region Description of PCR Annealing Temp. (°C) Primer Name Primer Sequence 
HI0123 
Amplification of the tRNA
Leu
 site 
HI0123 and its flanking region. 
55 
HI0123_F TCCGTAAAATACGCCCCGTT 
HI0123_R GGGCGATGTAGAAGAAGCGA 
HI0086 
Amplification of the tRNA
Leu
 site 
HI0086 and its flanking region. 
55 
HI0086_F CTCATCACTGCGATTGCCTG 
HI0086_R TGCACAACTACGGGCTTACT 
HI1631 
Amplification of the tRNA
Leu
 site 
HI1631 and its flanking region. 
57 
HI1631_F TTTCGACAAGCCTCCCGTTT 
HI1631_R CACAAGCTGTCATCGCATCG 
HI1424 
Amplification of the tRNA
Leu
 site 
HI1424 and its flanking region. 
55 
HI1424_F TCTTTTCTTCTTCCGCACCC 
HI1424_R CCCTGATTGAGCTCCTGCAA 
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7.2.7 Whole genome sequencing of transconjugants 
Select transconjugants were submitted for whole genome sequencing.  In addition to 
providing further confirmation of the presence of ICEPmu1 and its various components, 
including erm(42), msr(E) and mph(E), whole genome sequencing also allowed for the 
confirmation of the insertion point of ICEPmu1 indicated by the above PCRs, and also served 
as an alternative way to determine the insertion point should these PCRs indicate that it may 
be in an alternative site to those investigated above. 
A total of 6 transconjugants were submitted for whole genome sequencing.  Three of these 
(T65, T69 and T79) were primary transconjugants derived from two separate conjugation 
assays between the P. multocida donor and the H. influenzae recipient as described in section 
7.2.2.  The other three (A27, A28 and A37) were secondary transconjugants derived from two 
separate conjugation assays between the ICEPmu1-carrying H. influenzae Rd KW20 
generated in this study and a separate H. influenzae Rd KW20 recipient as described in 
section 7.2.5 (all three A transconjugants are H. influenzae Rd KW20). Transconjugants were 
submitted to the Ramaciotti Centre for Genomics (University of New South Wales, 
Australia). 
Sequences underwent quality checks as previously described in Chapter 3 of this thesis.  
After all Contigs were assembled, Contigs of a length less than 1000 bp were filtered out.  
The filtered Contig files were then ordered against the reference H. influenzae Rd KW20 
genome on GenBank (GenBank no.: NC_000907.1) using the Mauve Contig Mover.
310
  The 
ordered Contigs were joined into a single fasta sequence using the Artemis genome 
browser.
311
  The joined sequences were aligned to the H. influenzae Rd KW20 genome and 
visualised as a ring image using the BLAST Ring Image Generator (BRIG).
312
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The joined fasta files were uploaded to CLC Main Workbench 7 for visual inspection and 
analysis to detect the presence of ICEPmu1 in the transconjugants and to determine the 
integration site of the ICE into the H. influenzae Rd KW20 genome. 
7.2.8 Effect on fitness of ICEPmu1 and ICEPmu1 stability 
The fitness cost of ICEPmu1 was determined by competition experiments between H. 
influenzae Rd KW20 and H. influenzae Rd KW20/ICEPmu1, adapted from a protocol 
previously described by San Millan et al. (2015),
313
 in sBHI (refer to Chapter 3 for further 
information).  Briefly, strains were grown overnight on chocolate agar, and then 10
6
 CFU of 
H. influenzae Rd KW20 were mixed with 10
6
 CFU of H. influenzae Rd KW20/ICEPmu1 in 2 
mL of sBHI.  This mix was grown at 37°C and 150 rpm for 24 hours, and 10
6
 CFU was 
subsequently transferred to 2 mL of fresh sBHI every 24 hours (1/1000 dilution, or 2 µL of 
growth in fresh sBHI to a total volume of 2 mL).  This was done for 6 consecutive days; 
samples were collected at time zero and every 24 hours thereafter.  For each sample, aliquots 
were plated on non-selective chocolate agar, and the proportion of resistant colonies was then 
estimated by plating of 100 colonies on chocolate agar plates containing 30 µg/mL of 
kanamycin.  At each 24 hour time point, the ratio of resistant vs. susceptible colonies was 
determined by dividing the number of CFUs with ICEPmu1 by 50 (50 is the expected CFU 
count if the number of cells with ICEPmu1 was equal to the number of cells without 
ICEPmu1).  As an additional measure of fitness, the selection coefficient was calculated as 
previously described.
313
  To control for selection bias, five replicate experiments were 
performed, and the average ratio across these replicates was determined at each 24 hour time 
point. 
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The stability of ICEPmu1 in H. influenzae was determined in a similar experiment to that 
described above, but with H. influenzae Rd KW20/ICEPmu1 growing alone rather than in 
competition with H. influenzae Rd KW20.  Three replicate experiments were performed. 
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7.3 Results and Discussion 
The initial screen for the detection of erm(42), msr(E) and mph(E) failed to detect evidence of 
any of these genes in our collection of NTHi respiratory isolates.  Given that we had also 
failed to detect these genes in any of the whole genome sequences included in the AMRG 
screen performed in Chapter 5 of this thesis, we have therefore found no evidence that 
acquisition of these genes by NTHi has occurred naturally among our collection of isolates.  
However, in vitro conjugative transfer of ICEPmu1 from the P. multocida donor to H. 
influenzae Rd KW20 was successful using the conditions described previously at a frequency 
of 5.73 x 10
-6
 per recipient.  The identity of the transconjugants was confirmed by their PCR 
identification profiles: isolates were negative for kmt-1 and positive for P6 and ICEPmu1 
relaxase and integrase, indicating that the CFUs recovered from the selective plates were H. 
influenzae isolates with ICEPmu1 (see Table 7.6). 
To further characterise ICEPmu1 in our transconjugants, PCR for the detection of specific 
resistance markers was performed on select transconjugants.  Of the AMRGs carried on 
ICEPmu1, only erm(42) was successfully transferred to H. influenzae Rd KW20.  A number 
of resistance markers of ICEPmu1, including msr(E) and mph(E), were not detected in the H. 
influenzae transconjugants, suggesting that ICEPmu1 had become truncated during 
conjugation.  Interestingly, all of the genes that were not transferred are located on the same 
resistance region (region 2) of ICEPmu1, and tet(H) was the only resistance marker on this 
resistance region that was transferred.  By contrast, resistance region 1 appeared to be 
transferred intact (Table 7.6). 
Susceptibility testing revealed increases in MICs of a number of antibiotics, including high-
level increases of erythromycin, clindamycin and tilmicosin, attributed to the acquisition of 
erm(42) (Table 7.7).  A relatively modest increase in MIC of tulathromycin was also  
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Table 7.6: PCR results for transconjugants. 
 Isolate 
 PCR P. multocida (donor) H. influenzae Rd KW20 (recipient) H. influenzae Rd KW20 (with ICEPmu1) 
kmt-1 + - - 
P6 - + + 
Relaxase + - + 
Integrase + - + 
     
R
e
si
st
a
n
ce
 R
e
g
io
n
 1
 
aphA1 + - + 
sul2 + - + 
floR + - + 
erm(42) + - + 
aphA1-strA + - + 
strA-strB + - + 
strA-ISCR21 + - + 
sul2-strA + - + 
ISCR21-floR + - + 
floR-erm(42) + - + 
ISCR2-ISApl1 + - + 
     
R
e
si
st
a
n
ce
 R
e
g
io
n
 2
 
aadB + - - 
blaoxa-2 + - - 
msr(E) + - - 
aadA25 + - - 
mph(E) + - - 
tet(H) + - + 
tetR-IS26 + - - 
aadB-blaoxa-2 + - - 
blaoxa-2-msr(E) + - - 
mph(E)-tet(H) + - - 
msr(E)-mph(E) + - - 
IS26-tnp + - - 
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Table 7.7: MIC results for transconjugants. 
 Isolate 
Antibiotic P. multocida (donor) H. influenzae Rd KW20 (recipient) H. influenzae Rd KW20 (with ICEPmu1) 
Gentamicin 32 0.5 0.5 
Neomycin ≥128 2 ≥128 
Tetracycline 64 0.5 32 
Tilmicosin ≥128 16 ≥256 
Tulathromycin ≥64 4 32 
Chloramphenicol 16 0.5 4 
Florfenicol 8 0.25 4 
Streptomycin ≥1024 1 256 
Ampicillin 0.25 0.12 0.12 
Erythromycin ≥64 8 ≥64 
Clindamycin ≥128 8 ≥128 
Spectinomycin 256 8 8 
Kanamycin 512 4 ≥256 
Sulfamethoxazole 512 256 ≥1024 
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observed, despite the loss of msr(E) and mph(E) during conjugation as demonstrated by PCR.  
Of the antibiotics tested, only gentamicin, spectinomycin and ampicillin MIC did not show 
notable increases, probably attributable to the loss of the resistance region 2 genes aadB, 
aadA25 and blaOXA-2 during conjugation and further indicating that ICEPmu1 had truncated 
during conjugation to H. influenzae. 
Based on the PCR and antibiotic susceptibility testing results, we initially speculated that 
ICEPmu1 had undergone a recombination event involving the two copies of tetR within 
resistance region 2 that resulted in the loss of all resistance genes between the tetR copies.  It 
is worth noting that tet(H), the only resistance marker from resistance region 2 that was 
retained in the transconjugants and the marker which codes for resistance to our selective 
agent (tetracycline), is not located between the two copies of tetR (see Figure 7.2).  This may 
have allowed for transconjugants with this truncated variant of ICEPmu1 to be selected for.  
We initially tested this hypothesis by running an additional PCR for the presence of the 
linkage between tetR and tnp, using the primers ICE_past1-fw and ICE_past2-rv (see Table 
7.4) and an annealing temperature of 55°C.  Our rationale was that if region 2 was lost 
through recombination of tetR, a single copy of tetR should still be present and the use of 
these primers would result in an amplicon approximately 2900 bp in size.  Using P. 
multocida with the complete ICEPmu1 as a positive control, this PCR resulted in the 
production of the expected amplicon, indicating that the tetR-tnp linkage was intact and 
further supporting the above hypothesis. 
Attempts to transfer the truncated ICEPmu1 to another H. influenzae Rd KW20 mutant were 
successful using the previously described conditions, at a frequency of 1.14 x 10
-7
 per 
recipient.  This indicates that the transfer functions of ICEPmu1 remained active after the 
initial transfer from P. multocida to H. influenzae, even in this truncated form.  However, 
attempts to transfer the truncated ICEPmu1 to the two NTHi strains included here (H.  
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Figure 7.2: Resistance region 2 of ICEPmu1 with lost segment indicated.  Resistance markers located between the tetR copies (highlighted 
in red) were not transferred to transconjugants generated in this study.  The only marker from this resistance region to be transferred 
successfully, tet(H), is located outside of this range. 
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influenzae NCTC 4560 and Ci6) were not successful under any of the conditions described 
previously, so transfer of ICEPmu1 from H. influenzae Rd KW20 to NTHi was not 
demonstrated in this study.  The capacity of ICEPmu1 to conjugatively disseminate amongst 
H. influenzae strains if naturally acquired from P. multocida remains unclear. 
To establish the insertion point of ICEPmu1 into the H. influenzae genome, we initially used 
PCR to analyse various tRNA
Leu
 sites to detect any interruptions caused by the insertion of 
ICEPmu1.  However, the amplicons produced by our transconjugants using all 4 sets of 
tRNA
Leu
 primers (see Section 6.2.6 in Methods) appeared to be identical in size to the 
amplicon produced by our untransformed H. influenzae Rd KW20.  This indicated that the 
tRNA
Leu
 sites were not interrupted by insertion of the ICE, and that ICEPmu1 was inserted 
into a different position.  Whole genome sequencing was utilised as an alternative method to 
establish the insertion point of ICEPmu1.  This would also allow for the nature of the 
truncation event involving resistance region 2 to be confirmed.  All six transconjugants that 
were submitted (3 first generation transconjugants and 3 second generation transconjugants) 
appeared to be identical after all Contigs were assembled, ordered and aligned against H. 
influenzae Rd KW20 using BRIG (see Figure 7.3).  Based on the output given by BRIG, the 
transconjugants were shown to possess two relatively large segments of additional DNA that 
H. influenzae Rd KW20 lacked (indicated by (a) and (b) in Figure 7.3). 
The largest of these segments was revealed to represent ICEPmu1.  The integration site was 
shown to be between nucleotides 1513266 and 1513267 of the H. influenzae Rd KW20 
genome (based on the numbering system of NC_000907.1 on GenBank).  This site 
represented a tRNA
Leu
 site, listed as HI1424.1 on GenBank (nucleotides 1513211-1513296) 
and located between HI1424 (a putative integrase/recombinase region) and HI1425 (a 
fumarate reduction transcriptional regulator).  The sequence of this site is demonstrated in  
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Figure 7.3: Ordered transconjugant sequences aligned against H. influenzae Rd KW20 (the outside ring.  Two noticeable gaps in H. 
influenzae Rd KW20 (indicated by (a) and (b)) were apparent and indicated the presence of extra DNA segments inserted in those sections 
of the genome. 
 
 
(a) 
(b) 
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Figure 7.4a with the specific integration point indicated.  Curiously, this contradicted the 
previous PCR result that indicated that this site was uninterrupted in the transconjugants; the 
reasons for this discrepancy remain unresolved but it may be reflective of poor specificity of 
the primers designed for this study.  At the left terminus of ICEPmu1 (defined based on the 
orientation of ICEPmu1 within the genome of H. influenzae Rd KW20), the previously 
described
264
 flanking sequence 5’-GATTTTGAATCAA-3’ was observed (see Figure 7.4b).  
At the opposite terminus, a similar sequence (5’- GATTTTGAATCCG-3’) was found (see 
Figure 7.4c), although this did not represent a direct repeat of the sequence flanking the left 
terminus, as is the case in P. multocida 36950.
264
 
Analysis of ICEPmu1 revealed that the non-resistance regions of the ICE were intact.  Within 
resistance region 2, tnp, tet(H) and a single copy of tetR were observed.  The second copy of 
tetR, the remaining resistance genes (aadB, aadA25, blaOXA-2, msr(E) and mph(E)), and the 
transposase genes located on region 2 in the native ICEPmu1 were not detected within the 
ICEPmu1 of the transconjugants nor within the rest of the genome (see Figure 7.5).  This was 
indicative of a truncation event involving the recombination of the tetR copies that resulted in 
the loss of all DNA situated in between the copies, thus corroborating the findings of the 
various PCRs and antibiotics resistance tests previously performed as part of this work that 
had suggested such an event. 
Surprisingly, most of resistance region 1 was not detected within the ICEPmu1 of the 
transconjugants.  While the first 46 nucleotides of region 1 were detected in its expected 
position within the ICE, the rest of the region and an 81 nucleotide-long segment that should 
immediately follow it were missing (see Figure 7.6).  Further analysis of the genomes of the 
transconjugants revealed that these missing components were contained within a separate  
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Figure7.4a: tRNA
Leu
 site HI1424.1 of H. influenzae Rd KW20.  The main ICE structure appeared to be integrated in this site, between the 
nucleotides highlighted in blue. 
 
 
 
Figure 7.4b: Flanking region of the left terminus of the main ICE structure.  The flanking sequence 5’-GATTTTGAATCAA-3’ was detected 
here (highlighted in red). 
 
 
 
Figure 7.4c: Flanking region of the right terminus of the main ICE structure.  The flanking sequence 5’-GATTTTGAATCCG-3’ was 
detected here (highlighted in red).  Note that this was not a direct repeat of the flanking sequence of the left terminus but carried. 
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Figure 7.5: The truncated resistance region 2 (highlighted in blue). 
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Figure 7.6: Segment of resistance region 1detected in the main ICE structure (highlighted in blue).  The complete resistance region 1 
appeared to have been integrated in another segment of the H. influenzae Rd KW20 genome. 
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section of the genome, separated from the main ICE.  In all transconjugants, region 1 
appeared to be integrated in a site between metR (1815309-1816238 of NC_000907.1 on 
GenBank) and a copy of 16S rRNA (1820456-1822004).  This was represented in the ring 
diagram in Figure 7.3 as the “smaller” gap of the outer ring (H. influenzae Rd KW20). 
While this “excision” was observed in all transconjugants submitted for sequencing 
(including the second generation transconjugants), we initially had reservations about 
whether this separation of region 1 from the ICE was a true event and not simply an 
erroneous artefact from processing the assembled Contig files.  In addition to the event 
seeming biologically unlikely, such an event has not been reported in other species in which 
ICEPmu1-carrying transconjugants have been generated.  Furthermore, the tRNA
Leu
 site of 
interest is located among a cluster of RNA-related structures and it is not unreasonable to 
assume that there is a possibility that region 1 could have been misplaced during the process 
of ordering the Contig file in Mauve.  Notably, a number of features normally located 
between metR and this copy of 16S rRNA in H. influenzae Rd KW20 appear to have been 
displaced, including copies of 5S and 23S rRNA, and tRNA-Ala and tRNA-Ile sites. 
Strategies such as PCR mapping of ICEPmu1 are being utilised to establish whether the 
separation of region 1 was merely an artefact of the analysis or a true event; investigations are 
currently ongoing in this regard.  In any case, preliminary investigations of resistance region 
1 established that all of the resistance genes that are contained in this region (including 
erm(42) in the native ICE are present in this site, albeit with some apparent rearrangement.  
The first 1062 nucleotides (the range of which includes the ISApl1 insertion sequence 
positioned closer to the left terminus in ICEPmu1)
263
 were a match against the native 
ICEPmu1.  After this point, the remaining segment of region 1 appeared to have been 
inverted relative to its original direction in the ICE.  A rough diagrammatic representation of  
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this inversion is shown in Figure 7.7.  This resulted in the region no longer being bracketed 
by ISApl1 insertion sequences; instead, the insertion sequences are positioned adjacent to one 
another.  As previously stated, region 1 was located between metR and a copy of 16S rRNA 
in the H. influenzae Rd KW20 genome.  The left (5’-TTCTTGAATTG-3’) flanking region of 
region 1 in the transconjugants appeared to match the sequence that normally flanks region 1 
of the native ICE; the right flanking region was not immediately recognisable, however.  
Further work is required to confirm the positioning of resistance region 1 in the 
transconjugants.  Inverse PCR would be a useful approach in this situation; by designing 
primers recognising the edges of region 1 and amplifying the flanking regions, it could be 
determined whether the region is truly positioned separately from the ICE or if the 
positioning apparent in the ordered sequence files is due to a processing error. 
While there is some unresolved uncertainty about the location of resistance region 1 in the 
transconjugants, what is clear from the WGS analysis is that the main structure of ICEPmu1 
integrates into a tRNA
Leu
 site, similar to P. multocida, E. coli and M. haemolytica.
264
  This 
was the case with both first generation and second generation transconjugants.  The analysis 
also confirmed the nature of the recombination event of resistance region 2.  Due to financial, 
legal and quarantine constraints, we were unable to perform further conjugation experiments 
using P. multocida strain 36950, and as such we were unable to attempt to transfer the 
complete ICEPmu1, including msr(E) and mph(E), into H. influenzae Rd KW20.  However, 
given the nature of the truncation event, there is merit in reattempting these experiments with 
the replacement of tetracycline with alternate selective agents that may promote the selection 
of transconjugants with the complete ICEPmu1.  The genes aadB and aadA25 both fall 
within the region that was lost during truncation and code for resistance to gentamicin and 
spectinomycin, respectively.  Therefore, either of these antibiotics may make appropriate 
agents for selection of transconjugants with the complete ICEPmu1.  Ampicillin may also be  
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Figure 7.7: Diagram demonstrating the apparent recombination of resistance region 1.  The first 1062 nucleotides of the region appeared to 
be unchanged while the rest of the region was inverted so that the ISApl1 copies were adjacent and all genes within the inverted segment 
were transcribed in the opposite direction. 
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a possible alternative agent for this purpose due to the presence of blaOXA-2 within the lost 
segment, but given that it has previously been shown that this blaOXA-2 does not confer 
resistance to β-lactam antibiotics in P. multocida and M. haemolytica hosts,263 it is uncertain 
whether this gene will confer resistance to β-lactams to H. influenzae and because of this 
ampicillin may not be an appropriate agent to use in this situation. 
The colony counts for the five replicate fitness assays are summarised in Table 7.8.  Some 
between-replicate variation in the counts was apparent.  This may be indicative of the 
occurrence of selection bias during these assays.  However, when the average of these counts 
at each time point was taken, the ratio of cells with ICEPmu1 to cells without ICEPmu1 was 
at or close to 1:1 for most time points.  When these ratios were plotted (see Figure 7.8), no 
obvious trend favouring one genotype or the other was apparent and all ratios were within 
one standard error of 1:1 (represented by an H. influenzae (ICEPmu1):H. influenzae value of 
1 on Figure 7.7), indicating that the acquisition of ICEPmu1 did not have an effect on the 
fitness of H. influenzae Rd KW20.  In addition, the s values calculated for each replicate and 
the average of these values (see Table 7.8) did not differ significantly from 0, further 
supporting the conclusion that ICEPmu1 acquisition does not significantly impact fitness.  
During the stability assays, the number of CFUs that grew on the selective chocolate plates 
(30 µg/mL kanamycin) remained high across the entire 6 day run; at no point did the cell 
count fall below 99 CFUs (see Table 7.9).  This suggests that ICEPmu1 is a relatively stable 
element in H. influenzae and is able to maintain itself even in the absence of selective 
pressure.  Furthermore, the stability results provide further support to the idea that ICEPmu1 
has no appreciable effect on the fitness of H. influenzae.  While occasional cells without 
ICEPmu1 were generated during the stability assays, these cells did not dominate the 
replicates of the fitness or stability experiments as would have been expected if carrying  
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Table 7.8: Colony counts from the fitness assays. 
 Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Average 
Time (h) A B A:B A B A:B A B A:B A B A:B A B A:B A B A:B 
0 41 59 0.82 38 62 0.76 73 27 1.46 35 65 0.70 76 24 1.52 53 47 1.05 
24 23 77 0.46 9 91 0.18 88 12 1.76 6 94 0.12 53 47 1.06 36 64 0.72 
48 24 76 0.48 34 66 0.68 97 3 1.94 8 92 0.16 95 5 1.90 52 48 1.03 
72 15 85 0.30 24 76 0.48 93 7 1.86 44 56 0.88 77 23 1.54 51 49 1.01 
96 50 50 1.00 16 84 0.32 87 13 1.74 19 81 0.38 77 23 1.54 50 50 1.00 
120 85 15 1.70 57 43 1.14 66 34 1.32 8 92 0.16 100 0 2.00 63 37 1.26 
144 83 17 1.66 51 49 1.02 33 77 0.66 2 98 0.04 100 0 2.00 54 46 1.08 
                   
S 0.0321 0.0197 -0.0239 -0.0209 0.0161 0.0046 
A = No. (H. influenzae Rd KW20 CFUs with ICEPmu1), B = No. (H. influenzae Rd KW20 CFUs without ICEPmu1) 
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Figure 7.8: Average cell counts from the fitness assays at each 24 hour time point.  Cell counts are represented as ratios between the number 
of cells with ICEPmu1 and those without.  Note that the error bars represent standard error 
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Table 7.9: Colony counts from the stability assays. 
 Replicate 1 Replicate 2 Replicate 3 
Time (h) A B A:B A B A:B A B A:B 
0 100 0 2.00 100 0 2.00 100 0 2.00 
24 100 0 2.00 99 1 1.98 99 1 1.98 
48 100 0 2.00 100 0 2.00 100 0 2.00 
72 100 0 2.00 100 0 2.00 99 1 1.98 
96 100 0 2.00 100 0 2.00 100 0 2.00 
120 100 0 2.00 99 1 1.98 100 0 2.00 
144 99 1 1.98 100 0 2.00 100 0 2.00 
A = No. (H. influenzae Rd KW20 CFUs with ICEPmu1), B = No. (H. influenzae Rd KW20 CFUs without ICEPmu1) 
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ICEPmu1 resulted in a fitness cost for H. influenzae.  Therefore, we conclude that the 
acquisition of ICEPmu1 has no appreciable cost on fitness of H. influenzae. 
To summarise the findings of this study, while we have been unable to naturally transfer 
msr(E) and mph(E) to H. influenzae in this study, we have been able to transfer erm(42) and 
its associated macrolide resistance to H. influenzae.  Using ICEPmu1 as a model, we have 
demonstrated the potential for AMRG-carrying elements from animal-derived sources such 
as P. multocida to transfer naturally to H. influenzae, as well as the potential for H. influenzae 
to acquire macrolide resistance via this mechanism.  We have also demonstrated that 
ICEPmu1 (even in the truncated form observed here) is a relatively stable element that has 
little apparent fitness cost in this species and retains its transfer potential after acquisition by 
H. influenzae, although inter-strain transfer was not observed. 
Macrolides and related MLSB antibiotics remain widely used in animal husbandry 
worldwide; in Australia specifically, macrolide and streptogramin antibiotics represented 
approximately 24% of the total animal therapeutic antibiotic market over a 5 year period 
(2005-2010), with an estimated 54.2 tonnes sold for therapeutic use and 10.7 tonnes sold for 
growth-promotant use across the period of 2009-2010 alone.
314
  While the impact of 
antibiotic use (particularly for growth promotion) on human health has historically been a 
controversial issue,
315
 links between antibiotic use and resistance in animals have been 
demonstrated.
315,316
  For example, Garcia-Migura et al. (2014) have, in analysing data on the 
use of antibiotics across nine European countries, previously used linear regression analysis 
to demonstrate a strong positive correlation between the emergence of resistance among 
animal flora and the consumption of macrolides in animal husbandry.
317
  While we have not 
found any evidence of the transfer of these particular animal-derived AMRGs among our 
own collection of isolates (or among the whole genome sequences included in the work of 
Chapter 5) at this time, it is interesting to speculate about the potential for high-level 
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macrolide resistance resulting from the acquisition of these genes occurring in and 
disseminating among clinical isolates of NTHi in the future, especially in light of both the 
increasing emergence of macrolide resistance in animal-derived Pasteurellaceae (potentially 
resulting from macrolide use in animal husbandry) and previous findings related to the 
interspecies dissemination of β-lactam resistance involving Pasteurella and 
Haemophilus.
262,268
 
In considering the likelihood of ICEPmu1 and other AMRG-harbouring resistance elements 
transferring macrolide resistance to NTHi, it is important to consider the frequency of β-
lactamase-mediated ampicillin resistance among Haemophilus spp. in general.  Since the 
1970s, β-lactamases in H. influenzae have increased in frequency worldwide, and these 
elements have frequently been carried on genomic islands capable of horizontal transfer, the 
most well-known of which is ICEHin1056 (previously referred to as p1056).
294,295,318
  It is 
known that these elements integrate specifically into tRNA
Leu
,
294,295
 much like ICEPmu1.  
Therefore, in making a judgement regarding the likelihood of ICEPmu1 transferring to NTHi 
in a non-laboratory context, it would be important to establish whether ICEPmu1 is able to 
integrate into tRNA
Leu
 in isolates in which ICEHin1056 has already been integrated.  If the 
presence of ICEHin1056 inhibited the ability of ICEPmu1 to integrate into the H. influenzae 
genome, this would significantly limit the potential for ICEPmu1 and related elements to 
establish themselves in NTHi.  Therefore, a potential future study would be to perform the 
work in this Chapter again using an H. influenzae recipient known to carry ICEHin1056. 
In any case, we can conclude that transfer events involving AMRG-carrying elements 
between Haemophilus spp. and animal-sourced members of the family Pasteurellaceae do 
not appear to be prevalent at this time and that macrolide resistance through the natural 
acquisition of animal-derived AMRGs has not been demonstrated in NTHi.  However, a 
potential pathway by which these genes and their associated macrolide resistance phenotype 
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could be acquired by and disseminated among H. influenzae has been identified through this 
study.  Although it is currently unclear how much of a threat such transfer events pose to the 
susceptibility of NTHi to macrolides, the work presented here may suggest a need to closely 
monitor the presence of these animal-sourced genes among NTHi isolates. 
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Chapter 8: General Discussion and Summary 
Investigation of the occurrence and effect of acquired macrolide resistance genes (AMRGs) 
in NTHi is complicated by a number of inter-related and compounding factors.  Firstly, there 
is an extremely large number of different AMRGs (at least 42 erm genes, 24 macrolide efflux 
genes, and 26 macrolide-inactivating enzyme genes have been described),
95
 so decisions 
needed to be made as to whether a study will search for a specific set of these genes, or use 
an approach that essentially looks for all of those that have currently been described.  
Secondly, once these genes are detected, determining the effect of these genes on the 
macrolide susceptibility phenotype is complicated by the presence of complex regulatory 
regions in some genes that may limit their expression in the genetic environment of the new 
host.  The effect on phenotype of AMRGs is further complicated by the possible presence of 
a range of chromosomal mutations that may also contribute to resistance in a given AMRG-
carrying isolate.  The effect of specific AMRGs on phenotype is perhaps best determined in a 
controlled genetic background, either by artificially introducing the AMRG on its native 
replicon, or by cloning into a suitable vector.  Again, these approaches are complicated by 
inefficient conjugative transfer of AMRGs into H. influenzae from many of the organisms in 
which AMRGs are prevalent, and by both the difficulty in sourcing appropriate vectors and 
the difficulty in transforming many strains of H. influenzae.  These difficulties have been 
encountered and dealt with in various ways throughout the work of this thesis. 
The work of Chapter 4 was primarily focused on the AMRGs erm(A), erm(B), erm(C), 
erm(F), mef(A) and mef(E).  It is important to stress that these AMRGs were not selected 
specifically because they are commonly encountered among particular species in which 
genetic exchange with H. influenzae occurs readily.  These genes were selected because, in 
addition to being frequently encountered among a wide variety of species, they were recently 
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reported in high prevalence among NTHi isolates derived from a specific CF patient group.
93
  
Our search for these genes in 186 clinical respiratory isolates of NTHi, from both CF and 
non-CF patients, did not uncover any isolates with any of these genes.  Given the previous 
report of Roberts et al. (2011),
93
 this finding was somewhat surprising despite variations in 
the patient groups from which the isolates of both studies were derived.  In any case, our 
failure to detect any isolates with at least one AMRG limited our options to further 
investigate the role these genes play in reducing macrolide susceptibility in NTHi, and as it 
was not possible to source any such isolates from the authors of the only study in which these 
genes were detected in large numbers, alternative approaches were required. 
One of the options was to attempt to transfer these genes into H. influenzae by conjugative 
transfer in vitro, described in Chapter 6 of this thesis.  However, these attempts did not 
produce any AMRG-carrying H. influenzae transconjugants.  This finding was not surprising, 
and the fact that transfer does not occur even in optimised laboratory conditions perhaps 
reflects the rarity of these genes in NTHi compared to the prevalence of these genes in other 
species that frequently occupy the upper respiratory tract.  This is further supported by our 
inability to detect AMRGs among any of the NTHi isolates examined in Chapter 4, or among 
the 89 publicly available whole genome sequences (WGSs) interrogated in Chapter 5. 
Given the inability to transfer these genes by conjugation, they were artificially cloned into a 
shuttle vector, pLS88, and then transformed into H. influenzae Rd KW20. This vector is a 
naturally occurring plasmid that has not been further manipulated to allow for additional 
useful functions such as controlling the level of expression. The use of a dedicated expression 
vector may have provided additional useful data, but these are not readily available for H. 
influenzae, and modification of our existing vector was beyond the scope of this study.  The 
cloning of the AMRGs into pLS88, with consistent expression, was useful as it allowed us to 
confirm expression of these genes and correlate this expression to a phenotype.  This had the 
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advantage of demonstrating the effect of these genes in isolation of other underlying 
mechanisms such as chromosomal mutations.   A useful future extension of this current work, 
would be to examine the effect of various AMRGs in unison with other specific mechanisms, 
including specific L4, L22 and 23S rRNA mutations, or overexpressed acrAB due to 
alterations in acrR.  The relevance of this approach is demonstrated by the previous 
description of H. parainfluenzae with both a mef(A) and L4 substitution, where the respective 
contributions of each mechanism to the high level resistance phenotype was not 
determined.
257
  These types of studies will be challenging in H. influenzae in the absence of 
optimised systems in which to create specific alterations of these genes, although in future 
studies this may be possible through the use of a potentially suitable suicide vector for 
unmarked allelic exchange.
319
  This approach would be useful to examine the degree to which 
L4 and L22 mutations affect the resistance phenotype observed with various AMRGs because 
the specific mutations in L4 and L22 associated with resistance are well known. This 
approach may not yet be feasible for the acrR mutations, as this area is relatively new in H. 
influenzae and further work would be required to establish what specific mutations should be 
introduced. Additional difficulties would be encountered for examining the effect of 23S 
rRNA mutations in this context. This is because the number of mutated copies required to 
produce reduced susceptibility has not been determined, and controlling the number of 
mutant copies generated in a mutagenesis experiment would be challenging. 
In addition to the rationale provided by the findings of Roberts et al.,
93
 the initial selection of 
the AMRGs described above was made based on the likelihood of an encounter between 
NTHi and other organisms in which these genes are highly prevalent.  However, another 
approach is to look at AMRGs found in organisms that are more closely related to H. 
influenzae phylogenetically.  This is especially useful for organisms in which there is a 
precedent for transfer of antibiotic resistance determinants to H. influenzae, as is the case for 
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P. multocida.
268
  ICEPmu1, a mobile element detected in a bovine-derived P. multocida 
isolate and that has had its complete structure elucidated,
263,264
 is a carrier of the AMRGs 
erm(42), msr(E) and mph(E).  As a result of a presentation given by myself on behalf of our 
group at the Australian Society for Microbiology Annual Scientific Meeting in Canberra 
(2015) on the work described in Chapter 4 of this thesis and a subsequent encounter with Dr. 
Stefan Schwarz (Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut, Neustadt-
Mariensee, Germany) after this presentation, I was given a unique opportunity to travel to Dr. 
Schwarz’s laboratory in Germany and perform conjugation experiments involving the 
transfer of ICEPmu1 from P. multocida to H. influenzae.  While it was possible to 
conjugatively transfer ICEPmu1, a recombination event occurred during the conjugation that 
produced a truncation of the ICE.  This truncation resulted in the loss of the msr(E) and 
mph(E), although the erm(42) was retained and did produce a macrolide resistant phenotype.  
The ICE was additionally shown to be stable in H. influenzae and maintained its transfer 
functions while having little apparent effect on the fitness of the host organism.  This 
provides some evidence for an alternative potential pathway in which AMRGs could be 
acquired by NTHi. 
Chapter 5 represents a preliminary examination of the use of whole genome sequencing 
(WGS) to screen for AMRGs in our clinical isolates with high level macrolide resistance.  
The panel for this screen included the same AMRGs investigated in Chapter 4, where these 
genes were absent from the clinical isolates screened; the failure to detect any of these 
AMRGs in these WGSs supported the findings of Chapter 4.  The advantage of using WGS 
for this purpose was that it was possible to screen for a very large set of genes that would 
have been impractical with conventional PCR.  Although we did not detect any AMRGs, an 
additional advantage of this approach was that we could also look for the presence of 
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established chromosomal mutations that may have been contributing to the resistant 
phenotype. 
The research findings presented in this thesis suggest that acquisition and subsequent 
expression of erm(A), erm(B) and erm(C) would produce a macrolide resistant phenotype in 
H. influenzae in the absence of any contributory mutations in macrolide-relevant 
chromosomal genes.  However, AMRGs do not appear to be widespread among wild-type 
isolates of NTHi and the high prevalence of AMRGs described in the Roberts et al.
93
 study 
seems to be unique to the circumstances of that particular study.  At present, high-level 
macrolide resistance in NTHi can primarily be attributed to chromosomal mutations, 
including in the L4 and L22 genes, and in 23S rRNA.  To reconcile these observations and 
potentially foresee how prevalence of these genes in NTHi could shift in the future, it is 
important to consider issues relating to the mechanisms through which these genes could be 
acquired by and disseminated in NTHi.  The variety and high prevalence of AMRGs in Gram 
positive bacteria of the respiratory tract attests to the presence of sufficient selective pressure 
to render the acquisition and maintenance of these genes attractive in an evolutionary sense.  
Whether the inherent intrinsic low susceptibility of H. influenzae to macrolides presents the 
same advantages for the acquisition and maintenance of these genes is difficult to assess, but 
the presence of naturally occurring isolates with high level macrolide resistance due to 
mutations in ribosomal elements suggests that this is a distinct possibility.  Despite this, there 
are two different but plausible pathways by which Haemophilus spp. might acquire AMRGs.  
One possibility is acquisition from Gram positive organisms in which AMRGs are highly 
prevalent.  Previous reports suggest that there is the general flux of resistance genes that 
favours movement from Gram positive organisms to Gram negative organisms.
320
  In the case 
of AMRGs, acquisition from Gram positive organisms is favoured by both the high 
prevalence of these genes in Gram positive respiratory organisms and the frequency of 
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interaction between these organisms and Haemophilus spp. afforded by their co-habitation in 
the respiratory tract.
321
  As previously discussed in this thesis, many of these AMRGs are 
present on conjugative elements in Gram positive organisms,  and conjugation is a 
mechanism of genetic transfer of very broad host range.
321,322
  However, while resistance 
determinants from Gram positives are readily expressed in Gram negatives, a barrier is 
presented by the frequent inability of the conjugative elements to replicate well in the new 
Gram negative host.
320,321
  However, if the genes are on transposable elements, then 
conjugation followed by transposition of the AMRGs either to the recipient genome or co-
resident native extra-chromosomal genetic elements is a plausible mechanism for the 
transfer.
321
  This proposed mechanism is supported by the observation that many AMRGs in 
Gram positive organisms are on transposable elements and that Haemophilus spp. frequently 
carry plasmids or ICEs that could act as vectors for these transposable elements.  The other 
possibility, which we have briefly examined in this thesis, is that Haemophilus spp. might 
acquire AMRGs from less phylogenetically distant organisms such as animal-derived 
organisms of the family Pasteurellaceae.  While the prevalence of AMRGs within organisms 
of this family may be high in some situations, the barrier here is the infrequency with which 
human isolates of NTHi would encounter these organisms in a manner conducive to 
conjugation, although as previously discussed, there is precedent for this to occur.
262,268
 
While we conclude that there is currently little evidence of the widespread emergence of 
AMRGs in NTHi, recent developments in this area have reinforced the need to monitor for 
AMRGs in NTHi.  Since the commencement of this thesis, there has been at least one other 
report of an AMRG in a clinical isolate of NTHi which must be addressed here.  Seyama et 
al. (2016) have reported the presence of mef(A) in a paediatric respiratory isolate of NTHi 
exhibiting high-level macrolide resistance (azithromycin MIC = 64 µg/mL; clarithromycin 
MIC = 128 µg/mL).
254
  This isolate was not found to carrying known macrolide resistance-
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associated mutations in L4, L22 or 23S rRNA, and did not exhibit overexpression of acrB, 
leading the authors of that study to conclude that mef(A) was likely producing the macrolide 
resistance phenotype of the isolate.  Further analysis of the isolate revealed that tet(M) was 
located close by to mef(A), and that the 6445bp region from tet(M) to mef(A) was identical to 
a segment of the streptococcal transposon Tn916, suggesting that these genes may have been 
acquired from a streptococcal species.  However, the authors were not able to demonstrate 
conjugative transfer of mef(A) to H. influenzae Rd KW20 or to clinical isolates of H. 
influenzae or S. pneumoniae.  No mention of msr(D) is made throughout the report, but we 
performed a BLAST search of CDS_5 of the 6445bp region deposited on GenBank 
(GenBank accession LC168847) which indicates that msr(D) is present on the element 
adjacent to mef(A), and as such its role in the exhibited phenotype should not be ruled out.  
Regardless, this very recent study further demonstrates that AMRG acquisition by NTHi can 
occur naturally, and we believe that this evidence, in conjunction with other issues such as 
the increasing use of macrolides in both animals and humans, the prevalence of AMRGs in 
other organisms, and the numerous potential pathways through which AMRG transfer could 
occur, suggest that the emergence of AMRGs may be an imminent threat and that it is 
prudent to undertake ongoing periodic surveillance for these genes in NTHi. 
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Appendix 2: Supplementary data from analyses performed in 
Chapter 5 
Table A2.1: List of polymorphisms in CA1. 
Pos.* Gene Ref CA1 Pos.* Gene Ref CA1 Pos.* Gene Ref CA1 Pos.* Gene Ref CA1 
878699 tpx C T 886944 gpmA A G 893061 nadR G T 898547 ftsX G A 
878815 tpx A C 887034 gpmA T C 893151 ribB G A 898563 ftsX G C 
878917 C G 887058 gpmA A G 893259 ribB A C 898598 ftsX T C 
878954 T G 887190 gpmA C T 893268 ribB C T 898625 ftsX A G 
879065 G A 887310 gpmA C T 893292 ribB T C 898634 ftsX C T 
879067 A G 887373 gpmA A G 893304 ribB T C 898688 ftsX G A 
879419 purL T G 887484 gpmA T A 893311 ribB C A 899005 atoB A G 
879458 purL C T 887643 rpmE G A 893318 ribB C A 899092 atoB C T 
879491 purL T C 887703 rpmE G A 893392 ribB T C 899373 atoB C T 
879563 purL A G 887715 rpmE A G 893433 ribB A C 899389 atoB A G 
880948 purL G A 887751 rpmE C A 893445 ribB C T 900252 atoE C T 
881180 purL G A 887780 rpmE C T 895833 NTHI0928 T C 900260 atoE T C 
881240 purL A G 887847 rpmE G A 896003 ftsY A G 900408 atoE T G 
881262 purL T C 887857 rpmE C T 896048 ftsY A G 900474 atoE C T 
881277 purL G T 887927 mutY G A 896103 ftsY A G 900489 atoE T A 
881303 purL T C 887988 mutY T C 896106 ftsY C A 900497 atoE T G 
881508 purL A G 888004 mutY T C 896186 ftsY G T 900534 atoE C T 
881528 purL C T 888016 mutY G A 896198 ftsY G T 900603 atoE G A 
881546 purL G C 888061 mutY C A 896264 ftsY G A 900618 atoE C T 
881603 purL C T 888151 mutY T C 896372 ftsY G T 900660 atoE T A 
881642 purL G A 888238 mutY A G 896375 ftsY G A 900669 atoE G A 
881679 purL C T 888280 mutY C T 896412 ftsY G A 901691 atoA A C 
881696 purL T C 888286 mutY A G 896438 ftsY T C 901853 atoA G A 
882050 purL T C 888292 mutY A G 896669 ftsY C T 902211 atoD T C 
882197 purL C T 888319 mutY G A 896678 ftsY T C 902220 atoD T G 
882212 purL A T 888343 mutY G A 896822 ftsY G A 902325 atoD T C 
882319 purL G A 888376 mutY C T 896894 ftsY C T 902391 atoD T A 
883052 purL T C 888622 mutY T A 896903 ftsY A G 902565 atoD C G 
883300 G C 888644 mutY A G 896936 ftsY C T 902848 atoD A G 
883302 T C 888756 mutY A G 896966 ftsY A G 902849 atoD A G 
883325 G A 888798 mutY A C 897181 ftsE A G 902871 NTHI0936 A G 
883353 T G 888806 mutY T G 897236 ftsE A C 902907 NTHI0936 C T 
883920 lex2B A C 888819 mutY A G 897239 ftsE C G 902968 NTHI0936 G A 
883970 lex2B G A 888860 mutY C T 897338 ftsE G A 902992 NTHI0936 G A 
884917 NTHI0914 G C 889160 NTHI0920 T C 897666 ftsE C T 903114 NTHI0936 G A 
884938 NTHI0914 C T 889172 NTHI0920 T A 897668 ftsE A G 903372 NTHI0936 T C 
885121 NTHI0914 T C 889221 NTHI0920 G A 897695 ftsE C T 903534 NTHI0936 C T 
885298 NTHI0914 T C 889223 NTHI0920 T C 897764 ftsE C T 903840 NTHI0936 T C 
885443 NTHI0915 A G 889286 NTHI0920 G A 898046 ftsX C A 903849 NTHI0936 C T 
885576 NTHI0915 G C 889355 NTHI0920 T C 898109 ftsX A G 903891 NTHI0936 G A 
885596 NTHI0915 A G 889381 mltC C T 898118 ftsX C T 904767 rplC C T 
885678 NTHI0915 A T 889873 mltC A T 898133 ftsX A G 905732 rplW T C 
885852 NTHI0915 T C 889909 mltC T C 898199 ftsX C T 905747 rplW G A 
885870 NTHI0915 T C 889913 mltC G A 898244 ftsX G T 905750 rplW C T 
886193 NTHI0915 T C 889939 mltC A G 898247 ftsX A G 906220 rplB A C 
886265 NTHI0915 G T 889948 mltC A G 898273 ftsX T C 906247 rplB T C 
886331 NTHI0915 T C 892805 nadR G A 898292 ftsX G A 907812 rpsC T C 
886376 NTHI0915 G A 892811 nadR A G 898469 ftsX C T 1006144 NTHI1058 C G 
886428 NTHI0915 T G 893034 nadR G A 898478 ftsX C A 1849392 nth A C 
886521 NTHI0915 T A 893057 nadR C T 898520 ftsX G A 
*Position numbering based on that of NC_007146
Appendix 2 
261 
 
 
 
Table A2.2a: List of polymorphisms in CA4 and CA6, part 1. 
Pos.* Gene Ref CA Pos.* Gene Ref CA Pos.* Gene Ref CA Pos.* Gene Ref CA 
3808 HI0003 T C 527908 HI0511 A T 586935 gyrB A T 592499 oxyR C A 
45496 HI0043 G A 529704 hindIIM G T 587220 gyrB C T 592517 oxyR G A 
46301 HI0043 A T 551578 tyrP T A 587223 gyrB G T 592568 oxyR A G 
47284 
 
A T 558150  G A 587271 gyrB C T 592974 HI0572 C T 
52337 HI0051 G A 559856 aspA G T 587334 gyrB A G 593008 HI0572 T A 
52396 HI0051 G A 566055 groEL C A 587412 gyrB A G 593085 HI0572 C T 
54392 HI0053 C A 583301 asnA A C 587646 gyrB G T 593124 HI0572 C T 
55727 uxuA G A 583385 asnA G A 587649 gyrB C T 593934 fkpA A G 
61735 msbA A C 583625 asnA T A 587682 gyrB G A 593936 fkpA A G 
68938 HI0066 C T 583628 asnA C T 587706 gyrB A C 594022 fkpA C T 
77720 recN G A 583670 asnA C T 587712 gyrB T C 594220 fkpA T C 
84550 
 
C T 583676 asnA T C 587733 gyrB A T 594310 fkpA C G 
107030 hitC T A 584093 gph C G 587736 gyrB A G 594406 fkpA A G 
108089 
 
G T 584094 gph G T 587961 gyrB C T 594553 fkpA G A 
117334 HI0109 C T 584146 gph C T 588165 tex T C 594794 HI0575 C G 
153327 rnhA C A 584155 gph A G 588169 tex A G 594848 HI0575 G A 
153443 rnhA C A 584652 gph G A 588205 tex A G 594866 HI0575 C T 
161008 HI0145 G A 584671 gph A G 588211 tex C G 594869 HI0575 C T 
161069 HI0145 C G 584842 dod G A 588224 tex T C 594971 HI0575 T C 
161070 HI0145 G C 584851 dod T A 588225 tex G T 594974 HI0575 C T 
183645 HI0170 C A 584857 dod C T 588246 tex G A 595013 HI0575 T C 
185412 
 
C A 584893 dod G T 588249 tex A G 595016 HI0575 T C 
186728 HI0173 A T 585001 dod A G 588402 tex C T 595066 HI0575 T C 
186732 HI0173 T A 585040 dod C T 588612 tex C T 595070 HI0575 G T 
205057 fur G C 585046 dod A G 588654 tex G T 595205 HI0575 C T 
205178 fur C T 585068 dod A G 588662 tex T C 595265 HI0575 T A 
205195 fur C T 585076 dod A G 588684 tex C T 595271 HI0575 T C 
209262 HI0195.1 T A 585178 dod C T 588717 tex A G 595375 HI0576 G A 
224199 dam A T 585202 dod G A 588804 tex T A 595408 HI0576 A T 
240237 HI0219a G A 585208 dod G A 590489 tex A C 595409 HI0576 T G 
240329 HI0219a T C 585235 dod T A 590596 greB G A 595425 HI0576 A G 
241737 HI0220.2 A T 585268 dod C T 590647 greB G A 595453 HI0576 T C 
241739 HI0220.2 A T 585277 dod C T 590692 greB T C 595498 HI0576 C T 
255835 brnQ G T 585491 dod C T 590695 greB T C 595550 HI0576 G A 
283562 HI0251 C T 585534  T A 590740 greB A G 595702 HI0576 G A 
283574 HI0251 C T 585585 gyrB C T 590857 greB T C 595716 HI0576.1 A G 
286431 dapA G A 585684 gyrB T C 590959 greB C A 596051 HI0576.1 G A 
291927 HI0261 G A 585765 gyrB C T 591135 HI0570 T C 596123 HI0577 A C 
292028 
 
G A 585789 gyrB A G 591150 HI0570 T A 596129 HI0577 T C 
341460 HI0308 C T 585807 gyrB C T 591168 HI0570 T C 596581 tuf A G 
351674 HI0322 T A 585812 gyrB A G 591195 HI0570 A C 596620 tuf G C 
375590 napC C A 585924 gyrB T C 591368 HI0570 A G 596656 tuf G A 
390021 HI0366 G A 586041 gyrB C T 591639 HI0570 T C 596659 tuf T A 
401469 HI0380 G A 586062 gyrB A T 591654 HI0570 G T 596782 tuf T C 
402013 
 
C T 586110 gyrB C A 591660 HI0570 A C 597232 tuf G T 
412858 rnd G A 586195 gyrB T C 591708 oxyR T C 597265 tuf G A 
453173 glmS C G 586200 gyrB A G 592451 oxyR A G 597298 tuf A T 
453174 glmS G C 586452 gyrB G C 592454 oxyR T C 597875 fusA C T 
474778 HI0452 G C 586809 gyrB G A 592463 oxyR A G 597878 fusA A T 
474826 HI0452 G A 586902 gyrB C T 592487 oxyR C T 597935 fusA A T 
*Position numbering based on that of NC_000907 
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Table A2.2b: List of polymorphisms in CA4 and CA6, part 2. 
Pos.* Gene Ref CA Pos.* Gene Ref CA Pos.* Gene Ref CA Pos.* Gene Ref CA 
598268 fusA G A 827415 nadR G A 832318 ftsE T C 837482  A G 
598300 fusA C G 827421 nadR A G 832319 ftsE T G 837496  G A 
598352 fusA T G 827644 nadR G A 832357 ftsE C A 837518 HI0775 C T 
598370 fusA A G 827667 nadR C T 832534 ftsX G A 837579 HI0775 G A 
598412 fusA G A 827671 nadR G T 832705 ftsX A G 837603 HI0775 G A 
598649 fusA T C 827761 ribB G A 832762 ftsX C T 837725 HI0775 G A 
598772 fusA G A 827780 ribB T C 832783 ftsX A G 838699 rpsJ C T 
599959 rpS7 G A 827869 ribB A C 832789 ftsX C T 839851 rplD A G 
599974 rpS7 G A 827878 ribB C T 832795 ftsX T C 840223 rplD C A 
599983 rpS7 G A 827902 ribB T C 832858 ftsX A G 840256 rplD G A 
600040 rpS7 C T 827917 ribB T C 832884 ftsX T C 840271 rplD G A 
600199 rpS7 A G 827928 ribB C A 832885 ftsX T G 840830 rplB A C 
600661 rpsL C T 827951 ribB G G 832900 ftsX C T 840857 rplB T C 
600718 rpsL A G 828040 ribB C T 832909 ftsX A T 840929 rplB C T 
600793 rpsL A T 828043 ribB T C 832975 ftsX G A 842032 rplV G C 
600806 rpsL T C 828055 ribB C T 833517 atoB C A 842265 rpsC G A 
601538 gidA C A 828061 ribB T C 833984 atoB C T 845361 rplX C G 
601544 gidA A C 830360 HI0767 C T 834000 atoB A G 845396 rplX C T 
601560 gidA C T 830378 HI0767 G T 834042 atoB A T 845489 rplX A G 
601568 gidA A G 830390 HI0767 A T 834219 atoB G A 845995 rplE A G 
601625 gidA C A 830395 HI0767 T C 834627 atoB G A 846034 rplE T C 
601642 gidA A G 830426 HI0767 A C 834743 atoE A G 846109 rplE T C 
601673 gidA T C 830429 HI0767 T A 834845 atoE C T 846921 rpsH C T 
601706 gidA T A 830821 ftsY T A 834938 atoE A C 847747 rplR T A 
601748 gidA T C 830845 ftsY A G 835085 atoE C T 847756 rplR A C 
601772 gidA G A 830924 ftsY G A 835100 atoE T A 847837 rplR A T 
608507 pepE C T 831001 ftsY T C 835145 atoE C T 848301 rpsE A G 
615544 
 
T A 831043 ftsY C T 835214 atoE G A 848722 rplO G A 
615545 
 
A G 831052 ftsY C T 835229 atoE C T 850015 secY C T 
622425 recA A T 831130 ftsY A G 835271 atoE T A 850345 secY A G 
623483 tfoX G T 831137 ftsY G A 835280 atoE G A 850484 rpmJ C T 
633274 cyaA C T 831202 ftsY A G 835510 atoE T C 851073 rpS11 C G 
639329 HI0608 C T 831262 ftsY A T 835646 atoE C T 851074 rpS11 G C 
641342 
 
C T 831433 ftsY G A 836034 atoA C A 853414 rplQ T C 
677077 HI0635 T A 831547 ftsY C T 836440 atoA A G 853730  G A 
677143 HI0635 C T 831607 ftsY A G 836463 atoA A C 853743  C T 
677144 HI0635 G T 831643 ftsY C T 836464 atoA G A 854380  T A 
677154 HI0635 T C 831835 ftsE C T 836522 atoA T G 854763  T C 
677157 HI0635 T C 831841 ftsE A G 836822 HI0774 T C 854772  T C 
678411 HI0636 C T 831850 ftsE C G 836831 HI0774 T G 858995 pckA G A 
682239 rplJ C G 831877 ftsE T A 836846 HI0774 C T 865937 alaS G C 
682240 rplJ G C 831964 ftsE T C 836946 HI0774 C T 880989 HI0829 G A 
705310 oapA G C 832009 ftsE G A 837002 HI0774 T A 885555 frdA C G 
725490 
 
C A 832054 ftsE C T 837026 HI0774 G A 885556 frdA G C 
737510 hel G A 832084 ftsE T A 837029 HI0774 G A 885762 frdA C T 
745159 HI0698 G A 832087 ftsE A G 837059 HI0774 T A 885810 genX G T 
753312 mutS T G 832159 ftsE A G 837137 HI0774 G T 885944 genX A T 
760350 HI0712 A G 832222 ftsE A G 837441 HI0774 C T 899386 HI0852 C A 
760386 HI0712 A G 832270 ftsE A G 837459 HI0774 A G 907024 clpB C G 
765944 nusG G C 832306 ftsE C T 837460 HI0774 A G 907025 clpB G C 
*Position numbering based on that of NC_000907 
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Table A2.2c: List of polymorphisms in CA4 and CA6, part 3. 
Pos.* Gene Ref CA Pos.* Gene Ref CA Pos.* Gene Ref CA Pos.* Gene Ref CA 
924509 wbaP C T 1016913 rumB C T 1025443 HI0967 T C 1032320  T C 
931827 HI0878 G A 1016994 exoII G A 1025444 HI0967 G A 1032344  T C 
932121 rpmA A C 1016999 exoII A G 1025687 menB T A 1032362  C T 
932122 rpmA C T 1017134 exoII G C 1025708 menB T C 1032647  C A 
932799 
 
T A 1017369 exoII A G 1025732 menB G C 1032710 HI0974.1 C T 
964472 mutT C T 1017375 exoII C A 1025846 menB T C 1034266 panF T C 
965182 kefC A T 1017417 exoII C T 1025864 menB T C 1034377 panF A G 
988537 HI0929 T A 1017426 exoII C T 1025963 menB C T 1034380 panF G A 
991317 eno T G 1017452 exoII C A 1025993 menB G C 1034404 panF A C 
996089 HI0936 G A 1017528 exoII G A 1026020 menB G T 1034872  C T 
1004762 degS C G 1017852 exoII T C 1026062 menB C T 1034883  G A 
1011540 radC A T 1017999 exoII T G 1026170 menB T G 1035622 fic C G 
1011816 radC G A 1018547 HI0961 C T 1026206 menB G A 1035678 fic T C 
1012673 dfp T C 1018813 HI0961 T A 1026209 menB T C 1035838 fic T C 
1012677 dfp C A 1018857  A G 1026230 menB A C 1035847 fic C A 
1012708 dfp T C 1018993  C T 1026479 menC G A 1035888 fic G T 
1012709 dfp T G 1019077  A G 1026580 menC C T 1036120 prmA A G 
1012786 dfp G A 1019197  G A 1026596 menC A C 1036291 prmA C T 
1012810 dfp C A 1019203  C T 1026656 menC T C 1036309 prmA G A 
1012819 dfp G A 1019631  T C 1026682 menC A T 1036549 prmA T A 
1012966 dfp T C 1019875  A C 1026877 menC C T 1036648 prmA C T 
1012982 dfp A T 1019896  A G 1026892 menC A G 1036687 prmA T C 
1012993 dfp T A 1019926  G A 1026895 menC A G 1036703 prmA A G 
1013050 dfp T C 1019935  G C 1027047 menC T C 1036759 prmA C T 
1013092 dfp C T 1019989  C T 1027098 menC C A 1036771 prmA A G 
1013110 dfp G A 1020013  G A 1027119 menC T C 1036783 prmA T C 
1013113 dfp T C 1020023  A G 1027207 menC A C 1036889 prmA A G 
1013215 dfp T G 1020061  G A 1027238 menC C G 1036999  T C 
1013225 dfp G T 1020064  A G 1027276 menC T C 1037146 HI0979 G A 
1013348 dut T C 1020085  C T 1027291 menC T A 1037759 HI0979 C T 
1013427 dut T A 1020109  G A 1027354 menC C T 1037760 HI0979 A G 
1013451 dut T C 1020115  A C 1027515 aroQ C T 1037918 HI0979 G A 
1013472 dut C T 1020244  C G 1027707 aroQ G A 1038321 fis T C 
1014132 slmA A G 1020313  A G 1027995  T C 1038596 smpB G A 
1014483 slmA C A 1020355  A G 1028154 accB T C 1038626 smpB A G 
1015023 crp G T 1020679  T C 1028244 accB A G 1038671 smpB A G 
1015221 crp C T 1021583  T A 1028341 accB A T 1038883 smpB C A 
1015463 
 
A G 1021586  T A 1028364 accB G A 1039256 pfkA C T 
1015656 
 
A G 1023888 mviN G A 1028403 accB G C 1039437 pfkA A G 
1015688 
 
G A 1024170 mviN T G 1028457 accB T A 1039443 pfkA A G 
1016074 rumB C T 1024338  C T 1029222 accC C T 1039455 pfkA T A 
1016251 rumB A G 1024340  A G 1029225 accC C T 1039458 pfkA A T 
1016288 rumB G A 1024466 rpsT T C 1029237 accC T C 1039578 pfkA A G 
1016337 rumB C T 1024756 rpsT A T 1029258 accC A C 1069382 HI1004 G A 
1016354 rumB C T 1024844  G T 1029351 accC C G 1072736 ispH A T 
1016366 rumB A G 1024992 HI0966 G A 1029360 accC C T 1072819 ispH G T 
1016444 rumB T C 1025024 HI0966 T C 1029462 accC T C 1072888 ispH G A 
1016516 rumB T C 1025048 HI0966 G A 1029687 accC T C 1088553 tktA C T 
1016673 rumB G A 1025062 HI0966 T C 1032291  T C 1091950 lyx C G 
1016815 rumB G C 1025321 HI0966 T C 1032313  A G 1091951 lyx G C 
*Position numbering based on that of NC_000907 
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Table A2.2d: List of polymorphisms in CA4 and CA6, part 4. 
Pos.* Gene Ref CA Pos.* Gene Ref CA 
1099040 serB C A 1392165 nlpC A T 
1099698 
 
A T 1394221 HI1317 C G 
1100915 HI1036 A T 1427066 cdd C A 
1101939 HI1037 C T 1429988 putP T A 
1105881 HI1041 C T 1431515 cafA C G 
1108618 napF C G 1431516 cafA G C 
1110933 dmsB G A 1432996 glnS A T 
1114268 HI1048 C G 1442596 glgA T G 
1132239 nrfB A T 1447571 pntA A G 
1132341 nrfB A T 1472592 sbcB A T 
1135980 hrpa A T 1492796 HI1394 G T 
1139736 cydB T A 1493411  G A 
1142385 
 
G T 1493416  C T 
1161493 HI1099 C T 1495274 fumC T C 
1170104 xylR C T 1514945 HI1426 C A 
1172379 nhaC A T 1522710 ybaK A T 
1183146 comM A T 1539782 msrA C T 
1183188 comM A G 1544271 HI1462 G A 
1191409 oppA T C 1565250 HI1482 T A 
1191430 oppA T C 1569195  C A 
1201240 murF A G 1572018 HI1499 T A 
1202608 mraY A T 1592990  G A 
1205776 ftsW A T 1617029 HI1545 C T 
1236315 ompA T C 1618602 aroG T A 
1236606 HI1165 C T 1641556 pykA C T 
1242825 metX A T 1659631 HI1590 A C 
1242945 metX A T 1659756 HI1590 C G 
1253815 uvrD A T 1659808 HI1590 A C 
1255853 uvrD C G 1663108  G T 
1255854 uvrD G C 1670319 HI1604 A T 
1260260 gcvA T A 1677620 sfsA G A 
1278988 lysS G A 1693922  G T 
1279145 
 
C G 1696354 purA A T 
1279146 
 
G C 1698672  G T 
1281204 
 
C A 1748745 HI1680 C T 
1287875 lctP A T 1765727 HI1695 A T 
1288052 lctP C A 1783777 crr G C 
1302647 aceF C G 1783778 crr C G 
1307119 mgsA A T 1823900 murI T A 
1344453 gyrA C A 1828855  G A 
1360967 infB G A     
*Position numbering based on that of NC_000907 
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Table A2.3a: List of insertions and deletions in CA4 and CA6, part 1. 
Pos.* Gene Ref CA Pos.* Gene Ref CA 
32329 HI0030 G GA 565145 ureB T TG 
52066 HI0050m C CA 576723  GA G 
104315 hitA A AG 576860  C CG 
117269 
 
G GC 576862  T TG 
130905 
 
AT A 579246  G GT 
131983 mltA GGT G 579334 HI0559.1 A AT 
140552 ppa TC T 585570  GA G 
142122 
 
TG T 588149 tex AG A 
143334 afuB G GCA 590522 tex AT A 
145323 
 
T TTC 591067  TAA T 
162572 HI0147 C CA 600488 rpS7 C CT 
162573 HI0147 C CA 607968  G GC 
162605 HI0147 G GA 608500 pepE GC G 
166073 
 
A AT 615586  T TG 
170592 
 
C CT 615588  T TG 
173171 fabD AG A 615595  AG A 
173261 
 
GC G 620939 ccrB G GT 
201555 tatA AG A 632170 hemX CCT C 
201574 tatA AG A 647284  G GA 
204720 
 
A AG 647287  C CAG 
233416 hsdS A ACC 654433  GC G 
234640 
 
A AGG 663137 fmt G GC 
235320 
 
A AC 678160  T TG 
240354 
 
TC T 678162  T TG 
263467 
 
C CT 721475 HI0680 G GT 
265439 
 
TC T 729849 glpA GC G 
266933 
 
G GT 764934  C CT 
354945 
 
G GC 765075 secE G GT 
369921 
 
G GC 787178  T TAA 
370788 
 
GC G 787337  A AT 
389958 HI0366 AC A 787392  A AT 
391547 HI0367 AG A 791739 HI0737 TC T 
393956 HI0370 G GA 804315  C CA 
401967 
 
AC A 810715  AG A 
401979 
 
TA T 850970 rpsM A AG 
415061 
 
G GA 853658  T TA 
428027 accA AG A 853846  A AT 
443488 
 
C CA 885804 genX GT G 
443690 
 
T TG 892480  A AG 
446124 
 
AT A 916490  G GA 
467750 
 
T TA 921808  AG A 
485132 HI0463 G GC 922034  CA C 
510227 
 
AG A 929031  CA C 
511410 aphA CA C 936290  G GC 
517873 
 
CTCCGAT C 951866  T TG 
534983 
 
T TCG 968666  G GC 
534996 
 
T TC 983710 glyS C CT 
560060 ureH GC G 989395 HI0930 A AT 
*Position numbering based on that of NC_000907 
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Table A2.3b: List of insertions and deletions in CA4 and CA6, part 2. 
Pos.* Gene Ref CA Pos.* Gene Ref CA 
997218 HI0938 TC T 1347623  C CA 
1014632  AG A 1370921 truB A AGC 
1016976 rumB A AT 1377957  T TG 
1018743 HI0961 T TA 1422174 potC G GT 
1024796  GA G 1439011 glgX G GC 
1027982 aroQ TA T 1439050 glgX G GCC 
1028638  G GCC 1476596  TC T 
1034913  T TA 1480065 pstS G GA 
1036073 prmA G GA 1505885 HI1410 G GC 
1037040 HI0979 GC G 1509059 HI1418 G GC 
1037047 HI0979 TA T 1511667  A AGC 
1038089 HI0979 A AG 1514364  A AG 
1066228 trmE G GC 1523231 cspD CG C 
1068024 HI1004 GC G 1523755  GC G 
1073492  GC G 1525290  GT G 
1104427 ureF C CT 1527279 ispA G GCAC 
1114929 merT G GC 1564858 muB C CG 
1114934 merT G GC 1564863 muB G GC 
1117514 HI1051 G GA 1566212  T TA 
1120361  C CCG 1568766  A AG 
1127714  G GT 1569019  G GC 
1128978  T TC 1570070 HI1493 T TG 
1128980  T TC 1571863 HI1498.1 CG C 
1132302 nrfB A AACG 1575666 HI1502 T TG 
1139146  G GC 1577703 HI1504 C CG 
1144510  CG C 1580044  G GC 
1144973  AC A 1587908  A AG 
1158617 dsbE G GA 1590314 HI1521 G GC 
1195317  TG T 1604806 grxA AG A 
1195324  TG T 1607054  GT G 
1195695  C CA 1608081  G GC 
1229388 HI1159m TC T 1617702 HI1546 CA C 
1231426 HI1162 G GGC 1621283 bioD G GA 
1231800 HI1162 T TCCGC 1634585  TC T 
1239757  TC T 1637524  G GC 
1243218  A AG 1662092  A AG 
1243512 sprT TG T 1662266  AT A 
1249451  G GC 1662939  AC A 
1257711  TA T 1675969 tyrS G GT 
1257768  TG T 1687060  TG T 
1257775  TG T 1689811 HI1625 AT A 
1257781  TG T 1710521 fbp G GA 
1277877 lysS GA G 1718873 tldD A AG 
1296983 uraA CA C 1734148  G GC 
1307316  A AG 1738448 HI1670 G GC 
1307904  T TA 1775364 HI1703 ATC A 
1330978  AG A 1782454 ygiX G GC 
1331102  C CT 1789588  GC G 
1331439  C CT 1828820 spoT A AC 
1341700  A AC     
*Position numbering based on that of NC_000907 
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Table A2.4a: List of additional polymorphisms in CA4 only (region 1). 
Pos.* Gene Ref CA4 Pos.* Gene Ref CA4 Pos.* Gene Ref CA4 
806546 ndh A T 812262 tpx T C 822626 mutY G A 
806549 ndh A T 812332 tpx C T 822671 mutY C A 
806585 ndh C G 812550  C G 822854 mutY A G 
806807 ndh G A 812599  A G 822890 mutY C T 
806834 ndh G A 812894 purL G A 822896 mutY A G 
807719 HI0748 A C 812996 purL A G 822962 mutY T A 
807722 HI0748 A G 813001 purL T C 822986 mutY C T 
807907 HI0748 T C 813011 purL T C 823052 mutY A G 
808096 HI0748 C T 813068 purL T G 823192 mutY T C 
808378 HI0748 A G 813107 purL C T 823254 mutY A G 
808645 HI0748 C T 813140 purL T C 823366 mutY A G 
809428 HI0748 G A 814550 purL T G 823429 mutY A G 
809536 HI0748 C T 814589 purL C T 823470 mutY C T 
810686 lexA T C 814911 purL T C 823535 mutY G A 
810778 dapF T G 814921 purL T C 823550 mutY A G 
811315 dapF G C 814926 purL A T 823565 mutY A G 
811318 dapF T C 815129 purL T G 823589 mutY C T 
811327 dapF T C 815195 purL G C 823590 mutY A C 
811393 dapF T C 815218 purL T A 823610 mutY C T 
811410 dapF G A 815219 purL A C 823643 mutY A G 
811511 dapF T G 815252 purL C T 823656 mutY C T 
811531 dapF C A 815291 purL T A 823770 HI0760 T C 
811549 dapF A G 815328 purL C T 823782 HI0760 T A 
811993 tpx C T 815423 purL C T 823794 HI0760 C G 
812098 tpx C T 815429 purL G A 823831 HI0760 G A 
812116 tpx A G 815558 purL A G 823896 HI0760 G A 
812218 tpx A G 815699 purL T C 823965 HI0760 T C 
*Position numbering based on that of NC_000907 
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Table A2.4b: List of additional polymorphisms in CA4 only (region 2). 
Pos.* Gene Ref CA4 
854888 
 
T C 
854943 
 
G A 
854978 
 
G T 
855041 
 
T C 
855531 HI0806 A G 
*Position numbering based on that of NC_000907 
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Table A2.4c: List of additional polymorphisms in CA4 only (region 3). 
Pos.* Gene Ref CA4 Pos.* Gene Ref CA4 
935574 HI0883 T A 936817 arcA G A 
935631 HI0883 G A 936861 arcA C T 
935689 HI0883 C T 936862 arcA A G 
935769 HI0883 A C 936894 arcA G A 
935901 HI0883 G T 936904 arcA G A 
935922 HI0883 A G 936945 arcA A G 
935940 HI0883 T C 937027 arcA C T 
935964 HI0883 G A 937045 arcA G A 
935967 HI0883 C T 937132 arcA C T 
936268 
 
G A 937183 arcA A G 
936393 
 
T C 937218 arcA T C 
936439 
 
T C 937272 arcA T G 
936466 
 
C T 937364 dipZ A C 
936503 
 
C A 937402 dipZ T C 
936526 arcA A G 937451 dipZ C T 
936577 arcA G T 937646 dipZ A G 
936655 arcA G C 937733 dipZ G C 
936757 arcA T C 937736 dipZ T A 
936760 arcA T C 937769 dipZ C T 
936790 arcA G A     
*Position numbering based on that of NC_000907 
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Table A2.5: List of additional insertions and deletions in CA4 only. 
Pos.* Gene Ref CA4 
937308 arcA TG T 
937841 dipZ CG C 
947226 HI0893 G GA 
*Position numbering based on that of NC_000907 
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Table A2.6a: The erm BLAST score ratio output for genomes 1-14.* 
 Isolate* 
Gene 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
erm(A) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(B) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(C) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(D) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(E) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.08 0.08 0.09 0.09 0.09 0.09 0.08 
erm(F) 0.06 0.06 0 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 
erm(G) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(H) 0.1 0.1 0.1 0.1 0.1 0.11 0.1 0.1 0.1 0.1 0.1 0.1 0.11 0.1 
erm(N) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(O) 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 
erm(Q) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.11 0.12 
erm(R) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(S) 0.08 0.07 0.08 0.08 0.07 0.08 0.08 0.08 0.07 0.08 0.08 0.08 0.07 0.08 
erm(T) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.14 0.15 
erm(V) 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.08 0.08 0.08 0.08 0.08 0.08 
erm(W) 0.09 0.08 0.09 0.09 0.09 0.09 0.09 0.08 0.08 0.09 0.09 0.09 0.08 0.08 
erm(X) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.13 0.13 0.12 0.12 0.12 0.12 0.13 
erm(Y) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.14 0.15 
erm(31) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
erm(32) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(33) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
erm(34) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(35) 0 0 0 0 0 0 0.06 0 0 0 0.06 0 0 0 
erm(36) 0.12 0.12 0.12 0.12 0.11 0.12 0.11 0.11 0.11 0.12 0.12 0.12 0.12 0.11 
erm(37) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(38) 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.07 0.07 0.08 0.08 0.08 0.08 0.07 
erm(39) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.12 0.12 0.13 0.13 0.13 0.13 0.12 
erm(40) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.14 0.13 
erm(41) 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 
erm(42) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(43) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.6b: The erm BLAST score ratio output for genomes 15-28.* 
 Isolate* 
Gene 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
erm(A) 0.14 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(B) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(C) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(D) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(E) 0.09 0.09 0.09 0.08 0.09 0.09 0.08 0.09 0.09 0.09 0.09 0.09 0.09 0.08 
erm(F) 0.06 0.06 0.06 0.06 0.06 0 0 0 0.06 0.06 0.06 0.06 0 0 
erm(G) 0.13 0.13 0.13 0.13 0.13 0.13 0.12 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(H) 0.11 0.1 0.11 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
erm(N) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(O) 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 
erm(Q) 0.11 0.12 0.11 0.12 0.12 0.12 0.11 0.12 0.12 0.12 0.12 0.12 0.12 0.13 
erm(R) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(S) 0.07 0.08 0.07 0.08 0.08 0.07 0.07 0.07 0.08 0.08 0.08 0.08 0.07 0.07 
erm(T) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(V) 0.08 0.08 0.08 0.07 0.08 0.07 0.07 0.08 0.08 0.08 0.08 0.08 0.08 0.07 
erm(W) 0.08 0.09 0.08 0.08 0.09 0.09 0.08 0.09 0.08 0.09 0.09 0.09 0.09 0.09 
erm(X) 0.12 0.12 0.12 0.13 0.12 0.12 0.12 0.12 0.13 0.12 0.12 0.12 0.13 0.13 
erm(Y) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 
erm(31) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
erm(32) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(33) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
erm(34) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(35) 0 0 0 0 0 0 0.06 0.06 0 0 0 0 0.06 0.06 
erm(36) 0.12 0.12 0.12 0.11 0.12 0.12 0.12 0.11 0.11 0.12 0.12 0.12 0.12 0.12 
erm(37) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(38) 0.08 0.08 0.08 0.07 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 
erm(39) 0.13 0.13 0.13 0.12 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(40) 0.14 0.13 0.14 0.13 0.13 0.13 0.14 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(41) 0.11 0.11 0.11 0.11 0.11 0.12 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.12 
erm(42) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(43) 0.16 0.16 0.16 0.16 0.16 0.17 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.6c: The erm BLAST score ratio output for genomes 29-42.* 
 Isolate* 
Gene 29 30 31 32 33 34 35 36 37 38 39 40 41 42 
erm(A) 0.15 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(B) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(C) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(D) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(E) 0.09 0.09 0.08 0.09 0.09 0.09 0.09 0.08 0.09 0.09 0.09 0.09 0.09 0.09 
erm(F) 0.06 0.06 0 0 0.06 0.06 0.06 0 0.06 0.06 0.06 0.06 0.06 0.06 
erm(G) 0.13 0.12 0.12 0.13 0.13 0.13 0.13 0.12 0.13 0.13 0.13 0.13 0.13 0.13 
erm(H) 0.1 0.1 0.1 0.11 0.1 0.1 0.1 0.1 0.11 0.1 0.1 0.11 0.1 0.1 
erm(N) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(O) 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.09 0.08 0.08 0.08 0.08 0.08 
erm(Q) 0.13 0.11 0.11 0.12 0.12 0.12 0.12 0.11 0.12 0.12 0.12 0.11 0.12 0.12 
erm(R) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(S) 0.07 0.08 0.07 0.08 0.08 0.08 0.08 0.07 0.08 0.08 0.08 0.07 0.08 0.08 
erm(T) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.14 0.14 
erm(V) 0.08 0.08 0.07 0.08 0.08 0.08 0.08 0.07 0.08 0.08 0.08 0.08 0.08 0.08 
erm(W) 0.08 0.08 0.08 0.09 0.09 0.09 0.09 0.08 0.09 0.09 0.09 0.08 0.09 0.09 
erm(X) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.13 0.12 0.12 0.12 0.12 0.12 
erm(Y) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.14 0.14 
erm(31) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
erm(32) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(33) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
erm(34) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(35) 0 0 0.06 0.06 0 0 0 0.06 0 0 0 0 0 0 
erm(36) 0.11 0.11 0.12 0.12 0.12 0.12 0.12 0.12 0.11 0.12 0.12 0.12 0.12 0.12 
erm(37) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(38) 0.07 0.07 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 
erm(39) 0.13 0.12 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(40) 0.13 0.13 0.14 0.13 0.13 0.13 0.13 0.14 0.14 0.13 0.13 0.14 0.13 0.13 
erm(41) 0.12 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 
erm(42) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(43) 0.15 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.6d: The erm BLAST score ratio output for genomes 43-56.* 
 Isolate* 
Gene 43 44 45 46 47 48 49 50 51 52 53 54 55 56 
erm(A) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.14 0.14 
erm(B) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(C) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(D) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(E) 0.08 0.09 0.09 0.09 0.09 0.08 0.08 0.09 0.09 0.08 0.08 0.08 0.09 0.08 
erm(F) 0.06 0.06 0.06 0.06 0.06 0.06 0 0.06 0.06 0.06 0 0 0.06 0.06 
erm(G) 0.13 0.13 0.13 0.13 0.13 0.13 0.12 0.13 0.13 0.13 0.12 0.13 0.13 0.13 
erm(H) 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
erm(N) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(O) 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 
erm(Q) 0.12 0.12 0.12 0.12 0.12 0.12 0.11 0.12 0.13 0.13 0.11 0.12 0.12 0.12 
erm(R) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(S) 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.08 0.07 0.07 0.07 0.07 0.08 0.08 
erm(T) 0.15 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(V) 0.08 0.08 0.08 0.08 0.08 0.07 0.07 0.08 0.08 0.07 0.07 0.07 0.08 0.07 
erm(W) 0.08 0.09 0.09 0.09 0.09 0.08 0.08 0.09 0.08 0.09 0.08 0.08 0.09 0.08 
erm(X) 0.13 0.12 0.12 0.12 0.12 0.13 0.12 0.12 0.12 0.13 0.12 0.13 0.13 0.13 
erm(Y) 0.15 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.14 
erm(31) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
erm(32) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(33) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
erm(34) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(35) 0 0 0 0 0 0 0.06 0 0 0.06 0.06 0.06 0.06 0 
erm(36) 0.11 0.12 0.12 0.12 0.12 0.11 0.12 0.12 0.11 0.12 0.12 0.12 0.12 0.11 
erm(37) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(38) 0.07 0.08 0.08 0.08 0.08 0.07 0.08 0.08 0.07 0.08 0.08 0.08 0.08 0.07 
erm(39) 0.12 0.13 0.13 0.13 0.13 0.12 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.12 
erm(40) 0.13 0.13 0.13 0.13 0.13 0.13 0.14 0.13 0.13 0.13 0.14 0.13 0.13 0.13 
erm(41) 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.12 0.12 0.11 0.12 0.11 0.11 
erm(42) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(43) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.15 0.16 0.16 0.16 0.16 0.16 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.6e: The erm BLAST score ratio output for genomes 57-70.* 
 Isolate* 
Gene 57 58 59 60 61 62 63 64 65 66 67 68 69 70 
erm(A) 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.14 
erm(B) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(C) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(D) 0.12 0.13 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(E) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
erm(F) 0.06 0.06 0.06 0.06 0.06 0 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 
erm(G) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(H) 0.1 0.1 0.11 0.1 0.1 0.11 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
erm(N) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(O) 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 
erm(Q) 0.12 0.11 0.12 0.12 0.13 0.11 0.12 0.12 0.12 0.13 0.12 0.12 0.12 0.12 
erm(R) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(S) 0.08 0.07 0.08 0.07 0.07 0.07 0.08 0.07 0.08 0.07 0.07 0.07 0.08 0.07 
erm(T) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(V) 0.08 0.07 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 
erm(W) 0.09 0.09 0.09 0.09 0.08 0.08 0.09 0.08 0.09 0.08 0.08 0.08 0.09 0.08 
erm(X) 0.12 0.13 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(Y) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(31) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
erm(32) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(33) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
erm(34) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(35) 0 0 0 0.06 0 0 0 0.06 0 0 0.06 0 0 0 
erm(36) 0.12 0.12 0.12 0.11 0.11 0.12 0.12 0.12 0.12 0.11 0.12 0.12 0.12 0.12 
erm(37) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
erm(38) 0.08 0.08 0.08 0.08 0.07 0.08 0.08 0.08 0.08 0.07 0.08 0.08 0.08 0.08 
erm(39) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(40) 0.13 0.13 0.13 0.13 0.13 0.14 0.13 0.13 0.13 0.13 0.13 0.14 0.13 0.13 
erm(41) 0.11 0.12 0.11 0.11 0.12 0.11 0.11 0.12 0.11 0.12 0.12 0.11 0.11 0.11 
erm(42) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(43) 0.16 0.16 0.16 0.16 0.15 0.16 0.16 0.16 0.16 0.15 0.16 0.16 0.16 0.16 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.6f: The erm BLAST score ratio output for genomes 71-81.* 
 Isolate* 
Gene 71 72 73 74 75 76 77 78 79 80 81 
erm(A) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(B) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(C) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(D) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(E) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.08 0.09 
erm(F) 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 
erm(G) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(H) 0.1 0.11 0.1 0.11 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
erm(N) 0 0 0 0 0 0 0 0 0 0 0 
erm(O) 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 
erm(Q) 0.12 0.12 0.12 0.11 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(R) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(S) 0.08 0.08 0.08 0.07 0.08 0.08 0.08 0.08 0.08 0.08 0.08 
erm(T) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(V) 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.08 
erm(W) 0.09 0.09 0.09 0.08 0.09 0.09 0.09 0.09 0.09 0.08 0.09 
erm(X) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.13 0.12 
erm(Y) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(31) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
erm(32) 0 0 0 0 0 0 0 0 0 0 0 
erm(33) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
erm(34) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(35) 0 0 0 0.06 0 0 0 0 0 0 0 
erm(36) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.11 0.12 
erm(37) 0 0 0 0 0 0 0 0 0 0 0 
erm(38) 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.08 
erm(39) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.12 0.13 
erm(40) 0.13 0.13 0.13 0.14 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(41) 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 
erm(42) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(43) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.6g: The erm BLAST score ratio output for genomes 82-92.* 
 Isolate* 
Gene 82 83 84 85 86 87 88 89 90 91 92 
erm(A) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 
erm(B) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(C) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(D) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(E) 0.09 0.09 0.09 0.08 0.08 0.09 0.09 0.09 0.09 0.08 0.09 
erm(F) 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0 0.06 0 
erm(G) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(H) 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.11 0.1 0.11 
erm(N) 0 0 0 0 0 0 0 0 0 0 0 
erm(O) 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 
erm(Q) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.11 0.12 0.12 0.11 
erm(R) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 
erm(S) 0.07 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.07 
erm(T) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(V) 0.08 0.08 0.08 0.07 0.07 0.08 0.08 0.08 0.08 0.07 0.08 
erm(W) 0.09 0.09 0.09 0.08 0.08 0.09 0.09 0.09 0.09 0.08 0.08 
erm(X) 0.12 0.12 0.12 0.13 0.13 0.12 0.12 0.12 0.12 0.13 0.12 
erm(Y) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
erm(31) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
erm(32) 0 0 0 0 0 0 0 0 0 0 0 
erm(33) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
erm(34) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
erm(35) 0 0 0 0 0 0.06 0 0 0.06 0 0 
erm(36) 0.11 0.12 0.12 0.11 0.11 0.11 0.12 0.11 0.12 0.11 0.12 
erm(37) 0 0 0 0 0 0 0 0 0 0 0 
erm(38) 0.08 0.08 0.08 0.07 0.07 0.07 0.08 0.08 0.08 0.07 0.08 
erm(39) 0.12 0.13 0.13 0.12 0.12 0.13 0.13 0.12 0.13 0.12 0.13 
erm(40) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.14 
erm(41) 0.12 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 
erm(42) 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
erm(43) 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.15 0.16 0.16 0.16 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.7a: The efflux gene BLAST score ratio output for genomes 1-14.* 
 Isolate* 
Gene 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
car(A) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
lmr(A) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
lsa(B) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.16 0.19 0.19 
lsa(C) 0.15 0.15 0.14 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
lsa(E) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 0.14 
mef(A) 0.06 0.06 0.05 0.05 0.05 0.05 0.06 0.05 0.06 0.05 0.06 0.05 0.05 0.06 
mef(E) 0.05 0 0 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
msr(A) 0.15 0.15 0.16 0.15 0.16 0.16 0.15 0.16 0.16 0.15 0.15 0.15 0.15 0.15 
msr(C) 0.19 0.2 0.17 0.19 0.19 0.19 0.19 0.19 0.19 0.17 0.19 0.17 0.19 0.19 
msr(D) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
msr(E) 0.18 0.17 0.16 0.17 0.17 0.17 0.18 0.17 0.17 0.16 0.17 0.16 0.18 0.17 
ole(B) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
ole(C) 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 
sal(A) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
srm(B) 0.21 0.21 0.2 0.21 0.21 0.21 0.21 0.21 0.21 0.2 0.21 0.2 0.21 0.21 
tlr(C) 0.21 0.21 0.21 0.2 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
vga(A) 0.19 0.19 0.17 0.19 0.19 0.19 0.19 0.19 0.19 0.17 0.19 0.17 0.19 0.19 
vga(B) 0.19 0.19 0.17 0.19 0.19 0.19 0.19 0.19 0.19 0.17 0.19 0.17 0.19 0.19 
vga(C) 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 
vga(D) 0.17 0.16 0.17 0.17 0.16 0.16 0.16 0.17 0.16 0.16 0.17 0.16 0.17 0.17 
vga(E) 0.19 0.2 0.19 0.19 0.19 0.2 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.7b: The efflux gene BLAST score ratio output for genomes 15-28.* 
 Isolate* 
Gene 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
car(A) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
lmr(A) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
lsa(B) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
lsa(C) 0.15 0.14 0.15 0.15 0.15 0.15 0.15 0.15 0.14 0.15 0.15 0.15 0.15 0.15 
lsa(E) 0.15 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
mef(A) 0.05 0.06 0.06 0.06 0.05 0.06 0.06 0.06 0.06 0.05 0.06 0.05 0.06 0.06 
mef(E) 0.05 0.05 0.05 0.05 0.05 0 0 0 0.05 0.05 0.05 0 0 0.05 
msr(A) 0.15 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.15 0.15 0.15 0.16 0.16 0.15 
msr(C) 0.19 0.19 0.19 0.19 0.19 0.2 0.19 0.2 0.19 0.17 0.19 0.2 0.2 0.19 
msr(D) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
msr(E) 0.18 0.17 0.17 0.18 0.18 0.17 0.17 0.17 0.17 0.16 0.18 0.17 0.17 0.17 
ole(B) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
ole(C) 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 
sal(A) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
srm(B) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
tlr(C) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
vga(A) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
vga(B) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.17 0.19 0.19 0.19 0.19 
vga(C) 0.18 0.19 0.18 0.18 0.18 0.18 0.18 0.18 0.19 0.18 0.18 0.18 0.18 0.18 
vga(D) 0.17 0.16 0.16 0.16 0.17 0.16 0.17 0.17 0.16 0.17 0.16 0.16 0.16 0.17 
vga(E) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.2 0.19 0.2 0.2 0.19 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.7c: The efflux gene BLAST score ratio output for genomes 29-42.* 
 Isolate* 
Gene 29 30 31 32 33 34 35 36 37 38 39 40 41 42 
car(A) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
lmr(A) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
lsa(B) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
lsa(C) 0.14 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.14 0.15 0.15 0.15 0.15 
lsa(E) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
mef(A) 0.04 0.06 0.06 0.06 0.06 0.05 0.05 0.06 0.05 0.06 0.05 0.05 0.06 0.06 
mef(E) 0 0 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
msr(A) 0.15 0.16 0.16 0.16 0.16 0.15 0.16 0.16 0.16 0.15 0.16 0.15 0.16 0.15 
msr(C) 0.19 0.19 0.19 0.2 0.19 0.19 0.2 0.19 0.19 0.15 0.19 0.19 0.19 0.19 
msr(D) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
msr(E) 0.17 0.17 0.17 0.16 0.17 0.17 0.17 0.17 0.17 0.16 0.18 0.18 0.17 0.17 
ole(B) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
ole(C) 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 
sal(A) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
srm(B) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
tlr(C) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
vga(A) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.17 0.19 0.19 0.19 0.19 
vga(B) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.17 0.19 0.19 0.19 0.19 
vga(C) 0.18 0.19 0.18 0.18 0.18 0.18 0.19 0.18 0.18 0.18 0.18 0.18 0.18 0.18 
vga(D) 0.16 0.17 0.17 0.16 0.17 0.16 0.17 0.17 0.16 0.16 0.17 0.16 0.16 0.16 
vga(E) 0.19 0.19 0.19 0.19 0.19 0.19 0.2 0.19 0.2 0.19 0.19 0.19 0.19 0.19 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.7d: The efflux gene BLAST score ratio output for genomes 43-56.* 
 Isolate* 
Gene 43 44 45 46 47 48 49 50 51 52 53 54 55 56 
car(A) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
lmr(A) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
lsa(B) 0.19 0.18 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
lsa(C) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
lsa(E) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
mef(A) 0.06 0.05 0.06 0.05 0.06 0.05 0.06 0.05 0.04 0.06 0.06 0.06 0.06 0.06 
mef(E) 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
msr(A) 0.15 0.15 0.15 0.15 0.15 0.15 0.16 0.15 0.15 0.15 0.16 0.16 0.15 0.16 
msr(C) 0.19 0.17 0.19 0.2 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.2 0.19 0.19 
msr(D) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
msr(E) 0.17 0.16 0.17 0.17 0.18 0.17 0.17 0.18 0.17 0.18 0.17 0.17 0.18 0.18 
ole(B) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
ole(C) 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 
sal(A) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
srm(B) 0.21 0.2 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
tlr(C) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
vga(A) 0.19 0.17 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
vga(B) 0.19 0.17 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
vga(C) 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 
vga(D) 0.17 0.16 0.16 0.17 0.16 0.17 0.17 0.16 0.16 0.16 0.17 0.17 0.16 0.16 
vga(E) 0.19 0.19 0.19 0.19 0.19 0.2 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.7e: The efflux gene BLAST score ratio output for genomes 57-70.* 
 Isolate* 
Gene 57 58 59 60 61 62 63 64 65 66 67 68 69 70 
car(A) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
lmr(A) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
lsa(B) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
lsa(C) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.14 0.15 
lsa(E) 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
mef(A) 0.05 0.04 0.06 0.06 0.04 0.06 0.06 0.06 0.05 0.06 0.06 0.06 0.06 0.06 
mef(E) 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0 
msr(A) 0.15 0.15 0.15 0.16 0.15 0.15 0.16 0.16 0.16 0.15 0.16 0.16 0.15 0.16 
msr(C) 0.19 0.2 0.19 0.2 0.19 0.2 0.19 0.19 0.19 0.19 0.19 0.19 0.15 0.2 
msr(D) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
msr(E) 0.18 0.17 0.17 0.17 0.17 0.17 0.18 0.18 0.18 0.17 0.18 0.17 0.16 0.17 
ole(B) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
ole(C) 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 
sal(A) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
srm(B) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
tlr(C) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
vga(A) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.17 0.19 
vga(B) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.17 0.19 
vga(C) 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.19 0.18 0.18 
vga(D) 0.16 0.17 0.17 0.16 0.16 0.17 0.17 0.16 0.17 0.16 0.16 0.16 0.16 0.16 
vga(E) 0.19 0.2 0.2 0.19 0.19 0.2 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.2 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.7f: The efflux gene BLAST score ratio output for genomes 71-81.* 
 Isolate* 
Gene 71 72 73 74 75 76 77 78 79 80 81 
car(A) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
lmr(A) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
lsa(B) 0.2 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
lsa(C) 0.15 0.15 0.15 0.15 0.15 0.15 0.16 0.14 0.15 0.14 0.15 
lsa(E) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 
mef(A) 0.06 0.06 0.05 0.06 0.05 0.06 0.05 0.06 0.04 0.04 0.06 
mef(E) 0.05 0.05 0.05 0.05 0.05 0 0.05 0.05 0.05 0.05 0.05 
msr(A) 0.15 0.15 0.15 0.15 0.15 0.16 0.16 0.15 0.15 0.15 0.15 
msr(C) 0.19 0.19 0.19 0.2 0.19 0.19 0.2 0.2 0.19 0.19 0.19 
msr(D) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.18 0.19 
msr(E) 0.17 0.17 0.17 0.16 0.17 0.17 0.17 0.17 0.17 0.17 0.18 
ole(B) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
ole(C) 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 
sal(A) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.19 0.2 
srm(B) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.2 0.21 
tlr(C) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
vga(A) 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
vga(B) 0.19 0.19 0.19 0.18 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
vga(C) 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.19 0.18 0.18 
vga(D) 0.17 0.17 0.16 0.17 0.17 0.17 0.16 0.17 0.17 0.16 0.16 
vga(E) 0.19 0.2 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.7g: The efflux gene BLAST score ratio output for genomes 82-92.* 
 Isolate* 
Gene 82 83 84 85 86 87 88 89 90 91 92 
car(A) 0.21 0.21 0.21 0.2 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
lmr(A) 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
lsa(B) 0.16 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
lsa(C) 0.14 0.15 0.14 0.15 0.14 0.15 0.16 0.15 0.14 0.14 0.15 
lsa(E) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 
mef(A) 0.05 0.06 0.06 0.04 0.04 0.06 0.06 0.05 0.06 0.06 0.05 
mef(E) 0 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
msr(A) 0.15 0.15 0.16 0.15 0.16 0.15 0.16 0.16 0.15 0.15 0.15 
msr(C) 0.17 0.2 0.15 0.19 0.17 0.19 0.19 0.19 0.17 0.17 0.19 
msr(D) 0.19 0.19 0.19 0.18 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
msr(E) 0.16 0.17 0.16 0.17 0.16 0.18 0.17 0.17 0.16 0.16 0.18 
ole(B) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
ole(C) 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 
sal(A) 0.2 0.2 0.2 0.19 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
srm(B) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.2 0.2 0.21 
tlr(C) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
vga(A) 0.17 0.19 0.17 0.19 0.17 0.19 0.19 0.19 0.19 0.19 0.19 
vga(B) 0.17 0.19 0.17 0.19 0.18 0.19 0.19 0.19 0.18 0.18 0.19 
vga(C) 0.18 0.18 0.18 0.18 0.18 0.18 0.19 0.18 0.19 0.19 0.18 
vga(D) 0.16 0.17 0.16 0.16 0.17 0.16 0.16 0.16 0.16 0.16 0.17 
vga(E) 0.19 0.2 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
 
 
 
 
 
Appendix 2 
285 
 
 
 
 
Table A2.8a: The deactivating gene BLAST score ratio output for genomes 1-14.* 
 Isolate* 
Gene 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
ere(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
ere(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
lnu(A) 0 0 0.09 0.09 0 0 0 0 0 0.09 0 0.09 0 0 
lnu(B) 0 0.06 0 0 0 0 0 0 0 0 0 0 0 0 
lnu(C) 0 0 0.08 0.08 0 0 0 0 0 0.08 0 0.08 0 0 
lnu(D) 0 0.09 0.1 0.1 0 0 0 0 0 0.1 0 0.1 0 0 
lnu(E) 0.08 0.08 0.08 0.08 0.09 0.08 0.08 0.08 0.09 0.08 0.08 0.08 0.08 0.09 
lnu(F) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(C) 0.05 0 0 0 0 0 0 0.05 0 0 0 0 0 0 
mph(E) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(F) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vat(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vat(B) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
vat(C) 0.09 0.07 0.07 0.09 0.09 0.09 0.07 0.07 0.09 0.07 0.09 0.07 0.09 0.09 
vat(D) 0.1 0.09 0 0.09 0.09 0.1 0.09 0.09 0.09 0 0.09 0 0.09 0.09 
vat(E) 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
vgb(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vgb(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.8b: The deactivating gene BLAST score ratio output for genomes 15-28.* 
 Isolate* 
Gene 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
ere(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
ere(B) 0 0 0 0 0 0 0 0 0 0 0 0 0.04 0 
lnu(A) 0 0 0 0 0 0 0 0 0 0 0 0.09 0 0 
lnu(B) 0 0 0 0 0 0 0 0 0 0 0 0.06 0 0 
lnu(C) 0 0 0 0 0 0 0 0 0 0 0 0.08 0 0 
lnu(D) 0 0 0 0 0 0 0 0 0 0 0 0.1 0 0 
lnu(E) 0.08 0.08 0.08 0.09 0.08 0.09 0.08 0.08 0.09 0.09 0.08 0.08 0 0.09 
lnu(F) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(C) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(E) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(F) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vat(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vat(B) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
vat(C) 0.09 0.09 0.07 0.09 0.09 0.09 0.09 0.07 0.07 0.07 0.07 0.07 0.07 0.07 
vat(D) 0.09 0.1 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
vat(E) 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
vgb(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vgb(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.8c: The deactivating gene BLAST score ratio output for genomes 29-42.* 
 Isolate* 
Gene 29 30 31 32 33 34 35 36 37 38 39 40 41 42 
ere(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
ere(B) 0 0 0 0.04 0 0 0 0 0 0 0 0 0 0 
lnu(A) 0.09 0.09 0 0 0 0.09 0.09 0 0 0 0 0 0 0 
lnu(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
lnu(C) 0.08 0.08 0 0 0 0.08 0.08 0 0 0 0 0 0 0 
lnu(D) 0.1 0.1 0 0 0 0.1 0.1 0 0 0 0 0 0 0 
lnu(E) 0.09 0.08 0.08 0.09 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.09 0.08 0.09 
lnu(F) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(C) 0 0 0 0 0 0 0 0 0 0 0 0.05 0 0 
mph(E) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(F) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vat(A) 0 0 0 0 0 0 0 0 0 0 0.06 0 0 0 
vat(B) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
vat(C) 0.09 0.09 0.09 0.07 0.09 0.07 0.07 0.09 0.09 0.09 0.07 0.07 0.07 0.09 
vat(D) 0.09 0.09 0.09 0.09 0.09 0 0.09 0.09 0.1 0.09 0.09 0.09 0 0.09 
vat(E) 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
vgb(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vgb(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.8d: The deactivating gene BLAST score ratio output for genomes 43-56.* 
 Isolate* 
Gene 43 44 45 46 47 48 49 50 51 52 53 54 55 56 
ere(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
ere(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
lnu(A) 0 0.09 0 0 0 0 0 0 0.09 0 0 0 0 0 
lnu(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
lnu(C) 0 0.08 0 0 0 0 0 0 0.08 0 0 0 0 0 
lnu(D) 0 0.1 0 0 0 0 0 0 0.1 0 0 0 0 0 
lnu(E) 0.09 0.08 0.09 0.08 0.08 0.08 0.08 0.08 0.09 0.08 0.08 0 0.08 0.09 
lnu(F) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(A) 0 0 0 0 0 0 0 0 0 0.05 0 0 0 0 
mph(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(C) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(E) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(F) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vat(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vat(B) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
vat(C) 0.09 0.07 0.09 0.07 0.09 0.07 0.09 0.09 0.09 0.07 0.09 0.07 0.07 0.09 
vat(D) 0.09 0 0.09 0 0.09 0 0.09 0.1 0.09 0.09 0.09 0.09 0.09 0.09 
vat(E) 0.1 0.1 0.1 0.09 0.1 0.09 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
vgb(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vgb(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.8e: The deactivating gene BLAST score ratio output for genomes 57-70.* 
 Isolate* 
Gene 57 58 59 60 61 62 63 64 65 66 67 68 69 70 
ere(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
ere(B) 0 0 0 0.04 0 0 0 0 0 0 0 0 0 0 
lnu(A) 0 0.09 0 0 0.09 0 0 0 0 0 0 0.09 0 0 
lnu(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0.06 
lnu(C) 0 0.08 0 0 0.08 0 0 0 0 0 0 0.08 0 0 
lnu(D) 0 0.1 0 0 0.1 0 0 0 0 0 0 0.1 0 0.09 
lnu(E) 0.09 0.09 0.08 0.08 0.09 0.08 0.08 0.08 0.08 0.09 0.08 0.09 0.08 0.08 
lnu(F) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(A) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(C) 0.05 0 0 0 0 0.05 0 0 0 0 0 0 0 0 
mph(E) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
mph(F) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
vat(A) 0 0 0 0 0 0 0 0 0.06 0 0 0 0 0 
vat(B) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
vat(C) 0.07 0.09 0.09 0.07 0.09 0.07 0.09 0.09 0.07 0.07 0.09 0.07 0.09 0.07 
vat(D) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
vat(E) 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
vgb(A) 0 0 0 0 0 0.05 0 0 0 0 0 0.05 0 0 
vgb(B) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.8f: The deactivating gene BLAST score ratio output for genomes 71-81.* 
 Isolate* 
Gene 71 72 73 74 75 76 77 78 79 80 81 
ere(A) 0 0 0 0 0 0 0 0 0 0 0 
ere(B) 0 0 0 0 0 0 0 0.04 0 0 0 
lnu(A) 0.09 0 0 0 0.09 0 0.09 0 0.09 0.09 0 
lnu(B) 0 0 0 0 0 0 0 0 0 0 0 
lnu(C) 0.08 0 0 0 0.08 0 0.08 0 0.08 0.08 0 
lnu(D) 0.1 0 0.09 0 0.1 0.09 0.1 0 0.1 0.1 0 
lnu(E) 0.08 0.08 0.08 0.08 0.08 0.09 0.08 0.09 0.08 0.09 0.08 
lnu(F) 0 0 0 0 0 0 0 0 0 0 0 
mph(A) 0.05 0 0 0 0 0 0 0 0 0 0 
mph(B) 0 0 0 0 0 0 0 0 0 0 0 
mph(C) 0 0 0 0 0 0 0 0 0 0 0 
mph(E) 0 0 0 0 0 0 0 0 0 0 0 
mph(F) 0 0 0 0 0 0 0 0 0 0 0 
vat(A) 0 0 0 0 0 0 0 0 0 0 0 
vat(B) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
vat(C) 0.07 0.09 0.07 0.07 0.07 0.09 0.09 0.07 0.09 0.09 0.07 
vat(D) 0.09 0.09 0.09 0.09 0 0.09 0.09 0.09 0.09 0.09 0.09 
vat(E) 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
vgb(A) 0 0 0 0 0 0 0 0 0 0 0 
vgb(B) 0 0 0 0 0 0 0 0 0 0 0 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Table A2.8g: The deactivating gene BLAST score ratio output for genomes 82-92.* 
 Isolate* 
Gene 82 83 84 85 86 87 88 89 90 91 92 
ere(A) 0 0 0 0 0 0 0 0 0 0 0 
ere(B) 0 0 0 0 0 0 0.04 0 0 0 0 
lnu(A) 0.09 0.09 0 0.09 0.09 0 0 0.09 0.09 0.09 0 
lnu(B) 0 0 0 0 0 0 0 0 0 0 0 
lnu(C) 0.08 0.08 0 0.08 0.08 0 0 0.08 0.08 0.08 0 
lnu(D) 0.1 0.1 0 0.1 0.1 0 0 0.1 0.1 0.1 0 
lnu(E) 0.08 0.09 0.08 0.09 0.09 0.08 0.09 0.09 0.09 0.09 0.08 
lnu(F) 0 0 0 0 0 0 0 0 0 0 0 
mph(A) 0 0 0 0 0 0 0 0 0 0 0 
mph(B) 0 0 0 0 0 0 0 0 0 0 0 
mph(C) 0 0 0 0 0 0 0 0 0 0 0 
mph(E) 0 0 0 0 0 0 0 0 0 0 0 
mph(F) 0 0 0 0 0 0 0 0 0 0 0 
vat(A) 0 0 0 0 0 0 0 0 0 0 0 
vat(B) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 
vat(C) 0.09 0.07 0.09 0.09 0.09 0.07 0.07 0.07 0.07 0.07 0.09 
vat(D) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0 0 0 0.09 
vat(E) 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
vgb(A) 0 0 0 0 0 0 0 0 0 0 0 
vgb(B) 0 0 0 0 0 0 0 0 0 0 0 
*Refer to Table 1 in Chapter 5 for interpretation of isolate numbers 
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Appendix 3: Constructed plasmids used for cloning 
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